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Colorectal cancer (CRC) is the second most deadly cancer globally, and 30% of these 
cancers occur in the rectum. The primary treatment for CRC is surgery, often 
radiotherapy with adjuvant chemotherapy is used before or following surgical 
resection.  
Treatment carries with it a high cost and side effect burden while response rates 
remain unpredictable. Approximately 20% of patients have total tumour regression 
post chemoradiotherapy; however, most patients receive only partial or no benefit 
from treatment. The ability to predict which patients would benefit from standard 
treatment and those who should be directed to an alternative treatment or an 
accelerated pathway to surgery would potentially avoid lengthy and costly 
treatments that may only cause side effects for patients, improving survival rates 
and quality of life.  
In this study, the microbiome, immune cells and patient gene expression were 
evaluated for their use as predictive biomarkers for response to chemoradiotherapy 
in rectal cancer patients. Tumour and adjacent normal tissue biopsies were taken 
before treatment and had DNA and RNA extracted and sequenced. 
First, the methodology for analysing microbiomes via shotgun sequencing data was 
evaluated and improved, increasing taxonomic assignment accuracy by 11% and 
potentially decreasing analysis time more than nine-fold. Secondly, the sequencing 
technologies, Oxford Nanopore, 16S rRNA and RNA-sequencing, were evaluated for 
their ability to assess the microbiome. The results demonstrated that platforms had 
concordance with one another; however, this was reduced at the species level.  
Third, microbial transcription was used to assess rectal cancer microbiomes, 
correlating them with response rates. The results showed that microbial diversity 
did not contribute to radiotherapy response, but that individual microbes may 
influence response. It was hypothesised that species such as Hungatella hathewayi, 
ii 
Fusobacterium nucleatum, Butyricimonas faecalis, Alistipes finegoldii, Bacteroides 
thetaiotaomicron, and B. fragilis may contribute to tumour regression by modulating 
metabolism and immune responses.  
Third, the abundance of infiltrating immune cells was predicted using RNA-
Sequencing data. Analysis indicated that the abundance of M1 macrophages and 
resting mast cells were correlated with response, while microbial transcription was 
correlated with the abundance of allergic and anti-tumour effector cells, as well as 
antigen-presenting cells. It was hypothesised that the microbiome might modulate 
anti-tumour immune responses directly, and indirectly by altering the tumour 
microenvironment. Microbes may help maintain a population of anti-tumour 
effector and antigen-presenting cells for tumour-antigen presentation during tumour 
cell death and neo-antigen uptake, which may be otherwise exhausted by targeting 
aspects of the inflammatory tumour microenvironment (i.e., lipid phagocytosis, anti-
bacterial and allergic responses).  
Lastly, machine-learning was employed to establish a panel of molecular biomarkers 
predictive of response, including microbial transcription, immune cells and gene 
expression. The final model demonstrated the ability to predict response with a 7% 
overall error rate, and that predicting response relied mostly on normal and tumour 
tissue gene expression, and tumour infiltrating immune cells. 
This study provides a panel of prognostic biomarkers which could be utilised to 
predict patient response. Additionally, it provides evidence for microbial-immune 
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1 CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
1.1 Introduction 
Colorectal cancer (CRC) has the third-highest incidence, and this frequency leads to 
the second-highest mortality of any cancer. Thirty percent of cases occur in the 
rectum [1]. In 2018 alone, 1.8 million new cases and 881,000 deaths were recorded 
globally, New Zealand and Australia had the second-highest rates of colon and 
rectal cancers (RC) [2]. There is increasing evidence that the microbiome plays a role 
in the development of CRC [3]. Fusobacterium nucleatum [4], enterotoxigenic 
Bacteroides fragilis [5], strains of Escherichia coli [6], and species from the oral cavity 
have been reported to produce potentially genotoxic compounds [7].  
RC is considered distinct from colon cancer and requires a different treatment 
strategy [1]. The greatest contributor to RC survival rates is early detection, while the 
disease is still localised [8]. Early detection allows for less invasive surgical resection, 
while higher stage tumours require more radical interventions, such as anterior 
resection and total mesorectal excision (TME), which involve defunctioning of the 
bowel before surgery, and often result in a temporary or permanent colostomy [1]. 
Although early detection is increasingly common in countries with nationalised 
bowel screening programmes, late-stage detection still frequently occurs. 
1.1.1 Epidemiology 
New Zealand and Australia have the second-highest RC incidence, at a rate of 15.6 
and 8.6 per 100,000 in males and females, respectively, and the third-highest 
mortality, globally [2]. RC accounted for 704,376 (3.9%) new cases and 310,394 (3.2%) 
cancer-related deaths in 2018, globally. Incidence and mortality rate is related to 
regional development, with increases in both incidence and mortality in Eastern 
European nations, China and Latin America. There is increasing incidence but 
reducing mortality in Canada, the U.K., Denmark and Singapore, while both 
mortality and incidence are reducing in the U.S., Japan and France [2]. These trends 
2 
reflect increased survival as nations adopt screening programmes and improved 
treatment [9].  
1.1.2 Risk factors 
The risk factors for RC are poorly understood and less well studied than colon 
cancers, partly due to studies combining patients with rectal and colon cancers into 
generalised CRC cohorts [10]. As sporadic disease accounts for the majority of 
reported cases (~75%) and is characterised by having no known underlying genetic 
predisposition [11], the involvement of lifestyle factors (e.g., smoking, alcohol/drug 
use), diet (e.g., excessive processed and red meat and inadequate fibre intake), 
exercise and the microbiome [12] may partly explain underlying causes. Human 
papillomavirus (HPV) has been implicated in CRC risk [13]; however, this is not a 
universal finding, with some studies suggesting HPV is not involved in RC [14], or 
CRC carcinogenesis [15]. A meta-analysis of 2630 adenocarcinomas showed CRC 
HPV prevalence at 11.2%, with different regions having substantive differences, and 
adenomas having a lower prevalence (5.1%) [16]. Further investigation into the role 
of HPV in CRC is required, as it may depend on the viral strain, geography or an 
individual’s genetics. 
In a comparative study of colon and rectal cancers, only sex and age correlated with 
RC [17]; however, there is a developing trend of increasing RC incidence in younger 
patients [18]. The incidence per 100,000 is 23.6 for males and 16.3 for females 
globally, and 41.7 and 32.1 in Australia/New Zealand, respectively [19]. There are 
differences in incidence between pre- and post-menopausal women, with 
individuals that have hormone replacement therapy post-menopause have a lower 
incidence of CRC, indicating that oestrogen may play a role in CRC aetiology [20]. 
However, the menopause-related risk may be adipose dependant, as lean women 
have been reported to have higher risk after menopause, and obese patients have a 
higher risk before menopause [20, 21]. The frequent occurrence of KRAS and BRAF 
mutations in CRC, as KRAS expression can be mediated by estrogen receptor (ER) to 
3 
allow escape from cellular senescence [22] and BRAF overexpression often co-occurs 
with ER inactivation, and is associated with worse prognosis [23]. This evidence 
suggests a role for oestrogen playing a role in carcinogenesis and CRC treatment 
outcomes [24-26]. Environmental exposure to oestrogen and pseudo-oestrogens may 
partly explain age and sex associations with CRC risk [27-29]. 
There is evidence for fewer factors protective of RC than for colon cancers [30]. Red 
meat and processed food consumption are thought to increase colon cancer 
incidence but have weaker associations with RC [31]. The protective effects of 
exercise have been shown in CRC, but are still debated in RC [32, 33], with meta-
analyses providing conflicting results [34, 35]. The differences in the effect of exercise 
may be due to the underlying cause of disease. A mouse model was used to show 
that tumour occurrence could be reduced with exercise, but only when occurring 
before carcinogen exposure [36]. Due to the rectum's role as a storage organ, it is 
subject to continuous potential carcinogen exposure, which may make pre-empting 
carcinogen exposure with exercise less effective [17]. 
1.2 CRCs 
CRCs can be separated into hereditary or sporadic. Hereditary CRCs are a result of 
one or more mutations in multiple inherited genes. Well defined inherited 
syndromes are responsible for 2%–5% of CRCs, 25%–30% of cases have a family 
history of CRC, indicating a yet to be discovered link, and ~75% are sporadic (i.e., no 
identified inherited risk). Details of the incidence and conferred risk of hereditary 
CRC are summarised in Table 1.1 [37-43]. Hereditary conditions are conferred by 
autosomal dominant mutations, making familial history and genetic testing useful 
for early detection and potential risk for developing CRC [44]. 
Table 1.1. Hereditary CRC syndromes 








polyposis (FAP)  
Hundreds to thousands of 
adenomatous polyps in colon and 
rectum  
APC  100% 1% 
Hereditary non-polyposis 
colorectal cancer (HNPCC)  








Peutz–Jegher's syndrome  
Small bowel hamartomatous polyps 
in and peri-oral pigmentation  
LKB1, STK11  39%–57% 1% 
Juvenile polyposis  
Hamartomatous polyps in stomach 




Details from [45], [46] and [47]. 
Sporadic cancers are caused by somatic mutations occurring due to DNA damage 
from carcinogens and environmental factors, such as microbes capable of sulphate 
and nitrate reduction, genotoxins, smoking and sedentary lifestyles [48]. When a 
tumour develops below the sigmoid colon, it is termed RC, with adenocarcinomas 
being the most common form of sporadic cancers in the large intestine, originating 
from a gland-type cell. 
1.2.1 Diagnosis 
CRCs typically present with bloody stools and rectal bleeding, changes in bowel 
habits and abdominal/anal pain, which may prompt further investigation by a 
general practitioner, such as physical examination, faecal occult blood test (FOBT) or 
faecal immunochemical test (FIT) [49]. Approximately 70% of RCs are identified 
with a physical per rectum examination; however, additional testing is required such 
as sigmoidoscopy or colonoscopy, biopsies and radiological imaging to confirm the 
diagnosis [50]. Screening programmes have been developed for symptomatic 
individuals and those over 60 in New Zealand [51]. However, there is an increasing 
incidence in patients under 40 [18, 52], and many patients are asymptomatic [53, 54]. 
1.2.2 Histology and staging 
Histological grading of CRC is generally based on the proportion of glandular 
differentiation, although using cell cluster and glandular structure during grading is 
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also common [55]. Grading systems are still debated and updated regularly; 
however, there are variations in clinical interpretation and differences in institutional 
and national guidelines [52, 53]. 
Staging is performed via rectoscopy, trans-rectal ultrasound, and computer-aided 
tomography (CT) scan, while magnetic resonance imaging (MRI) is the most 
powerful imaging tool for staging, and for informing treatment and surgical options 
[56][50]. As the lower rectum's venous drainage bypasses the liver, lung nodules are 
more common than liver metastasis as a primary metastatic site, and chest CT or 
positronic electron emission (PET) scans are needed to detect suspected metastases. 
Accurate staging is crucial for discovering which patients are candidates for 
chemoradiotherapy before surgery [57]. CRC staging is performed using tumour 
stage (T), lymph node invasion (N) and metastatic status (M). T1 and T2 tumours are 
limited to the bowel wall, while T3 is characterised by infiltration into the mesorectal 
fat. T4 tumours have penetrated other structures, with T4a indicating invasion of the 
peritoneal reflection, while T4b indicates invasion into adjacent organs [51].  
Five-year survival rates in the USA for CRC are 92% for stage I, 65% and 87% for 
stage IIA and B, respectively, and 90%, 72% and 53% for stage IIIA, B and C, 
respectively, while for metastatic and stage IV CRC five-year survival rates are 12% 
[19]. For RC, the five-year survival rates are for stage I: 88%; stage IIA/B: 81% and 
50%, respectively; stage IIIA/B/C: 83%, 72% and 58%, respectively; and stage IV: 13% 
[19]. In NZ, colon cancer rates are as follows, stage I: 80%, stage II: 71%, stage III 
63%–50% (depending on nodal status), stage IV: 6%, and for RC are 65% and 10%, if 
metastatic [58]. The Australian Institute of Health and Welfare does not provide a 
distinction between colon and rectal cancers [59]; however for CRC, for stages I–IV 
the five year survival rates are 89%, 74.5%, 44.5% and 12.6%, respectively [60]. 
1.2.3 The rectum 
The rectum is the terminal point of the colon before the sphincter muscles. The 
rectum is in contact with luminal contents for more extended periods than other 
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parts of the bowel; its primary role is temporary storage for faeces before excretion. 
Therefore it is subject to high levels of metabolites and waste products from 
digestion and from the microbiome [61], which have been associated with 
carcinogenesis [62]. The rectum is supplied with blood from the interior, middle and 
superior rectal arteries. It is drained by the superior, middle and inferior rectal veins 
from the internal and external haemorrhoidal plexus which bypass the liver [63, 64].  
1.2.4 Prognostic markers for RC 
Prognostic markers used for RC survival are tumour stage, location, morphology, 
differentiation, lymph-node involvement, vascular or mesorectal invasion, and 
metastases. Advanced stage, poorly differentiated [65], mucinous, and signet-ring 
cell cancers [66] are associated with poor prognosis, while a greater distance from 
the anal verge is a positive prognostic indicator for surgical outcomes [67]. 
1.3 The microbiome 
A microbiome is the community of microorganisms living in a given environment 
[68]. The gut microbiome has the highest microbial abundance in the human body, 
with hundreds of species being present in individuals from a pool of potentially 
thousands across the human population. It contains more than 30 times the number 
of human genes and usually exists in a symbiotic relationship with the host [69]. 
Microbes can affect host health in many ways, from metabolic activities [70], to 
altering nutrient absorption [71], and immune functionality [72, 73]. The gut 
microbiome can be influenced by host genetics [74], diet [75], lifestyle [76] and 
medical interventions [77]. A pathological imbalance in the gut microbiome is called 
dysbiosis. Dysbiosis can have consequences for health, being associated with 
irritable bowel syndrome (IBS) [78], malnutrition [79], mental health [80] and cancer 
[81]. Microbes can produce a variety of beneficial metabolites in the gut [79, 82]. Of 
the most well studied are short-chain fatty acids (SCFA), such as butyrate, 
propionate and acetate, produced from metabolising dietary fibre [83]. Summary 
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data for faecal levels of SCFAs can be found in Table 1.2. SCFAs can have 
immunomodulatory, neuronal, and microbial regulatory effects [84, 85], and 
butyrate can be used as an energy source for colonocytes [86, 87].  
Table 1.2. Short-chain fatty acids in different populations 
Study Population and Diet Acetate Propionate Butyrate 
  (mg/g faeces) 
Fleming et al. [88] US; self-selected, low and high fibre 2.75 1.22 1.64 
  (mM faeces) 
Muir et al. [89] 
Simulated Australian 56.1 15 18.4 
Simulated Chinese 39.9 12.8 12.2 
Takahashi et al. [90] 
Japanese; self-selected 36 22.3 17.5 
Japanese; controlled 45.2 23.6 19 
  (mmol/kg faeces) 
Høverstad et al. [91] Norwegian; self-selected 37.3 12.5 12.4 
Table adapted from [92]. 
1.3.1 The microbiome and CRC 
The majority of CRCs are thought to be sporadic and lifestyle and environmental 
factors (such as microbiomes), likely play a role in their initiation [11]. Bacterial 
species such as Fusobacterium nucleatum, Bacteroides fragilis and Helicobacter pylori 
have been shown to affect carcinogenesis [93-95].  
1.4 Microbial carcinogenesis 
Members and activities of the microbiome may not be sufficient for carcinogenesis 
alone, as the Knudson hypothesis suggests that an underlying predisposition may be 
required [96], such as gene mutations or a diet that can be metabolised into 
carcinogenic compounds [97-100]. The gastrointestinal tract acts as selective 
environments with differing shearing forces, oxygen levels, and nutrients that lead 
to differences in the microbiomes between proximal and distal CRCs [101]. Nutrient, 
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metabolite and oxygen levels change throughout the gut and are spatially 
distributed, with oxygen levels being higher closer to the lumen wall [102]. Simple 
carbohydrates are taken up rapidly by the host and the microbiome, the latter of 
which can convert simple nutrients into complex metabolic products [103]. In this 
sense, the gut can be thought of as a complex Winogradsky column, with species 
cross-feeding on the preceding communities' metabolic products [104].  
The tumour microenvironment is separate from the lumen and is generally hypoxic, 
due to unrestricted cell growth, which in turn forces anaerobic glycolysis and selects 
for anaerobic microbes [105, 106]. Facultative anaerobes may also maintain the 
hypoxic tumour environment, impacting treatment efficacy [107]. 
A significant increase in the diversity in tumours compared to controls was noted in 
a study of RC tumour microbiomes, and the samples were clustered into two 
enterotypes [108]. The majority of samples were those dominated by Bacteroides and 
Dorea genera, and another group had elevated amounts of Pseudomonas and 
Brevundimonas [108]. Higher levels of anaerobic bacteria were found in tissues, which 
is consistent with other CRC tumour microbiome studies [109], while ectosymbiont 
Parcubacteria and the Planctomycetes phyla, were identified as possible biomarkers 
for RC [108].  
The differences in microbes in CRC tumours could also be due to each area of the 
intestine expressing different genes, and primary tumour location is known to 
impact treatment efficacy [110-112], with left-sided tumours having better survival 
rates than right-sided tumours [113]. The colonisation of tissues by microbes is 
reflective of the selective microenvironment, and therefore, could be used as a 
prognostic marker [93, 109].  
1.4.1 Models of microbiome involvement in CRC 
There are three primary models for how the microbiome can contribute to cancer: 
the driver-passenger model, the keystone species model and the oral origin model. 
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The ‘driver-passenger’ model suggested by Tjalsma et al. states that toxigenic 
species, known as drivers, are causative of the disease, providing the “first hit”. 
Those microbes that are selected for by the subsequent tumour microenvironment 
are termed passengers [114]. However, drivers in one context may be passengers in 
another, and the presence of passenger species may be indicative of later-stage 
cancers [115].  
The keystone species model describes an organism which can alter its environment, 
allowing the colonisation of subsequent species which capitalise on the altered 
environment and cause carcinogenic changes in the host [116]. The keystone species 
model is similar to the driver-passenger model in that particular microbes produce 
alterations to the microbiome. However, it differs in that driver species may become 
displaced by passengers as the environment changes, whereas a keystone species 
might not be displaced. 
The oral origin model suggests that oral species are potential initiators of 
carcinogenesis [117], e.g. Fusobacterium nucleatum and Porphyromonas gingivalis, 
Parvimonas micra, Peptostreptococcus stomatis, Gemella morbillorum, Leptotrichia 
trevisanii [118], Selenomonas sputigena [109], Lachnospiracea intertie sedis [119], 
Treponema denticola and Tannerella forsythia [93], originate from the oral cavity and 
have been implicated in carcinogenesis. These species may require an already 
dysbiotic environment to establish residence in the gut and generate a genotoxic 
effect, requiring biofilm generation that is prevented in a healthy gut environment 
[120, 121].  
One model could explain carcinogenesis in one individual, while another may 
explain carcinogenesis in another. These models are not mutually exclusive, as an 
oral microbe may be a ‘driver’ or ‘keystone species’ when established in the 
gastrointestinal (GI) tract.  
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1.4.2 Mechanisms of microbiome associated CRC development 
Microbial species can contribute to carcinogenesis by altering their environment, 
causing inflammation, increasing cancer risk. Besides, microbes can act directly on 
cells in the gut to cause carcinogenesis in various ways.  
E-cadherin is a part of cellular junctions that maintain cellular adhesion and 
epithelial barrier functionality and can have immune-modulating effects [122]. It is a 
common cellular target for microbial pathogens, allowing bacteria to adhere and 
enter cells, and manipulate host cell signalling [123, 124].  
Enterotoxigenic Bacteroides fragilis can produce the Bacteroides fragilis toxin (BFT), a 
metalloprotease that leads to cleavage E-cadherin [125, 126], leading to the 
accumulation of free β-catenin that acts as a co-activator of T cell factor transcription 
factor (TCF), and the transcription of genes in the Wnt signalling pathway, which are 
involved in cell growth and proliferation [127]. Additionally, Fusobacterium 
nucleatum produces FadA, an adhesion protein that also interacts with E-cadherin, 
modulating β-catenin signalling [128, 129]. Other microbes that are known to target 
E-cadherin are Campylobacter jejuni [130], Escherichia coli [131], Shigella flexneri [132], 
Helicobacter pylori [133], Pseudomonas aeruginosa, Serratia marcescens [134], Clostridium 
perfringins [135] and Enterococcus facium [136]. Reduced E-cadherin membrane 
expression and increased cytosolic E-cadherin are associated with higher vascular 
endothelial growth factor-A levels and predict poor survival [137].  
Other carcinogenic compounds are known to be produced by bacteria. Colibactin 
from E. coli can cause double-strand breaks in DNA [138], and sulfidogenic 
compounds, such as hydrogen sulphide produced by Desulfobacter, Desulfobulbus, 
Desulfotomaculum, and Desulfovibrio genera and Bilophila wadsworthia [139], have also 
been shown to be genotoxic [140]. 
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1.4.3 Inflammation, oxygen and microbiota 
Mucous is the primary physical protection of the intestinal epithelium. If this 
mucous barrier is compromised, the gut's epithelial lining can be directly affected by 
microbial metabolites and toxins. Some Bacteroidetes and Clostridia can limit 
inflammation in the gut by producing SCFAs, which can inhibit pro-inflammatory 
neutrophil activity, stimulate regulatory T cells (Tregs), and enhance the intestinal 
barrier via regulating tight-junctions [141-143]. Additionally, Clostridia can stimulate 
mucous production, protecting the intestine from inflammatory stimuli, and 
decreasing gut permeability [144].  
Inflammation in the gut due to dysbiosis can increase blood flow to the area, which 
increases oxygen in the lumen. The sudden influx of oxygen can further dysbiosis 
via overgrowth of bacteria capable of aerobic respiration such as Enterobacteriaceae, 
which can rapidly outcompete anaerobic commensal species which cannot compete 
in an oxygen-rich environment [145]. Additionally, tumour hypoxia is frequently 
encountered in the tumour microenvironment and may play a role in microbial 
selection [102, 105, 146].  
Continued inflammation allows microbes and microbial compounds to interact 
directly with the epithelial surface causing damage and increased inflammatory 
responses [147]. The damaged epithelial cells provide a source of phospholipids, that 
when metabolised, the carcinogens ammonia and acetal aldehyde are produced as 
byproducts [148, 149]. This reduced defence against lumen content, microbial 
compounds, and pathogen colonisation increase CRC risk [150].  
Biofilms are structures comprised of a matrix of polymeric substances such as 
polysaccharides that give bacterial communities microenvironments in which they 
are protected from shearing forces, immune responses, and antimicrobial 
compounds, enhancing their survival and growth by concentrating metabolites [151, 
152]. In the oral cavity, biofilms can cover teeth and sequester acids that allow the 
microbes to survive, but also cause tooth decay and carcinogenesis [153], as they can 
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concentrate carcinogenic compounds, concentrating their effects in a localised area 
[154]. When inside a biofilm, microbes exhibit different phenotypes that can quickly 
change, leading to diversity among otherwise homogenous communities [155], as 
biofilms can facilitate horizontal gene transfer (HGT) from one species to another 
[156], and concentrating quorum sensing homoserine lactones can trigger pathogenic 
gene expression [157]. 
Receptor interactions between bacterial cells allow the co-aggregation of multiple 
species within biofilms [158]. Biofilm-producing species from the oral microbiome 
appear in the gut and may have a role in the early-stage carcinogenesis [159], such as 
the cancer-associated Porphyromonas gingivalis, which has been identified in CRC 
tissue samples [93]. Other transient oral species such as Treponema denticola, F. 
nucleatum and Tanerrella forsythia can survive in the gut by forming these proxy-oral 
communities, sheltered from the general gut environment [160]. Additionally, 
Campylobacter showae, strain CC57C, has been shown to co-aggregate with a 
carcinogenic strain of F. nucleatum via adhesion proteins [109].  
Increased biofilms have been seen on CRC tumours in comparison to adjacent and 
healthy tissues, particularly on right-sided tumours, which are associated with poor 
prognosis [161]. These associations may be not causative of CRC but may simply be 
more prominent in the CRC environment. 
1.4.4 The microbiome of tumour tissues 
Healthy gut microbiome communities average ~160 species per person from a pool 
of more than 1150 characterised species [162]. Studies investigating the gut 
microbiome routinely use faecal samples; however, faecal microbiomes are not 
representative of tissue microbiomes [163, 164]. Therefore, studies using tissue 
samples may be more relevant for the study of treatment and pathogenesis, as many 
bacterial toxins rely on interactions with host-cell components, such as E-cadherin, to 
have pathogenic outcomes [123]. Despite this potential for radical diversity, the 
microbial communities of tumour tissues are dominated by four main phyla, 
13 
Firmicutes, Bacteroidetes, Actinobacteria and Proteobacteria [165]. Therefore, the 
discriminatory power of communities based on lower taxonomic classifications such 
as phylum is lacking, and distinctions need to be identified at the species, strain and 
functional metabolic level for microbiome-based phenotype classifications. 
Furthermore, certain microbial products are only produced by certain species within 
a genus, and strains within a species, i.e., Escherichia coli are common microbiome 
constituents; however, some strains are benign while others are capable of 
producing deadly toxins [166]. 
1.4.4.1 Diversity 
Alpha diversity is the diversity (i.e., number of different members) of members 
within an individual sample. Tumours have been found to have higher levels of 
alpha diversity compared to controls [108, 167-169]; however, some studies have 
found the opposite [170], or find the differences to be insignificant [119, 139, 171, 
172]. Alpha diversity has been reported as being higher in CRC than in adenomas 
[173], and lower alpha diversity has been reported in survivors of CRC, compared to 
non-survivors [174]. The significance of alpha diversity in different studies may 
reflect the cohorts used, study design and chosen diversity measures [175].  
Differences in tumour diversity may be more significant in different 
countries/regions [172]. Another factor is biopsy location, as demonstrated in one 
experiment, which took adjacent tissue from 5 cm and 10 cm distant from tumours, 
and found greater diversity in the 10 cm samples, although this was not statistically 
significant [119]. 
Taking the studies above into account, and according to a recent meta-analysis, 
alpha-diversity cannot reliably be used to distinguish between disease states [176]. 
Instead, distinct taxa within communities should be considered the relevant factors 
[176]. 
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Beta diversity as a measure of differences in composition between groups. Beta 
diversity distinguishing between differences in taxa between individuals, rather than 
comparing the level of different taxa within individuals as with alpha diversity. For 
example, beta diversity allows for the categorisation of samples into enterotypes, or 
defined microbial communities, such as was performed by Arumugam et al. in 2011 
[177], placing subjects into one of three broad clusters, based on 16S analysis of 
faecal samples. Enterotyping was also utilised by Thomas et al. [108] in which the 
majority of RC patients were separated from healthy patients into an enterotype 
categorised by higher Dorea and Bacteroides [108]. Additionally, a study by Sobhani 
et al. found significant beta diversity differences between healthy and CRC patients, 
and between healthy patients with and without high methylation of genes associated 
with CRC [178]. Beta diversity is a more useful measure of evaluating differences 
between the microbial communities of disease states, as it takes into account inter-
sample variability. 
1.4.4.2 Composition of the CRC tumour microbiome 
1.4.4.3 Phyla 
The most dominant phyla in tissues reported are Firmicutes, Bacteroidetes and 
Proteobacteria [93, 108, 167, 170, 172, 174, 175]. Fusobacteria is also found to be a 
predominantly abundant phylum [93, 108, 167, 171, 173-175], although not as 
frequently. Additionally, some studies find Synergistetes [170], Actinobacteria [108, 
172], Verrucomicrobia, and Parcubacteria (candidate phyla OD1) [108] as highly 
abundant phyla in tumour tissues. Lower abundance of Firmicutes [167, 171, 172, 
179], Bacteroidetes [121, 167, 171], Clostridiales [171], and Bacilli [121] have been 
reported in tumours compared to normal tissue, while Proteobacteria have been 
reported as both scarce [175] and enriched [167], in different instances.  
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1.4.4.4 Genera 
Across studies, more than 80 genera are reported as enriched in colorectal tumours, 
with varied support. Fusobacterium [93, 109, 119, 164, 167, 170-175, 179-182], and 
Bacteroides [93, 108, 119, 164, 170, 175, 181, 183] are the most widely reported. Genera 
found to be enriched and depleted in tumour tissues (compared to normal tissues) 
can be found in Table 1.3. 
There is often an overlap with the genera found to be enriched in tumours in some 
studies and depleted in others, such as Bacteroides [118, 167, 171, 173], 
Faecalibacterium, Kluyvera [179], Blautia, Alistipes [173], Parabacteroides, Ruminococcus 
[168], Sutterella, and Collinsella [173]. Taxa found to be decreased in tumours, without 
contradiction appear in the literature more rarely, implying that the tumour 
microenvironment contains substantial heterogeneity across populations, selecting 
for a variety of microbiomes in different circumstances. However, this may also 
indicate technical limitations of microbiome studies, for instance, where different 
taxa are omitted with different cut-offs for rarity or sampling differences. Genera 
reported to be enriched consistently, and those with conflicting reports of 
enrichment will likely provide the greatest insight into differences between tumour 
microbiomes. 
1.4.4.5 Species 
Some species have been identified as being enriched in tumour tissue, although due 
to difficulties in resolving to the species level generally, and particularly using 16S 
rRNA, these reports are less frequent in the literature and should be considered to be 
less accurate assessments. Species found to be enriched and depleted in tumour 
tissues can be found in Table 1.4.  
Species associated with the oral microbiome are reported to be enriched in tumour 
tissues. They tend to be anaerobic, have biofilm production and modification 
capability, are implicated in dental plaques and oral disease, such as periodontitis 
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[184, 185]. Oral species found in tumours include F. nucleatum [109, 118, 171, 174, 181, 
182] F. periodonticum [118, 181], Parvimonas micra, Peptostreptococcus stomatis, Gemella 
morbillorum, Leptotrichia trevisanii [118], Selenomonas sputigena [109], Lachnospiracea 
intertie sedis [119], Porphyromonas gingivalis, Treponema denticola and Tannerella 
forsythia [93]. Faecalibacterium prausnitzii, is commonly associated with good gut 
health due to its ability to produce butyrate [186]; however, it has been reported as 
being both enriched [174, 181], and decreased [118, 169, 173] in tumours. 
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Table 1.3. Genera reported as enriched and depleted in tumour tissues. 
Enriched (E) Depleted (D) Conflicting Reports 
Genera Ref. Genera Ref. Genera Ref. Genera Ref. 
Bulleida [172, 175] Paraprevotella [119, 175] Anoxybacillus [109] Alistipes E: [139, 164]; D: [173] 
Campylobacter [109, 172, 175] Parvimonas [164, 172, 173, 175, 180] Bacilli [121] Bacteroides 
E: [93, 108, 119, 164, 
170, 175, 181, 183]; D: 
[118, 167, 171, 173] 
Clostridium [93, 108, 121, 164, 175] Peptostreptococcus [164, 170, 175, 180] Citrobacter [179] Blautia 
E: [93, 119, 164, 169, 
181]; D: [173] 
Coriobacterium [172, 179] Porphyromonas 





E: [93, 164, 174, 181]; D: 
[179] 
Desulfovibrio [108, 175] Prevotella [93, 119, 169, 170, 175] Enterobacteria [179] Kluyvera E: [179, 183]; D: [179] 
Dorea [108, 181] Roseburia [93, 164, 168, 172, 179] Holdemania [109] Parabacteroides E: [108, 139]; D: [168] 
Gemella [170, 172, 173, 180] Selenomonas [93, 109] Microbacterium [109] Ruminococcus 
E: [121, 139, 164]; D: 
[168] 
Granulicatella [170, 180] Shewanella [164, 174] Pseudoflavonifractor [109]   
Haemophilus [170, 180] Staphylococcus [139, 169] Serratia [179]   
Leptotrichia [109, 173] Streptococcus [115, 119, 170-172, 175, 180] Shigella [179]   
Odoribacter [108, 139, 175] Treponema [93, 175] Sutterella [173]   
Fusobacterium [93, 109, 119, 164, 167, 170-175, 179-182] Veillonella [115, 170, 180] Collinsella [173]   
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Table 1.4. Species reported as enriched and depleted in tumour tissues. 
Enriched (E) Depleted (D) Conflicting Reports 
Species Ref. Species Ref. Species Ref. Species Ref. 
Aggregatibacter aphrophilus [171] Fusobacterium necrophorum [118, 181] Acinetobacter baumannii [171] Faecalibacterium prausnitzii 
E: [174, 181]; D: 
[118, 169, 173] 
Akkermansia muciniphila [169] Fusobacterium nucleatum [109, 118, 171, 174, 181, 182] Acinetobacter sp. [171]   
Bacteroides fragilis [108, 118, 174, 181] Fusobacterium periodonticum [118, 181] Alistipes putredinis [173]   
Bacteroides massiliensis [181] Gemella morbillorum [118] Bacteroides dorei [118]   
Bacteroides uniformis [108] Hafnia alvei [183] Bacteroides stercoris [118]   
Bilophila sp. [108] Lachnospiracea intertie sedis [119] Bacteroides vulgatus [118]   
Blautia coccoides [169] Leptotrichia hofstadii [109] Collinsella aerofaciens [173]   
Blautia sp. Marseille [181] Leptotrichia trevisanii [118] Enterobacter cloacae [171]   
Campylobacter showae [109] Methylobacterium suomiens [174] Fusobacterium mortiferum [118]   
Citrobacter freundii [183] Parvimonas micra [118] Fusobacterium necrogenes [118]   
Clostridium sensu strictu [119] Peptostreptococcus stomatis [118] Fusobacterium ulcerans [118]   
Comamonadaceae acidovrax spp. [119] Porphyromonas gingivalis [93] Fusobacterium varium [118]   
Coprococcus comes [181] Selenomonas sputigena [109]     
Dorea longicatena [181] Tannerella forsythia [93]     
Escherichia coli [183] Treponema denticola [93]     
Fusobacterium hwasooki [93]       
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1.4.5 Neoadjuvant treatment of RC 
The predominant treatment for RC is surgical resection, often with neoadjuvant 
chemoradiotherapy (nCRT). Neoadjuvant treatments are administered before surgery 
to shrink more advanced tumors in order to improve outcomes. These include 
chemotherapy, radiation therapy or hormone therapies. As well as the localised 
primary tumour effects, neoadjuvant treatments are used to control metastatic disease 
[187]. The main goal of neoadjuvant treatment in RCs is to reduce tumour mass before 
surgery to reduce the volume of tissue removed.  
1.4.6 Tumour regression grading 
Tumour regression grading (TRG) is a method of categorising the level of tumour 
regression after cytotoxic treatment, based on the relative amount of tumour remaining 
after therapy or level of fibrosis induced relative to the level of residual tumour. There 
are multiple systems for TRG, such as the American Joint Committee on Cancer (AJCC), 
Dworak, Mandard, and Ryan systems, as well as modified systems that take into 
account lymph nodes and primary tumour regression [188].  
Dworak TRG has five grades of regression: Four: complete regression where no residual 
tumour cells are seen, termed pathological complete response (pCR); three: near-
complete regression where very few tumour cells are seen; two: moderate regression 
where significant fibrotic changes are detected with few tumour cells or groups of cells; 
one: minimal regression where tumour cells are dominant with some fibrosis; and zero: 
where no regression is seen [189]. As Dworak scoring is the main method of regression 
scoring at Christchurch hospital, it was used for all patients throughout this thesis. 
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1.4.7 Adjuvant chemotherapy 
Capecitabine is a chemotherapy drug which is the currently prescribed prodrug of 5-
fluorouracil (5-FU). 5-FU is a uracil analogue with an attached fluorine atom, which 
once converted from the prodrug capecitabine, can be converted into three downstream 
metabolites that poison the available pools of uracil and thymine, which interrupts 
proper DNA and RNA synthesis. The incorporation of these analogous metabolites 
causes double-stranded breaks and improper DNA replication and RNA transcription, 
interrupting the cell cycle and leading to apoptosis.  
Normally, uracil is modified with a methyl group by thymidylate synthase (TS) to be 
converted into thymine. Fluro-deoxyuridine monophosphate (FdUMP) inhibits TS, 
preventing thymine conversion from uracil. 5-FU is converted into fluorodeoxyuridine 
triphosphate (FdUTP) and interferes with DNA synthesis when used in place of 
thymine. Additionally, conversion into fluorouridine triphosphate (FUTP) is used in 
place of uracil to inhibit RNA formation. 5-FU may cause hepatic toxicity; however, 
approximately 80% of the conversion process occurs in the liver, which is the primary 
location for colorectal metastases [190]. Despite this, even with severe liver dysfunction, 
it is considered effective and safe compared to other therapies [191]. 
Capecitabine has mostly replaced intravenous 5-FU due to its improved safety and 
efficacy profile [192]. It is the mainline drug used in nCRT for CRC treatment in NZ, 
and it can be used as an adjuvant monotherapy therapy and radiosensitiser, with tablets 
being taken on the day of radiotherapy treatment. The standard dose is 1250mg/m2 and 
is associated with several adverse events such as nausea, diarrhoea, vomiting, stomatitis 
(inflammation of the mouth and lips, which may result in ulceration), hand-foot 
syndrome, which results in tingling, numbness, and broken skin and ulceration of the 
hands and feet. Additionally, polymorphisms and copy number variation of the TS 
gene can lead to tumour resistance and patient oversensitivity [190].  
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Leucovorin is often included in a 5-FU therapy to mitigate the negative impact 5-FU has 
on healthy tissue by acting as a folate supplement, a precursor for thymine.  Leucovorin 
has also been shown to improve treatment and survival outcomes by increasing the 
pool of tetrahydrofolate, which can be utilised for TS inhibition and 5-FU metabolite 
synthesis [193]. The frequent lack of tolerance to the drug can often lead to patients 
ceasing their treatment early. Combination chemotherapies include FOLFOX 
(leucovorin, 5-FU and oxaliplatin) and FOLFIRI (leucovorin, 5-FU, irinotecan). Post 
initial treatment and surgery, a combination chemotherapy regimen of capecitabine and 
cisplatin (CAPOX) is often used to prevent or treat recurrence, with or without 
additional radiotherapy [194, 195]. 
1.4.8 Radiation therapy 
Radiation therapy involves using ionising radiation via linear energy transfer (LET) to 
kill cancer cells and has been used for this purpose since 1896, soon after x-rays were 
first discovered, although the mechanism of action was not understood at the time 
[196]. Approximately 50% of all cancer patients will receive radiation therapy during 
their treatment, particularly for non-operable cancers and palliative treatment [197].  
CRC patients receive short-course radiation over five days or long-course radiation over 
several weeks. The benefit of short-course radiation is that it can be delivered quickly in 
palliative care scenarios, or for patients with low tolerance to the treatment. A 
retrospective study of 28,193 non-metastatic RC patients receiving short- or long-course 
radiation found no statistically significant benefit of long-course over short-course 
radiation; however, it was found that a longer interval between therapy and surgery 
correlated with higher pathological complete response (pCR) rates [198].  
The primary mechanism of action for RT is causing damage to the cells and DNA of 
tumour tissue via direct damage to the DNA, or through LET ionising water molecules 
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in the cell, generating reactive oxygen species (ROS), which in turn damage DNA or 
proteins required for critical cell functions, resulting in cell cycle cessation, and cell 
death [197].  
Paradoxically, therefore, a lack of water in combination with tumour hypoxia, which 
would otherwise hinder the growth of tumour cells, are significant factors that can 
reduce the effectiveness of radiotherapy, and is thus an area of significant research 
interest [199-205]. Hypoxic conditions occur due to a lack of proper blood supply and 
increased metabolism and cell division which rapidly depletes available oxygen [105].  
As with many cancer therapies, radiotherapy impacts both tumour cells and healthy 
tissues of the patient, causing adverse side effects such as fatigue, mucositis, intestinal 
breakdown, gastrointestinal symptoms, bleeding, and changes in appetite, which are all 
associated with poor outcomes and quality of life reductions [206, 207].  
1.4.9 Surgery 
The surgical approaches post RT are usually limited resection of the malignant tissue or 
total mesorectal excision (TME) for advanced and invasive cancers [208]. Rates of good 
surgical outcomes and avoidance of temporary and permanent stoma differ between 
the sexes, principally due to anatomical differences between the musculature of 
respective pelvic floors [209, 210]. Additionally, the female colon is longer on average, 
with shorter anal canal and rectum than males, which may contribute to more 
significant surgical complications during resection and increased rates of stoma in older 
females [211, 212]. Stoma implementation can cause psychological issues and sexual 
dysfunction in both sexes [213, 214]. 
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1.4.10 Prognostic markers of response to neoadjuvant treatment 
The optimal result of neoadjuvant treatment is a pCR or complete regression. However, 
this outcome occurs only for approximately 10-25% of patients [215], with some studies 
reporting rates lower than 1% [216].  
Predictive markers for pCR is a field of research attracting significant attention. Clinical 
features also have predictive value for neoadjuvant treatment outcomes, such as 
tumour size, distance from the anal verge, nodal involvement, the time between nCRT 
and surgery, pre-treatment serum carcinoembryonic antigen (CEA) levels, 
differentiation, and macroscopic ulceration [217, 218].  
1.4.11 Molecular prognostic markers 
There are no predictive molecular biomarkers for nCRT response that have been 
validated for clinical use [219]. However, potential molecular markers for response to 
therapy include mutations and copy number of oncogenes. The roles of PT53, KRAS, 
BRAF and PIK3CA as prognostic markers in nCRT is not definitive, with some studies 
showing no association [220-222], while other researchers have shown positive 
associations with response to nCRT [223], such as wild-type PT53 gene being associated 
with a more significant response to nCRT [224]. It is speculated that these results may 
be due to the location of mutations in these genes, indicating that taking a personalised 
approach to research and treatment may provide better outcomes for some patients 
[225, 226].  
Groupings of tumours with common factors, such as the consensus molecular subtypes 
(CMS) [227] may be more informative [228-230]. Subtypes such as those exhibiting 
hypermethylation of DNA and chromosomal instability [231, 232] have proved the most 
informative in RCs. Gaedcke et al. found ten differentially methylated regions which 
were predictive of disease-free survival (DFS) [233] while Murcia et al. found higher 
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genetic instability associated with a greater response to nCRT [232]. Alternatively, as 
suggested by Ma et al., continuous subtypes may provide more reproducible results in 
terms of prognosis, stage, and grade using transcription data than the discrete 
subtyping CMSs provide [234]. 
Many differentially expressed genes have been associated with response to therapy, a 
summary of which can be found in Table 1.5. An increase in XRCC3 (x-ray repair cross-
complementing protein), a gene involved in DNA repair, has been associated with 
nCRT resistance [235, 236]. Karagkounis et al. showed that between responders and 
non-responders, decreased neuronal pentraxin-2 (NPTX2) expression in tumours was 
associated with an increased response to nCRT and DFS [237]. Differential expression of 
the zinc finger protein ZNF160, Helicase For Meiosis 1 (HFM1), additional sex combs-
like protein 2 (ASXL2), aldo-keto reductase family 1 member C3 (AKR1C3), C-X-C motif 
chemokine ligands (CXCL9–11), indoleamine dioxygenase-1 (IDO1) and matrix 
metalloproteinase-12 (MMP12) have also been used to discriminate between response 
groups, with varying accuracy [238]. However, these genes are not used clinically for 
routine screening. 
Table 1.5. Summary of genes thought to be involved in therapy response. 




Member of the RecA/Rad51-related protein family, participate in 




NPTX2 Neuronal pentraxin 2 
Involved in excitatory synapse formation and plays a role in the 
clustering of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid (AMPA)-type glutamate receptors at established synapses, 
resulting in non-apoptotic cell death of dopaminergic nerve cells. 
[237]  
ZNF160 Zinc finger protein 160 Zing-finger protein and may function in transcription regulation. [238]  
HFM1 Helicase for meiosis 1 ATP-dependant DNA helicase expressed mainly in germ-line cells. [238]  
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ASXL2 ASXL transcriptional regulator 2 
Epigenetic regulator that binds histone-modifying enzymes involved in 
assembly of transcription factors. Mutations in this gene have been 
associated with cancers across several tissue types. Has a role in 
neurodevelopment, cardiac function, adipogenesis and 
osteoclastogenesis. 
 [238]  
AKR1C3 
Aldo-keto reductase family 1 
member C3 
Member of the aldo/keto reductase superfamily. Catalyses reduction of 
prostaglandins, phenanthrenequinone and oxidation of 9-alpha,11-beta-
PGF2. May play a role in allergic diseases and controlling cell growth 
and differentiation. 
 [238]  
CXCL9 C-X-C motif chemokine ligand 9 




C-X-C motif chemokine ligand 
10 
Antimicrobial gene, stimulates monocytes, NK and T cell migration and 
modulation of adhesion molecule expression. 
[238]  
CXCL11 
C-X-C motif chemokine ligand 
11 
Antimicrobial gene, induces a chemotactic response in activated T cells, 
and is the dominant ligand for CXCLR3 and is induced by INF-γ. 
 [238] 
IDO1 Indoleamine 2,3-dioxygenase 1 
Catalyses the rate-limiting step in tryptophan catabolism. Thought to 
play roles in antimicrobial and anti-tumour processes, neuropathology, 
immunoregulation, and antioxidant activity. Expressed in dendritic 
cells, monocytes and macrophages and modulates T cell behaviour. 
[238]  
MMP12 Matrix metallopeptidase 12 
Involved in the breakdown of extracellular matrix. Degrades soluble 
and insoluble elastin and may play a role in aneurysm formation, and 




1.5 Microbial and immune interactions with neoadjuvant treatment 
When treating cancers, the microbiome is being increasingly shown to have 
consequences for cancer treatment. The microbiome has been shown to affect 




During 5-FU treatment, folate metabolism is a crucial factor due to its role in thymine 
and uracil synthesis [243, 244]. The gut microbiome is known to impact the uptake of 
metabolites [71] and research using a Caenorhabditis elegans model has demonstrated 
folate uptake is modulated by E. coli and can alter the lifespan of the host, independent 
of supplementation [245, 246]. The role of microbiota in the treatment of cancer with 5-
FU was investigated with live bacteria, and different strains of live E. coli were found to 
impact the efficacy of 5-FU [211]. Many different strains of E. coli are prominent in the 
gut microbiome and have been shown within CRC tumour tissues [109, 183, 247].  
Irinotecan, another drug used for CRC treatment, is deactivated by the liver via 
glucuronidation. It has been shown that when re-entering the intestine through the bile 
duct as waste, it can be reactivated by microbial β-glucuronidases [248]. This conversion 
increases the drug's toxicity and exacerbates side effects like diarrhoea, which affect the 
majority of CRC patients [249].  
1.5.2 Radiation therapy  
Radiation kills cells by using large amounts of energy in a targeted area to damage 
membranes, proteins and DNA by generating free radicals and ROS. As cells die, they 
release pro-inflammatory and immunostimulatory molecules which attract more 
immune cells to the site. The abscopal effect can also be induced, which produces a 
systemic immune response to distant malignancies with radiotherapy, in addition to 
localised effects [250]. The microbiome's role in radiation therapy outcomes and related 
immune interactions has been gaining attention in the research space [242]. 
One of the main side effects of nCRT therapy, particularly when used in areas 
containing mucosae, such as the oral cavity or pelvic region, is mucositis. Mucositis 
symptoms include pain, ulceration, bleeding, nausea vomiting diarrhoea and 
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constipation [251], which leads to reduced quality of life and poorer outcomes for 
patients [252]. Mucositis has been associated with upregulated expression of pro-
inflammatory cytokines IL-1β, IL-6, and tumour necrosis factor (TNF) [253]. The 
microbiome has been implicated in increasing severity of mucositis, with reported 
increases of Enterobacteriaceae and Bacteroides, and decreases in health-associated 
Bifidobacterium and F. prausnitzii [254]. 
As mentioned in a previous section, E-cadherin is a common target for numerous 
microbes and may have an immune-modulating effect [123]. The association of E-
cadherin expression with survival may be immunologically mediated, as it has been 
demonstrated that E-cadherin adhesion disruption causes dendritic cells (DCs) to 
mature to a regulatory phenotype, rather than an antigen-presenting effector phenotype 
[122], leading to enhanced tumour progression, lack of T cell proliferation, and 
microbial persistence [255]. 
E-cadherin mediated maturation of dendritic cells is impactful, as DCs are antigen-
presenting cells that act as a central regulator of immune activity. DCs are capable of 
uptaking and presenting antigens for CD8 and natural killer (NK) cells to target. This 
factor is exacerbated by the immunosuppressive effects of radiation on dendritic cells, 
causing continued release IL-10 and becoming less effective at priming T-cells [256].  
1.6 Microbiome sequencing and analysis 
Sequence analysis pipelines involve data processing (quality control and sequencing 
trimming), analysis and statistical validation. With advances in Next-Generation 




Figure 1.1. The Carlson Curve. Demonstrating the cost of sequencing over time. Image sourced from National Human Genome 
Research Institute (www.genome.gov/about-genomics/fact-sheets/Sequencing-Human-Genome-cost) 
The first sequencing experiments involved fragmenting sequences and transforming 
them into a bacterial artificial chromosome (BAC) to be amplified as the bacterial 
population that contains it multiplies [257]. Alternatively, Sanger sequencing is a low 
throughput method, that involves binding fluorescently tagged nucleotides to a 
template sequence, which are then used to generate a digital sequencing read via 
fluorescence detection [258].  
Using modern NGS techniques, higher throughput options are available. With millions 
of sequence reads being produced from template sequences directly with synthesis-
based methods such as bridge amplification used in Illumina sequencers, or non-
synthesis-based methods like Oxford Nanopore Technologies (ONT) long-read 
sequencing.  
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In this thesis, RNA-Seq was performed using Illumina sequencing, 16S rRNA 
sequencing was performed using amplicon sequencing on an Illumina platform, and 
ONT sequencing was carried out on the GridION 5X. RNA-Seq was used for host and 
microbiome analysis of transcribed genes, while 16S rRNA and ONT sequencing were 
used only to analyse the microbiome. 
1.6.1 Illumina sequencing 
Illumina sequencing has evolved considerably since its inception, with the MiSeq, 
HiSeq and most recently, NextSeq and NovoSeq platforms now available. The principal 
difference between Illumina sequencing and other technologies is the employment of 
bridge amplification [259]. This process involves binding primers to nucleotide 
sequences, which are then attached to adapters that allow binding to a flow cell. The 
sequences are separated into a single strand, and the bound sequences are then 
supplied with raw nucleotides with fluorescent tags, which produce signals when 
incorporated during synthesis. These signals can then be interpreted and recorded as 
the supplied strand is sequenced, which provides a digital sequencing read. The 
synthesised double strand is then separated again, rebound, and sequenced again, thus 
amplifying the original sequence repeatedly. 
1.6.2 Oxford nanopore long-read sequencing 
ONT sequencing is a relatively new, non-synthesis-based method [260]. The reads can 
be up to a million base pairs long; however, they carry an inherently high error rate, 
which is decreasing over time with the introduction of new tools and technology [261].  
New tools for aligning sequences that incorporate ONT reads efficiently are becoming 
more widely available [262-264]. These tools often work a lot faster than traditional 
sequence aligners as the query sequence tends to be much larger unbroken sequence 
and can thus match to fewer places on a reference genome. The errors in ONT reads are 
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most common in homopolymeric repeat regions. Algorithms can be designed to 
compress homopolymeric regions into homopolymer compressed mers (HPC), allowing 
the algorithm to map long reads to a reference very rapidly; however, HPCs reduce 
ONT read sensitivity for some applications [265]. 
1.7 Sequencing techniques and methods 
1.7.1 Amplicon sequencing 
Amplicon sequencing is a process by which a region or sequence of interest is amplified 
exponentially using polymerase chain reaction (PCR) and sequenced at high depth, 
allowing for greater discriminative analysis of a region of interest, such as universally 
conserved genes like 16S rRNA or cpn60 for identifying bacteria and assessing 
phylogenetic relationships [266], or for genotyping analysis [267]. High read depth is 
required for variation analyses to avoid spurious conclusions from sequencing errors, 
with the recommended depth to be approximately 100–300x depending on the sample 
type and the study design. Read depth is essential when analysing single nucleotide 
polymorphisms, where many reads of the same region are required to identify single-
base differences and separate these from potential sequencing errors [268].  
1.7.2 Shotgun sequencing 
Shotgun sequencing is a short read sequencing technique that refers to sequencing all 
available nucleotides in a query sample. As an agnostic method of sequencing, it does 
not use any selection method or selective discrimination, sequencing everything in a 
given sample, thus reducing bias in downstream analyses. However, a downside of this 
method is that the resulting sequencing is less targeted and does not provide control 
over which reads are sequenced, resulting in low read number and depth of regions of 
interest, and a less informative analysis [269]. Shotgun sequencing is used less often 
than amplicon sequencing for microbiomes due to increased computational complexity, 
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reduced microbial specificity (leading to a reduced ability to measure abundance 
accurately), and experiments investigating tissue microbiomes (i.e., tumour biopsies) 
the resulting sequencing data contains mostly host sequences. 
1.7.3 Sequence alignment 
A primary step in genetic analysis of all kinds is alignment. The generated sequence 
reads are mapped or aligned to a reference genome, allowing comparison of the 
sequenced reads and the reference, giving insight into changes between the reference 
and subject for variation analysis. Alignment software can take into account the 
presence of insertions, deletions and fusions with tools like TopHat2 [270], or be built 
for speed, with efficient splice aware alignment such as with STAR which allows RNA 
to be aligned to genomes taking into account the location of intergenic regions [271]. 
ONT sequencing data requires specialised algorithms. One such tool is MiniMap2 
which can leverage the longer read length to quickly map reads to a reference genome 
and tolerate the ~15% error rate that is common in ONT reads, this is because longer 
reads and increased query sizes give the ability to skip over repetitive homopolymeric 
regions more easily [263].  
1.8 Transcriptomics 
RNA sequencing is used to research active gene expression or transcription, a field 
known as transcriptomics. By analysing the RNA present in a sample, researchers can 
discern which genes are being transcribed or are in active use in the sample under 
certain conditions. A standard method of performing gene expression experiments is 
subjecting cells or isolates to different stimuli to determine which genes are expressed 
and in what amount; the method is often used to determine the effects of treatments in 
both in vivo experiments samples taken from case and control patients. Transcriptomics 
requires annotated sequences, assignment of a gene name to identify it and a function, 
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predicted or known via experimentation; RNA function is predicted based on what is 
known about similar sequences [272]. 
The advantage of transcriptomics in studying the microbiome is that it can be used to 
analyse microbial activity and not just abundance; however, this provides additional 
challenges. Bacterial genomes are not always well-annotated and frequently contain 
errors [273]. There is genetic similarity between species and differences within species 
[274], as well as the complicating factor of horizontal gene transfer, which allows 
microbes to express genes that are not originally part of their genome [275], thus 
making discriminating between microbial species using transcriptomics or assigning 
function to transcripts accurately, particularly difficult. 
1.8.1 Gene set expression analysis 
Gene set expression analysis (GSEA) can computationally determine the statistical 
significance of differences between different biological states or phenotypes. Profiles 
built from gene expression data are compared to a gene set database or genome 
annotations to determine which genes are being expressed and at what level. Many 
tools and methods are available for gene expression analysis, such as the GSEA tools 
built by the Broad Institute which utilises the molecular signatures database (MSigDB) 
[276] containing more than 22,500 annotated human genes in the latest release. Other 
commonly utilised databases include gene ontology (GO) [277], the Kyoto Encyclopedia 
of Genes and Genomes (KEGG) [278], and MetaCyc [279]. 
GSEA software first defines a baseline to compare genes by their level of expression, 
then uses increases or decreases from this point to determine the increase or decrease in 
expression of other genes [276]. Differentially expressed genes are given an enrichment 
score and ranked based on how distant from the centre they are. 
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Hypothesis testing by Student’s t-tests, Welch’s t-test, paired t-tests, analysis of variance 
(ANOVA), or linear models are carried out on the results to determine the results' local 
significance. Local significance is a test of the strength of gene associations with the 
phenotype or state, while other methods additionally use global tests, which are used to 
compare the calculated associations, such as Wilcoxon rank-sum, Fisher’s Exact and 
Pearson’s Chi-squared tests [280]. 
1.8.2 Immune infiltration 
Tumour heterogeneity affects not just the genetics of cancer cells but also the cells 
which comprise a tumour. Other cells in the tumour microenvironment include 
fibroblasts, vascular cells, stem cells, adipocytes, pericytes and immune cells [281]. 
Transcriptomics can be used to identify cell types by their associated gene expression, 
which allows the determination of the proportion of tumour cells compared to stromal 
or immune cells in a tumour. Tools such as ESTIMATE provide a score for the 
proportion of different cell types in the tumour microenvironment using gene 
expression data [282].  
Additionally, the different immune cells present can be further scrutinised by profiling 
individual immune cell gene expression to determine the subpopulations of immune 
cells and their level of activity or stage of maturation. Software like xCell [283] and 
CIBERSORT [284] use gene expression data and compare it to databases of gene 
expression profiles associated with different cells, allowing discrimination between 
different immune cell subpopulations, such as M0, M1 or M2 macrophages. 
1.8.3 Transcriptomic analysis tools 
Similar to DNA sequencing, RNA can be aligned to a reference genome or 
transcriptome. RNA alignment can be done effectively for single organisms with Bowtie 
[285], STAR [271], or with BWA (Burrows-Wheeler Alignment) [286], or gene 
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quantification software can be used, such as Salmon [287]. Software specifically 
designed for RNA sequencing is required for alignment, as algorithms need to consider 
features unique to RNA-seq such as splicing, coding regions, and uracil nucleotides, 
which are not present in genomic sequences [288]. Splicing in human RNA is common, 
but not in prokaryotes. Splicing allows a single transcribed RNA to be processed into 
many different forms depending on which introns are excised and thus altering their 
function. Splice aware aligners such as STAR are built to handle the RNA transcripts 
generated from the genome and map them accurately to the reference genome. 
Typically, rRNA depletion is used before sequencing to prevent excessive rRNAs 
sequencing, which would otherwise comprise a substantial proportion of sequencing 
reads than are not phenotypically informative, reducing read depth of informative 
genes. However, this is often an incomplete process and can have drawbacks when 
applying RNA-Seq for microbial identification. 
1.9 Metagenomics 
Metagenomics, is an interdisciplinary field of study for the investigation of microbial 
communities using genetic sequencing, involving methods and concepts from 
immunology [73, 289, 290], microbiology [291], genetics [292, 293], ecological [294] and 
computer science [295, 296]. Many species have proven difficult to culture due to 
undiscovered metabolic and environmental needs, the limitations of culturing for 
microbial identification, lead to research focusing on genetic analysis [297-300]. 
Sequencing the DNA or RNA of microorganisms is a method for studying 
microorganisms culture-free. With advancements in sequencing techniques, such as 16S 
rRNA analysis, transcriptomics and whole-genome sequencing, sequencing has become 
a standard bacterial classification method. Additionally, metabolomics is often used to 
detect and study the metabolites produced in a sample, typically using liquid or gas 
chromatography, to augment metagenomic studies [301].   
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Metagenomic microbiome analyses use the extracted and sequenced nucleotides 
present in a sample to assess the microbial community present [302]. One of the most 
significant hurdles in the field is the data analysis bottleneck, as data is being produced 
much faster than it can be analysed [303]. 
Amplicon sequencing discrete genomic regions can improve the speed of analysis and 
reduce computational requirements by restricting the analyses to the most biologically 
conserved or informative data [303]. Marker genes like 16S rRNA in bacterial and 
archaeal analysis and internal transcribed spacer (ITS) regions for analysis of fungi are 
most often used for taxonomic assignment, as they are well conserved across species 
[304]. Heavily conserved genes can be used to construct phylogenetic relationships 
between organisms using the slowly acquired variability between them, which results 
in a reliable phylum to genus level taxonomy. However, variability in conserved genes 
is often less apparent between species that are more recently evolutionarily separated, 
making precise species identification within metagenomic samples challenging.  
1.9.1 16S rRNA amplicon sequencing 
The 16S rRNA gene is the most commonly sequenced marker in bacterial 
metagenomics, used to measure the abundance of identified microbes. The transcribed 
gene is part of the small ribosomal subunit, the 16S denoting a Svedberg number, 
indicating how quickly it would sediment during ultracentrifugation. Ribosomes are 
present in all species and critical for protein synthesis, making their loss or rapid 
alteration over evolutionary time, unlikely.  
The 16S rRNA gene is useful as it often exists in multiple copies in the genome, 
containing conserved regions critical for function, which flank nine variable regions that 
can tolerate minor changes that can differentiate between organisms based on 
evolutionary divergence. A significant advantage of 16S rRNA sequencing in 
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microbiome metagenomic analysis is that primers are specific to prokaryotes, reducing 
the potential for host sequencing contamination. 
Initially, a technique to separate the 5S rRNA gene by separating it from mixed samples 
with electrophoresis was utilised in the 1980s; a phylogenetic analysis was performed to 
determine the evolutionary distance between sequences. This method proved useful for 
analysing unculturable species from extreme environments, such as hydrothermal vents 
[305]. Using the 120bp region of 5S rRNA had its limitations, as electrophoresis was 
needed to separate the gene from other molecules, limiting the process to low 
complexity samples.  
It was suggested that larger genes could be used to increase the fidelity of the 
technique, such as the 23S rRNA gene; however, at approximately 3000bp, it would be 
time-consuming to analyse [306]. The 16S rRNA gene is approximately half the length 
and was easier to analyse. The initial method involved making a DNA library in 
bacteriophage, allowing them to replicate, and using a 16S rRNA specific probe to select 
clones, which could then be phylogenetically analysed [307]. With PCR, this labour-
intensive process could be sped up by amplifying only the variable regions of interest 
using known priming sites in flanking conserved regions [308, 309]. 
1.9.2 16S rRNA analysis 
The most commonly used tools and pipelines for 16s rRNA analysis are mothur [310], 
UPARSE [311], DADA2 [312], and QIIME [313]. QIIME remains the most common 
despite it being no longer supported by the developer, while its successor QIIME2 is 
available with a graphical user interface, it is more computationally intensive still lacks 
some of the functionality of the original [313, 314].  
R packages can be easily combined with these pipelines, such as data visualisation 
tools, included as part of a pipeline or by linking into other R packages such as ggplot 
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[315], phyloseq [316], and vegan [317]. More recently, Kraken2 has gained support for 
16S rRNA analysis, with the authors suggesting it is faster and more accurate than 
alternatives [318]; however, this has not been independently tested.  
1.9.3 16S classification strategies 
Using the software mentioned above, the primary method for assigning taxonomy to 
16S rRNA data is to cluster variant genomic regions into operational taxonomic units 
(OTUs). These can be constructed de-novo or against a closed reference. An issue with 
de-novo OTU picking is that the resulting OTUs are clustered relative to the others in 
the sample (with a similarity threshold of 3%), further limiting species-level 
identification and making them incomparable between sample sets. Alternatively, 
closed reference OTU picking involves comparing sample sequences to a reference 
database. This approach's downside is that the taxa being investigated must be present 
in the database, and the same reference database used between studies for results to be 
accurately compared [319]. However, the choice of a reference database for comparative 
purposes may lead to the use of inaccurate or out of date databases, such as the widely 
utilised GreenGenes (GG) database, last updated in 2013 [320-323]. 
Amplicon sequence variants (ASVs), produced by DADA2 and qiime2 [324] were 
developed to overcome the shortcomings of OTU picking [319]. They use no arbitrary 
dissimilarity threshold. They infer the biological reality in the sample before sequencing 
and take into account amplification errors. Studies show that ASVs can be more 
sensitive than OTU picking and better discriminate between ecological patterns in the 
environment [312, 325]. ASVs provide a higher resolution taxonomy assignment due to 
distinguishing between single nucleotides, rather than by overall sequence similarity 
[326], allowing more reliable assigning of sequences to the species level [327]. ASVs can 
also be used in other analysis pipelines, such as QIIME, where feature tables can be 
populated with ASVs in place of OTUs.  
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1.10 Metagenomic shotgun sequencing 
Metagenomic shotgun sequencing has advantages over 16S rRNA amplicon sequencing 
in that it can produce longer reads that are more useful for species detection and gene 
prediction [328]. Also, host DNA in a sample can be used to genotype the host at the 
same time as the microbial component, allowing for the simultaneous assessment of 
host-microbiome combinatorial phenotypes [329, 330], assuming appropriate read 
depth can be achieved.  
Colonisation potential, drug interactions, the presence of pathogens and polymicrobial 
signatures can be investigated, which can inform diagnosis, treatment, probiotic and 
prebiotic applicability. Additionally, discriminating between host and microbial reads 
bioinformatically is preferable to enriching the microbial community and remove host 
sequences before sequencing, which may introduce bias to the analysis [329, 331-333]. 
1.10.1 Taxonomic assignment with shotgun sequencing data 
With massive datasets being produced more routinely, more efficient methods for 
processing data are needed. Utilising k-mers makes it possible to use data containing 
sequences from multiple organisms and rapidly classify them. Many k-mer based 
classification tools are available for metagenomics, including 16s rRNA data [334] and 
single-threaded options [335]. One of the most popular options is Kraken [336]. While 
the Kraken successor, Centrifuge, was faster and required lower computational 
resources due to database compression, it had lower accuracy [337] and was ultimately 
superseded by Kraken2 [338].  
The major hurdle with k-mer based metagenomic classification is constructing 
databases, as publicly available databases are often generalised or severely out of date. 
Construction of a custom database requires more computational resources than are 
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required to utilise them; this requirement increases with the number of taxa used in an 
index, leaving them out of reach for many researchers [339].  
1.10.2 Meta-transcriptomics 
16S rRNA amplicon sequencing is used to answer questions of microbial abundance, 
‘How represented are microbes in the community?’, while meta-transcriptomics is used 
to measure the activity of microbes, ‘What are these microbes doing?’. Transcriptomics 
is used to infer what proteins are produced in a cell, in different environments or 
conditions [272]. Protein-coding genes are well enough conserved to allow for high-
resolution taxonomic assignment with RNA-Seq data [340].  
Software that can be used for this classification type are DIAMOND [338] and Kaiju 
[339], rapidly assigning sequences to taxa using translated protein databases. For 
instance, Kaiju has the advantage of providing accession numbers for the gene/protein 
of the aligned sequence, if the associated reference has been annotated, allowing for 
gene expression analysis at a community level. However, annotation of prokaryote 
genomes is incomplete and sometimes unreliable due to lineage trends [341], leading to 
homology-based automated annotation using software such as Prokka resulting in 
significant hypothetical proteins and unannotated regions [342, 343].  
1.11 Thesis hypotheses and aims 
This thesis's main aims were to investigate the bacterial and host factors associated with 
chemoradiotherapy outcomes and determine which could be used as predictive 
prognostic indicators. 
My hypotheses are that: 
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(i) Residual host reads interfere with the accuracy of taxonomic assignment 
in tissue microbiome analysis. 
(ii) Microbiomes influence host response to chemoradiotherapy; the with 
microbiomes differing between response groups. 
(iii) Bacteria are differentially abundant and have differential gene expression 
in different response groups, and their and gene expression impacts 
therapeutic outcomes. 
(iv) Immune cell infiltration significantly contributes to therapeutic outcomes, 
and the microbiome influences this immune infiltration. 
(v) In combination with host gene expression, immune cells and bacterial 
expression can be used as prognostic and predictive biomarkers of 
chemoradiotherapy response. 
 
To test these hypotheses, using a cohort of rectal tumours and adjacent normal tissue 
samples collected before chemoradiation therapy, this thesis aims to: 
(i) Improve methods for microbial assignment and database construction. 
(ii) Compare sequencing technologies for their applicability in microbiome 
analysis. 
(iii) Examine microbial gene expression using RNA-sequencing to identify 
taxa that may influence response to CRT in RC. 
(iv) Investigate immune cell infiltration in rectal tumours and relate this to the 
microbial abundance, microbial gene expression, and therapeutic 
response. 
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(v) Investigate the utility of the above factors in combination with patient 
gene expression to discover potential biomarkers of response to CRT. 
2 CHAPTER 2: METHODS 
2.1 Summary  
First, to validate method alterations, a synthetic dataset with known contents was used, 
and clinical RNA-Seq and Oxford Nanopore Technology (ONT) datasets were then 
used to determine the alterations' impact in a real-world context. Second, sequencing 
samples' comparative ability to assess the microbiome was assessed by sequencing 
samples RC patient tumour and normal tissue biopsies. The concordance of the relative 
bacterial abundance of taxonomies from the 16S rRNA, ONT and RNA-Sequencing 
platforms were assessed and measured using the altered methods.  
Third, the RNA-Seq data from the RC patient samples were used to evaluate and 
correlate bacterial transcription with chemoradiotherapy response. Fourth, RNA-Seq 
gene expression data was used to estimate the abundance of immune cells in patient 
biopsies. Then, the predicted immune cell abundance was correlated with response to 
radiotherapy and bacterial transcription. 
Finally, a panel of biomarkers was established by using sparse partial least squares 
regression. The biomarkers were refined during the development of a machine learning 
model to predict response to radiotherapy using bacterial transcription, immune cell 
abundance and gene expression. 
2.2 Ethics  
Informed written consent was given for the collection of tissues, and this study adheres 
to the relevant guidelines and regulations of the Health and Disability Ethics 
Committee (HDEC) and the University of Otago Human Ethics Committee (ethics 
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approval number: 18/STH/40), Māori consultation took place between Dr Purcell 
(primary supervisor) and the Māori Research Advisor, Karen Keelan, through the 
University of Otago, Christchurch Māori consultation process. A letter of support for 
the project was provided by Karen Keelan.  
2.3 Synthetic dataset 
The synthetic dataset consisted of RNA-sequencing (RNA-Seq) data from the NCBI 
read sequencing archive. Bioproject PRJNA588285, SRA: SRR10417449 and Bioproject 
PRJNA589694, SRA: SRR10445802 were accessed for both a human cell line (TPC-1, 
human papillary thyroid carcinoma) and Pseudomonas fluorescens sequencing reads, 
respectively. Both projects utilised Illumina 150 bp paired-end RNA-sequencing (RNA-
Seq) on the HiSeq X Ten platform. The human reads were concatenated with the P. 
fluorescens reads yielding the synthetic dataset, containing 31,233,071 and 9,590,255 
human and bacterial reads (23.49% bacterial and 76.5% human). The synthetic dataset 
was built by concatenating reads between the two read sets using the cat command. 
2.4 CRC cohort 
The CRC RNA-seq dataset (CRC-RNA) was taken from the repository of Visnovska et 
al., SRA: SRP117763, Bioproject PRJNA404030. An Illumina HiSeq 2500 was used to 
produce 125 bp paired-end RNA-seq reads from 33 CRC patients [344].  
2.5 RC cohort 
Rectal tumour samples and adjacent normal tissue were collected from 20 RC patients 
at Christchurch Hospital, New Zealand (CHCH). An additional cohort of 20 matched 
patient samples came from the Peter MacCallum Cancer Institute of Melbourne (PM), 
Australia. The PM cohort consisted of RNA samples extracted from patient tumour and 
adjacent tissue samples and is referred to as the PM cohort. All biopsies were collected 
prior to the commencement of treatment via colonoscopy or rectoscopy. 
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2.5.1 Metadata and cohort details 
Patient data were collected from the CHCH cohort medical records. All data was 
anonymised while age, sex, and information on disease status were collected (Table 2.1); 
however, only post-operative pathology reports were available for the PM cohort.  
Table 2.1. Demographics and tumour regression of combined Rectal Cancer (RC) cohort 
 Patients (n) 
Age  
32–86 years  











Lymphovascular invasion 13 






Patient medical records for the CHCH cohort were available (Table 2.2); however, the 
supplied metadata for the PM cohort was less comprehensive (Table 2.3). Patients 
received 5-FU based neoadjuvant chemoradiotherapy over the weeks before surgery. 
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Table 2.2. Christchurch cohort patient details 
Patient # Treatment RT dose Dworak Sex Age Tumour Size Metastasis Staging Biopsy date Differentiation 
1 LCCRT (capecitabine) 50.4 gy Four M 74 40 mm N T3N0M0 14/3/2018 Moderate 
2 LCCRT (capecitabine) 50.4 gy Three M 64 53 mm N T3dN2M0 2/07/2018 Well 
3 LCCRT (capecitabine) 50.4 gy One M 70 40 mm N T3N0M0 3/02/2018 Poor 
4 LCCRT (capecitabine) 50.4 gy Two M 59 32 mm Liver T4aN1M1 30/4/2018 Moderate 
5 LCCRT (capecitabine) 50.4 gy Four F 78 47 mm Lung T3N1M1 6/11/2018 Moderate 
6 LCCRT (capecitabine) 50.4 gy Four M 63 66 mm N T4aN0M0 6/11/2018 Moderate 
7 LCCRT (capecitabine) 50.4 gy Three M 65 53 mm N T3N2M0 19/3/2018 Well 
8 LCCRT (capecitabine) 50.4 gy Two F 50 50 mm N T3bN0M0 23/7/2018 Moderate 
9 LCCRT (capecitabine) 50.4 gy Two M 67 27 mm N T2N0M0 30/7/2018 Moderate 
10 LCCRT (capecitabine) 50.4 gy Two F 61 45 mm N T3bN1M0 8/01/2018 Moderate 
11 LCCRT (capecitabine) 50.4 gy Two M 75 75 mm N T4aN0M0 9/07/2018 NA 
12 LCCRT (capecitabine) 50.4 gy Two F 66 51 mm N T4N1M0 24/9/2018 Moderate 
13 LCCRT (capecitabine) 50.4 gy Four M 57 54 mm N T3N0M0 24/9/2018 NA 
14 RT 40 gy One M 80 42 mm N T3aN0M0 28/9/2018 NA 
15 LCCRT (capecitabine) 50.4 gy Three M 58 50 mm N T3N0M0 7/11/2018 Moderate 
16 LCCRT (capecitabine) 50.4 gy One F 73 60 mm N T3N1M0 13/12/2018 Moderate 
17 LCCRT (capecitabine) 50.4 gy One M 74 40 mm N T2N1M0 4/02/2019 Moderate 
18 LCCRT (capecitabine) 50.4 gy Two M 66 60 mm N T3N2M0 30/5/2019 Moderate 
19 LCCRT (capecitabine) 50.4 gy One M 76 80 mm N T4aN2M0 7/07/2019 Moderate 
20 LCCRT (capecitabine) 50.4 gy Two F 86 60 mm N T4bN2M0 9/08/2019 Moderate 
LCCRT: Long course chemoradiation therapy; RT: Radiation therapy; gy: gray unit; N: No; NA: Not Available; M: Male; F: Female 
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Table 2.3. Peter MacCallum cohort patient details 
Patient # Treatment RT dose Dworak Sex Age Differentiation 
21 LCCRT (capecitabine) 50.4 gy Three M 58 Moderate  
22 LCCRT (5-FU) 50.4 gy Two M 84 Moderate  
23 LCCRT (5-FU) 50.4 gy Four M 60 Moderate  
24 LCCRT (FOLFIRI) 50.4 gy Two M 62 Moderate  
25 LCCRT (NA) 50.4 gy Two M 39 Poor  
26 LCCRT (capecitabine) 50.4 gy Two M 62 Moderate  
27 LCCRT (capecitabine) 50.4 gy One M 44 Moderate  
28 LCCRT (capecitabine) 50.4 gy Two F 61 Moderate  
29 LCCRT (capecitabine) 50.4 gy One F 34 Moderate  
30 LCCRT (NA) 50.4 gy Two F 35 Moderate/Poor  
31 LCCRT (5-FU) 50.4 gy Two M 65 Moderate  
32 LCCRT (FOLFOX) 50.4 gy Two M 81 Moderate  
33 LCCRT(NA) 50.4 gy Two M 85 Moderate  
34 LCCRT (capecitabine) 50.4 gy  Two F 53 Moderate  
35 LCCRT (NA) 50.4 gy Two M 32 Moderate  
36 SCCRT (NA) 25 gy Two M 69 NA 
37 LCCRT (capecitabine) 50.4 gy Two M 75 Moderate  
38 LCCRT (FOLFIRI) 50.4 gy Two F 53 Moderate  
39 LCCRT (NA) 50.4 gy Three M 62 NA  
40 LCCRT (capecitabine) 50.4 gy Three F 69 NA 
LCCRT: Long course chemoradiation therapy; SCCRT: Short course chemoradiation RT: Radiation therapy; gy: gray 
unit; N: No; NA: Not Available; M: Male; F: Female 
 
The majority of patients receiving 50.4 gy of radiation throughout treatment, except for 
one patient receiving palliative therapy (40 gy) and another receiving short course (25 
gy). The age of patients ranged from 32–86 (mean = 63.5, median = 64.5), the cohort was 
30% female.  
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2.6 Nucleic acid extraction and sequencing 
2.6.1 Nucleic acid extraction 
The CHCH patient samples had both DNA and RNA extracted from tissue samples. 
The nucleotides were extracted from approximately 20 mg of tissue. Each of the tumour 
and matched normal biopsies were homogenised in a Precellys Evolution Homogenizer 
(Bertin Instruments, Montigny-le-Bretonneux, France), using zirconium beads and lysis 
buffer (Buffer RLT Plus, QIAGEN, Hilden, Germany). DNA and RNA were extracted 
using a QIAGEN Allprep DNA/RNA Mini Kit. Resulting DNA was quantified using a 
Qubit 2.0 instrument (Invitrogen, Carlsbad, CA, USA), and the DNA and RNA were 
quantified and Nanodrop 2000c spectrophotometer (Thermo Scientific, Asheville, NC, 
USA). The PM patient samples were previously extracted from tissue samples using the 
same method.  
2.6.2 GridION sequencing 
Size selection to 400 bp was performed on each of the samples, using a 0.45x volume of 
MAGBIO HighPrep magnetic beads (Gaithersburg, Maryland, USA). The Oxford 
Nanopore protocol (RBK_9054_v2_revD_23Jan2018) was followed for DNA sequencing 
using the SQK_RBK004 rapid kit. For each sample, triplicates of 400 ng genomic DNA 
were used, each had the volume adjusted to 7.5 µl with nuclease-free water, and 2.5 µl of 
barcode fragmentation mix added. The samples were incubated in a thermal cycler at 
30 °C for 1 minute and 80 °C for 1 minute. The barcoded samples were then pooled, and 
DNA was purified using AMPure XP beads and resuspended in 10 µl of 10 mM Tris-HCl 
pH 7.5 with 50 mM NaCl. Then, 1 µl of RAP (Rapid sequencing AdaPtor) was added to 
the barcoded DNA. The resulting libraries were loaded onto R9.4.1 (106) flow cells in 
groups of four and sequenced for 48 hrs. Base-calling was carried out using Guppy v3.0.3 
(Oxford Nanopore Technology developer access required). Porechop v0.2.3 
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(https://github.com/rrwick/Porechop) was used for demultiplexing, and barcode and 
adaptor removal.  
2.6.3 16S rRNA sequencing 
For each sample, 10 ng of DNA was used to prepare libraries that were sent for 16S 
rRNA amplicon sequencing by the Massey Genome Service (Massey University, New 
Zealand). The V3 to V4 regions of the 16S rRNA gene were amplified flanking primers: 
16SF_V3: 5′-TATG GTAATTGGCCTACGGGAGGCAGCAG-3′ and 16SR_V4: 5′-
AGTCAGTCAGCCGGACTACHVGGGTWTCTAAT -3′). Libraries were prepared using 
the Illumina MiSeq 500 cycle Kit (V2), and sequencing was performed with PhiX control 
sequences.  
2.6.4 RNA sequencing 
RNA-sequencing was performed on the NovoSeq 6000 platform by Novogene 
(Singapore) using the Illumina V2 library prep. Ribo-ZeroTM Magnetic Kit (Illumina) 
was used to deplete rRNA from the samples. Unstranded libraries were created using 
the following primers: 
5' Adapter: 5'-
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCG




2.7.1 Quality control 
Sequencing data were quality controlled with FastQC [345] and trimmed using bbduk2, 
part of the BBTools suite [346]. For RNA-seq and 16S rRNA amplicon data, only reads 
with a length < 50bp with a quality of 20 or greater and reads that had matching pairs 
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were kept for further processing while adapters and PhiX sequences were removed. 
Oxford nanopore reads were filtered for lengths > 400bp using FiltLong v0.2.0 
(https://github.com/rrwick/Filtlong).  
2.7.2 Host mapping 
RNA-Seq and GridION data were mapped to the GRC38p12 human genome using STAR 
v2.6.1 [271] and Minimap v2.16-r922 [347], respectively. Resulting sam files were 
converted to bam files, separated into human mapped and unmapped reads, and sorted 
using samtools v1.9 [348]. For taxonomic assignment analysis, only unmapped reads 
were retained unless otherwise specified, and additionally for RNA-seq and 16S rRNA, 
only matched paired-reads were retained. Bam files were converted into fastq files with 
bedtools v 2.26.0 [349]. 
2.7.3 Microbiome analysis 
Taxonomic assignment was performed using Kraken2 [350] using customised 
databases. For the taxonomic assignments, a database containing all complete 
assemblies for bacteria, fungi, protists and archaea, as well as the human genome 
(GRCh38p12) was used, termed All_DB (database contents can be found in 
Supplementary Table S2.1). Additionally, the database contained several taxa, 
regardless of the level of assembly completion, associated with CRC. The bacterial 
database (Bac_DB) contained only bacterial genomes, including those associated with 
CRC (database contents can be found in Supplementary Table S2.2). Taxonomic 
databases were constructed on 19 July 2019. Kraken reports were analysed using Pavian 
[351] and transformed into biom format using kraken-biom 
(https://github.com/smdabdoub/kraken-biom). Biom files were analysed using phyloseq 
v1.32 [316], vegan v2.5 [352], and ape v5.4 [353] R packages, and visualised with ggplot2 
v3.3.2 [315] and ggpubr v0.4 packages. 
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2.7.4 Gene quantification and expression data 
Gene quantification data were generated using Salmon. Reads were mapped to the 
human transcriptome using Salmon v1.2.1 [287]. First, a decoy transcriptome was 
constructed from the human transcriptome (GRCh38p12) to reduce low confidence 
mapping of reads to unannotated loci with sequence similarity to annotated regions 
[354]. An index of the transcriptome was constructed from the transcriptome and the 
decoy information, using an auxiliary k-mer hash over k-mer length of 31. The index 
was used for quasi-mapping of RNA-Seq paired-end reads to the human transcriptome 
with a mapping validation score of 30, based on fragment lengths and their level of 
direct mapping to a region; reads with lower mapping scores were discarded. Gene 
count results were visualised with the Integrative Genomic Viewer (IGV) [355] and 
ggplot2 [315]. 
2.7.5 Cellular estimation, prediction and subtyping 
The ESTIMATE [282] package was used to generate predictive tumour purity, immune 
and stromal scores from RNA-Seq gene expression data. CIBERSORT [284] was used to 
estimate the level of immune cell infiltration from RNA-Seq gene expression data. 
2.7.6 Functional and differential analysis 
Reads assigned to bacterial species using Kraken2 were extracted using the 
extract_kraken_reads script in the KrakenTools GitHub repository 
(https://github.com/jenniferlu717/KrakenTools). Extracted reads from assigned bacterial 
taxonomies were aligned to respective genome assemblies using STAR v2.6.1 [271] 
without splice aware alignment. Differential analysis was performed using edgeR [356]. 
Patient identifiers were used as blocking factors in a generalised linear model with 
likelihood testing.  
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2.7.7 Correlations 
Correlations were performed using Spearman’s rank correlation, and point biserial 
correlation using the cor, cor.test, ltm v1.1 [357], and Hmsic v4.4 R packages, using p-
value and false discovery rate correction (FDR) cuttoffs of 0.05, while Benjamini and 
Hochberg [358] was used for false discovery rate (FDR) correction. 
2.7.8 Biomarker analysis 
For the discovery of prognostic biomarkers, microbial taxonomy, immune cell 
infiltrates, and gene expression data were used. A predictive model was built to assess 
the data points most informative of therapeutic outcomes utilising a multi-block 
discriminant analysis, using the mixOmics package v6.12.2 DIABLO (Data Integration 
Analysis for Biomarker discovery using a Latent cOmponents) framework [359]. The 
model's inputs included data from both the normal and tumour tissue gene expression, 
immune cell infiltration, and microbiome data, and a pairwise patient blocked study 
design to mitigate interpersonal variation [360]. The cohort was split into training and 
test datasets, and leave-one-out validation was used to assess error rates. 
2.8 Code availability 
All scripts, supplementary files and R code used can be found on the GitHub 
repository: https://github.com/William-S-Taylor/MSc  
3 CHAPTER 3: METHODOLOGY AND PLATFORM COMPARISONS 
3.1 Introduction 
The gut microbiome and its relationship to human health and disease is an area of 
increasing research. Microbiome composition has been associated with diarrhoea [361], 
developmental disorders [362], immune system changes [290], Crohn’s disease [363], 
psychological disorders [364], irritable bowel disease [365], and CRC [366] the latter of 
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which has a high mortality (9.2% of all cancer deaths in 2018) and increasing global 
incidence (10.2% of all diagnosed cancers in 2018) [367, 368]. Despite this, the 
assessment of microbiomes in a clinical setting is not widely practised due to the lack of 
access to sequencing technology and clinical training for interpreting microbiome data 
[369]. Sampling, library preparation, and sequencing can be expensive and time-
consuming, reducing the feasibility of using the microbiome in clinical settings [303, 
370]. 
When performing metagenomic studies using tissue samples without a bacterial 
selection step, host reads may be misassigned as microbial. To counteract this, reads are 
first mapped to the host genome, and unmapped reads are then classified using a 
bacterial taxonomic database [93, 371]. Mapping the sequencing datasets to the host 
genome before classification is the most time-consuming and computationally intensive 
step of the taxonomic analysis, particularly with increasingly large datasets and host 
organism genomes. 
This chapter consists of two analyses. First, the efficacy of host genome mapping was 
investigated using three different datasets: Oxford Nanopore Technology (ONT) data 
from the CHCH cohort, RNA-Seq data from a CRC cohort from [371], and a synthetic 
RNA-Seq dataset. Taxonomic assignment was performed with Kraken2 and the 
taxonomic databases listed in Section 2.6.3, the Bac_DB and All_DB. Secondly, the three 
platform datasets from the CHCH cohort (16S rRNA, ONT and RNA-Seq) were 
compared using the methods employed in prior CRC tissue studies [93, 371], with 
alterations from the results of Analysis 1.  
My hypotheses for this chapter were as follows: 
- If a taxonomic classifier can be relied on to discriminate between different 
bacteria, it can also be relied upon to classify the host, thereby reducing the steps 
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required for microbiome analysis of patient samples while giving proportional 
information of the sample's microbial content.  
- The host mapping process may lead to increased type 1 classification errors, as 
residual host sequences may be misassigned as microbial. 
- Appropriately classifying residual host reads will improve inter-platform 
concordance. 
3.2 Methods 
Taxonomic assignment was performed using 0.1 confidence scores in Kraken2 v 2.0.7 
unless otherwise specified. The CRC-RNA dataset was comprised of CRC patient data 
(n = 33) from a previous study as described in Section 2.4 [344]. The Rec-ONT dataset 
was comprised of the CHCH cohort samples (n = 20) GridION sequencing data. 
Filtering was performed on the CRC-RNA and Rec-ONT datasets, and to remove any 
assignments with two or fewer counts. ONT, 16S rRNA and RNA sequencing data were 
prepared, and quality checked, as described in Sections 2.5 and 2.6. The R packages 
Pavian v1.0 [351], phyloseq v1.28 [316], VEGAN v 2.5 [352], ggplot2 v3.2.1 [315], stats 
[372] and Venny v2.1 [373] were used to evaluate and visualise the results. Scripts used 
for the analysis can be found here: https://github.com/William-S-Taylor/MSc.  
3.2.1 Statistics 
Statistical operations were performed using R version 3.6. The statistical significance 
between the differences in databases and mapping methodologies were tested using 
Wilcoxon signed-rank tests. The beta-diversity was tested using the adonis function in 
the VEGAN package. Concordance between platforms was investigated using the 
methodology used in [93] and [371], where Spearman’s rank correlation was utilized for 
comparing the level of concordance between different platforms. The stats package was 
used to assess the significance of platform concordance.  
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3.3 Analysis 1: mapping methodology 
3.3.1 Synthetic database 
To establish the effect of host mapping on taxonomic assignment, a large synthetic 
dataset with known bacterial and human content was created (the Synth dataset). The 
Synth dataset consisted of 31 million human and 9.5 million bacterial RNA-Seq paired-
end reads, generated using the same Illumina HiSeq X Ten sequencing platform (see 
Section 2.2). The resulting database was 23.49% bacterial, and 76.5% human (Figure 
3.1a). The reads were either mapped or not mapped against the human genome, and 
subsequently assigned taxonomy using the bacteria only database (Bac_DB) and a 
comprehensive database containing the human genome (All_DB). 
 
Figure 3.1. Classification of bacterial and human reads in the synthetic dataset. a) percentage of reads assigned, b) total numbers 
of reads assigned. All_DB, human genome containing database; Bac_DB, non-human genome containing database. 
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Using the All_DB with prior mapping to the human genome was the most accurate in 
its taxonomic assignment, assigning 2.52% more reads as bacterial than were present, 
followed by using the All_DB without prior mapping at 2.57%, while residual human 
reads not removed by mapping accounted for 11.23% of the post-mapped dataset. 
Using the All_DB and no prior host mapping, the eukaryotic and bacterial proportions 
were accurately assigned with a 0.74% difference between the assigned and expected 
values (Figure 3.1b). Using the Bac_DB, the number of assigned bacterial reads 
increased compared to using the All_DB by 5.6% and 24.8% with and without mapping, 
respectively. Using the Bac_DB and host mapping, there were 7.69% more bacterial 
assignments than existed in the sample, and 26.76% more without host mapping (Figure 
3.1b).  
Assigning taxonomy with the Bac_DB with prior mapping had a three-fold lower 
accuracy compared to the All_DB. Based on the findings from the Synth dataset, it was 
theorized that using the All_DB on other datasets with prior mapping would be the 
most accurate, deviating by ~2.52% and ~2.57%, with and without host mapping, 
respectively.  
3.3.2 Analysis time 
Using the Synth dataset, mapping to the human genome, removing host reads using 
samtools and converting the resulting bam files into fastq files required 1 hour, 10 min 
and 10 seconds of compute time, and subsequent taxonomic classification of those 
unmapped reads with the Bac_DB took 1 min and 15 seconds; totalling 1 hour, 11 
minutes and 25 seconds of compute time. Using the All_DB for taxonomic classification 
with no prior mapping, required 7 min and 27 seconds of compute time. Classification 
and mapping were carried out on a server with an Intel® Xeon® CPU E5-2683 v4 @ 
2.10GHz CPU with 32 cores and 250 GB RAM, running Ubuntu 18.04.3 LTS. 
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Classification time was higher when using the All_DB and no host mapping; however, 
when employing host mapping and the Bac_DB, compute time increased significantly, 
by 9.53-fold (Wilcoxon test p-value = 0.01, 95% confidence intervals (CI): 75.94–1441.64). 
3.3.3 Clinical Datasets 
Using CRC-RNA and Rec-ONT datasets from clinical tissue biopsies, taxonomic 
assignment was compared using the All_DB and the Bac_DB, with and without host 
mapping. 
Using the CRC-RNA dataset, there were a higher number of bacterial assignments in 
each sample using the Bac_DB database than with the All_DB (Table 3.1). There was a 
total bacterial read increase of more than 40% when using the Bac_DB database 
compared to using the All_DB database, with a difference of more than 41,000 bacterial 
reads, regardless of prior host mapping (Wilcoxon p-value = 0.0001, CI: 718–1702).  
Table 3.1. CRC-RNA taxonomic assignment 
 
Mapped Not mapped 
 All_DB Bac_DB All_DB 
Bacterial Percentage 13.05% 100% 2.17% 
Eukaryotic Percentage 86.95% 0% 97.83% 
Total Bacterial Reads 102,450 144,449 102,694 
Total Eukaryotic Reads 682,865 0 4,628,480 
 
Using the All_DB, there were 244 more bacterial reads when host mapping was not 
used; however, this was not statistically significant (Wilcoxon p-value = 0.7275, CI: -3.31 
× 106–5.65 × 105). The difference in bacterial reads assigned with the All_DB compared to 
the Bac_DB was over 40,000, and was significant, with (Wilcoxon p-value < 2.2 × 1016, CI: 
3.99–4.00) or without host mapping (Wilcoxon p-value < 2.2 × 1016, CI: 3.99–4.00). 
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The Rec-ONT DNA dataset had more samples with lower read counts. When using the 
All_DB, there were 545 more bacterial reads when host mapping was not used (Figure 
3.2); however, the difference was not statistically significant (Wilcoxon p-value = 0.9132, 
CI: -3.83 × 105–4.39 × 105).  
Table 3.2. Rec-ONT dataset taxonomic assignment 
 
Mapped Not Mapped 
 
All_DB Bac_DB All_DB 
Bacterial Percentage 3.74% 100% 0.25% 
Eukaryotic Percentage 96.26% 0% 99.75% 
Total Bacterial Reads 34,159 253,172 34,704 
Total Eukaryotic Reads 879,766 0 13,818,571 
 
The difference in bacterial reads assigned with the All_DB compared to the Bac_DB was 
greater than 218,000, and was significant, with (Wilcoxon p-value < 2.2 × 1016, CI: 8.00–
8.99) or without host mapping (Wilcoxon p-value < 2.2 × 1016, CI: 7.99–8.99). When 
assigning taxonomy to the RNA-CRC and Rec-ONT datasets with the All_DB, the 
number of bacterial reads differed by 244 (0.24%), and 545 (1.57%), when prior-host 
mapping was and was not performed, respectively. Additionally, reads assigned to 
Eukaryotes provided information on the samples' relative host content and the 
proportion of residual reads. 
3.3.3.1 Alpha and beta diversity 
The bacterial diversity of the CRC-RNA and Rec-ONT datasets was assessed to 
investigate the impact of host mapping. All reads not assigned bacterial taxonomy, or 
taxa with fewer than two reads assigned were removed before analysis.  
In CRC, the distribution of microbiota in the colon differs depending on location [374]. 
Using the CRC-RNA dataset, diversity was compared between left- and right-sided 
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tumours using observed diversity (richness of the sample), and the Shannon and 
Simpson diversity indexes (measures of evenness and dominance, respectively).  
When using the All_DB, alpha diversity did not change significantly regardless of host 
mapping (Figure 3.2). When using the Bac_DB, alpha diversity was higher compared to 
using the All_DB, with more than double the observed mean diversity when using prior 
host mapping.  
 
Figure 3.2. Alpha diversity measures for comparison of left- and right-sided tumours in the CRC-RNA dataset: a) using the 
All_DB and no prior host mapping, b) using the All_DB and prior host mapping, and c) using the Bac_DB and prior host 
mapping. Outliers are represented in grey. ns: not significant; ***: p <= 0.001; ****: p <= 0.0001. 
There was no statistically significant difference in the mean microbial diversity when 
using the All_DB regardless of prior host mapping (Table 3.3). Differences in mean 
diversity were statistically significant when using the All_DB compared to the Bac_DB, 
except for the Simpson diversity index.  
Table 3.3. CRC-RNA diversity Wilcoxon signed-rank test results 
 
Not Mapped All_DB vs 
Mapped Bac_DB 
Mapped All_DB vs 
Mapped Bac_DB 
Mapped vs not Mapped 
All_DB 
 
p-value 95% CI p-value 95% CI p-value 95% CI 
Observed 2.11 × 109 129–189 2.39 × 109 127–186 0.717 -27–23 
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Shannon 6.30 × 105 0.231–0.639 1.50 × 104 0.21–0.611 0.674 -0.258–0.205 
Simpson 0.382 -0.007–0.022 0.500 -0.008–0.02 0.704 -0.017–0.015 
95% CI: 95% confidence interval. 
When comparing the alpha diversity differences between left- and right-sided tumours 
within the CRC-RNA dataset, no measure was statistically significant (Figure 3.3). 
 
Figure 3.3. Alpha diversity measures for comparison of left and right side tumours within the CRC-RNA dataset: a) using the 
All_DB and no prior host mapping, b) using the All_DB and prior host mapping, and c) using the Bac_DB and prior host 
mapping. Outliers are represented in grey. ns: not significant. 
Using the Rec-ONT dataset, the impact of mapping on the diversity between tumour 
and matched normal tissue microbiomes was investigated.  
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Figure 3.4. Alpha diversity measures for comparison of tumour and normal tissues in the Rec-ONT dataset: a) using the All_DB 
and no prior host mapping, b) using the All_DB and prior host mapping, and c) using the Bac_DB and prior host mapping. 
Outliers are represented in grey. ns: not significant; **: p <= 0.001; ***: p <= 0.001; ****: p <= 0.0001. 
Host mapping when using the All_DB had little impact; however, there was a 
substantial difference between using the All_DB and Bac_DB (Figure 3.4). There was no 
statistically significant difference in any diversity measure if prior host mapping was or 
was not performed when using the All_DB; however, the differences between using the 
All_DB and Bac_DB were statistically significant (Table 3.4). 
Table 3.4. Rec-ONT diversity Wilcoxon signed-rank test results 
 Not Mapped All_DB vs Mapped 
Bac_DB 
Mapped All_DB vs Mapped 
Bac_DB 
Mapped vs not Mapped 
All_DB 
 p-value 95% CI p-value 95% CI p-value 95% CI 
Observed 9.13 × 1014 635–849 9.80 × 1014 635–848 0.873 -27–25 
Shannon 9.74 × 109 0.764–1.473 1.12 × 108 0.793–1.44 0.969 -0.415–0.390 
Simpson 0.0003 0.025–0.0836 0.0001 0.0255–0.0813 0.892 -0.035–-0.035 
 
When comparing the alpha diversity of tumour and normal tissues, only observed 
diversity differences were statistically significant (p < 0.05), regardless of mapping or 
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the database used (Figure 3.5). However, the p-value was six-fold lower when using the 
Bac_DB. 
 
Figure 3.5. Alpha diversity measures for comparison of tumour and normal tissue within the Rec-ONT dataset: a) using the 
All_DB and no prior host mapping, b) using the All_DB and prior host mapping, and c) using the Bac_DB and prior host 
mapping. P-values < 0.05 are considered significant. 
Beta-diversity was investigated using non-metric multi-dimensional scaling (NMDS) of 
Bray–Curtis distances for the CRC-RNA and Rec-ONT datasets. The side and tissue 
effect on the clustering of samples was tested using the adonis2 function in the VEGAN 
package. 
When using the All_DB, the impact of host mapping on the clustering of left- and right-
sided tumours in CRC-RNA dataset was insignificant (Figure 3.6a,b); however, using 
the Bac_DB resulted in a tight clustering of left-sided tumours (Figure 3.6c). 
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Figure 3.6. Bray–Curtis clustering of left- and right-sided tumours in the CRC-RNA dataset: a) using the All_DB and no prior 
host mapping, b) using the All_DB and prior host mapping, and c) using the Bac_DB and prior host mapping. 
 
The effect of side on the clustering of samples was statistically significant when using 
the All_DB and not when using the Bac_DB while the R2 value was similar regardless 
of the database used (Table 3.5). 
Table 3.5. Effect of side on CRC-RNA dataset 
Side All_DB mapped All_DB not mapped Bac_DB mapped 
R2 0.049 0.050 0.052 
Residuals 0.950 0.949 0.947 
p-value 0.037 0.043 0.085 
 
When using the Rec-ONT dataset, the impact of host mapping on the clustering of 
samples by tissue type was minor; however, tumour samples were more closely 
clustered than normal samples when using the Bac_DB and host mapping, which also 
resulted in substantive outliers (Figure 3.7). 
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Figure 3.7. Bray–Curtis clustering of normal and tumour tissues in the Rec-ONT dataset: a) using the All_DB and no prior host 
mapping, b) using the All_DB and prior host mapping, and c) using the Bac_DB and prior host mapping. 
Although the effect was slightly higher using the Bac_DB, the effect of tissue type was 
not statistically significant in the Rec-ONT dataset (Table 3.6). 
Table 3.6. Effect of tissue in Rec-ONT dataset 
Tissue All_DB mapped All_DB not mapped Bac_DB mapped 
R2 0.0241 0.024 0.023 
Residuals 0.975 0.975 0.976 
p-value 0.482 0.391 0.491 
 
3.3.3.2 Sample taxa compositions 
There was only a 0.1% difference in phyla assignment in the CRC-RNA dataset between 
mapped and unmapped samples when using the All_DB. The difference between using 
the Bac_DB and the All_DB with host mapping was substantial; there were 12.7% fewer 
Bacteroidetes, 2.3% fewer Fusobacteria, 2.6% fewer Firmicutes, and 15.6% more 
Proteobacteria when the Bac_DB was used (Table 3.7).  
Table 3.7. CRC-RNA dataset total phyla composition 
Phyla All_DB Mapped All_DB No Mapping Bac_DB Mapped 
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Bacteroidetes 59.5% 59.4% 46.7% 
Proteobacteria 4.4% 4.5% 20.1% 
Firmicutes 26.7% 26.7% 24.1% 
Fusobacteria 8.0% 8.0% 6.3% 
 
The genus-level differences between using the All_DB with or without host mapping 
were minor and did not exceed 0.1% between the top 15 genera (Table 3.8). Of the 15 
top genera when using the Bac_DB, six did not appear when using the All_DB. Klebsiella 
and Pasteurella were the third and second most abundant when using the Bac_DB, 
respectively, along with other genera such as Bacillus, Staphylococcus, Enterobacter and 
Ralstonia. Additionally, Bacteroides, Faecalibacterium and Fusobacterium were detected in 
lower proportions when using the Bac_DB. Those genera detected within the 15 most 
abundant when using the All_DB were Hungatella, Campylobacter, Eubacterium, 
Lachnoanaerobaculum, Leptotrichia and Alistipes. 
Table 3.8. CRC-RNA top 15 genera 
All_DB Mapped All_DB Unmapped Bac_DB Mapped 
Genus % Genus % Genus % 
Bacteroides 57.0 Bacteroides 56.9 Bacteroides 44.0 
Fusobacterium 8.7 Fusobacterium 8.7 Fusobacterium 6.9 
Prevotella 3.9 Prevotella 3.8 Klebsiella 4.3 
Porphyromonas 3.2 Porphyromonas 3.1 Pasteurella 3.3 
Faecalibacterium 3.1 Faecalibacterium 3.1 Lachnoclostridium 3.3 
Hungatella 2.5 Hungatella 2.5 Porphyromonas 2.8 
Roseburia 2.5 Roseburia 2.5 Prevotella 2.6 
Lachnoclostridium 1.9 Clostridium 2.0 Faecalibacterium 2.5 
Clostridium 1.9 Lachnoclostridium 1.9 Staphylococcus 2.3 
Blautia 0.9 Blautia 0.9 Clostridium 1.9 
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Campylobacter 0.8 Campylobacter 0.8 Enterobacter 1.8 
Eubacterium 0.7 Eubacterium 0.6 Ralstonia 1.4 
Lachnoanaerobaculum 0.6 Lachnoanaerobaculum 0.6 Roseburia 1.3 
Leptotrichia 0.6 Leptotrichia 0.6 Bacillus 0.9 
Alistipes 0.5 Alistipes 0.5 Blautia 0.7 
 
The Rec-ONT dataset differences at the phylum level when using the All_DB were 
minor, regardless of host mapping (Table 3.9). However, compared to using the 
Bac_DB, the differences were more considerable; Bacteroidetes were 30% higher while 
Proteobacteria and Fusobacteria were 30% and 1.5% lower, respectively. Firmicutes 
were detected at similar proportions regardless of database and host mapping. Using 
the Bac_DB, the differences were the highest for Proteobacteria and Bacteroidetes, with 
the former comprising >50% of the sample totals, and the latter less than 10%.  
Table 3.9. Rec-ONT total phyla 
Phyla All_DB Mapped All_DB No Mapping Bac_DB Mapped 
Bacteroidetes 40.1% 39.6% 9.6% 
Proteobacteria 26.3% 26.9% 57.6% 
Firmicutes 23.5% 23.4% 23.4% 
Fusobacteria 2.4% 2.4% 0.9% 
 
At the genera level, the differences between host mapping and no host mapping using 
the All_DB were less than 1% for the three most abundant genera; however, Salmonella 
and Campylobacter were absent with and without mapping, respectively (Table 3.10). 
Porphyromonas and Fusobacterium abundance were most impacted by host mapping, 
which increased by 1.2% when host mapping was used with the All_DB.  
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Staphylococcus, Pasteurella, Klebsiella, Candidatus Portiera, Ralstonia, Yersinia, Enterobacter, 
Mycoplasma and Burkholderia appeared in the top 15 most abundant genera when the 
Bac_DB was used (Table 3.10). Bacteroides was the most abundant genus when using the 
All_DB at >26% of sample totals; however, using the Bac_DB resulted in the abundance 
of Bacteroides being detected at less than 4% of sample totals. 
Table 3.10. Rec-ONT top 15 genera 
All_DB Mapped All_DB Unmapped Bac_DB Mapped 
Genus % Genus % Genus % 
Bacteroides 29.1 Bacteroides 26.7 Staphylococcus 13.6 
Escherichia 9.8 Escherichia 9.8 Pasteurella 13.3 
Porphyromonas 6.7 Porphyromonas 5.5 Klebsiella 8.2 
Faecalibacterium 3.1 Faecalibacterium 3.3 Candidatus Portiera 5.7 
Fusobacterium 2.6 Alistipes 2.4 Escherichia 5.6 
Alistipes 2.2 Hungatella 2.1 Bacteroides 3.6 
Hungatella 2.0 Oscillibacter 1.9 Ralstonia 3.5 
Oscillibacter 1.6 Pseudomonas 1.6 Yersinia 3.3 
Prevotella 1.3 Fusobacterium 1.4 Enterobacter 3.2 
Campylobacter 1.3 Prevotella 1.4 Mycoplasma 2.4 
Lachnoclostridium 1.3 Streptomyces 1.4 Bacillus 2.0 
Clostridium 1.3 Salmonella 1.4 Clostridium 1.9 
Streptomyces 1.2 Clostridium 1.4 Burkholderia 1.2 
Pseudomonas 1.2 Bacillus 1.3 Streptomyces 0.9 
Bacillus 1.1 Lachnoclostridium 1.2 Porphyromonas 0.9 
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3.4 Analysis 2: RC dataset platform comparison 
Once the appropriate methodology had been established for microbial taxonomic 
assignment of metagenomic sequencing reads, the comparative methodology from 
Section 1 was applied to the Christchurch (CHCH) cohort.  
The dataset contained sequencing data from the same three platform datasets, described 
in Section 2.6 (ONT, 16S rRNA and RNA-Seq). The cohort was comprised of 20 patients, 
with two samples per patient (tumour and adjacent non-malignant tissue).  
The taxonomy of each patient sample and the cross-platform correlations were carried 
out using the same methodology as in [93, 371]; with changes based on the results of 
Analysis 1; utilising a broad taxonomic database containing the host genome, and using 
the same taxonomic database and assignment software for all platform datasets. 
3.4.1 Data processing and information 
3.4.1.1 Quality control and read counts 
16S rRNA read length ranged from 52–247 bp, with per-sequence Phred scores of 28–38 
(Figure 3.8a) and per-base mean Phred scores of 33.8–38.8 (Figure 3.8b). 
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Figure 3.8. 16S rRNA quality scores. a) Per-sequence quality scores, b) mean quality scores 
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Figure 3.9. RNA-Seq quality scores. a) Per-sequence quality scores, b) mean quality scores 
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RNA-Seq reads ranged in length from 52bp–150 bp, with per-sequence Phred scores of 
24–37 (Figure 3.9a), and per-base mean Phred scores of 36.1–36.7 (Figure 3.9b). 
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Figure 3.10. ONT quality scores. a) Per-sequence quality scores, b) mean quality scores. 
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ONT reads had a mean length of 2600, ranging from 499–54,595 bp, with per-sequence 
Phred scores of 2–36 (Figure 3.10a), and per-base mean Phred scores of 2.6–27.8 (Figure 
3.10b). The mean number of raw reads per-sample for 16S rRNA, RNA-Seq and ONT 
were 75,137, 56,672,929 and 358,996, respectively (Table 3.11).  
Table 3.11. Number of reads per-sample 
 Raw Reads Processed/Unmapped Assigned Bacterial Taxonomy 
Sample 16S RNA ONT 16S RNA ONT 16S RNA ONT 
RT1N 47801 65797848 460355 41733 759910 29235 41645 130487 23 
RT1T 72039 50629572 316304 63027 381566 20635 62917 53451 102 
RT2N 64573 58393905 420266 56880 329306 24440 56825 39096 6 
RT2T 65109 67848414 379022 58546 290747 25578 55826 70508 6 
RT3N 146127 58274719 240536 121577 2340228 27625 121410 1653462 2889 
RT3T 51603 68019961 471354 44482 3032153 29651 44417 2330350 565 
RT4N 103582 55679261 318958 85448 357961 20016 85336 32318 195 
RT4T 148125 53838505 174438 121740 5063581 17674 121510 4923353 137 
RT5N 74483 69511002 223418 63375 392221 18646 63324 61397 194 
RT5T 102337 55610236 405361 89884 454105 23709 89837 183595 298 
RT6N 73255 44112606 355170 64091 311903 20377 62426 60026 12 
RT6T 85457 64679678 480529 70208 1177014 29912 70186 923117 2732 
RT7N 71763 44370270 151240 62667 243397 7885 62610 30539 5 
RT7T 33824 75592926 488667 29413 961405 20486 29276 352667 90 
RT8N 92311 45567364 217400 79901 289829 14187 79761 51956 11 
RT8T 35565 76497189 577258 31486 4033741 27791 31441 3717615 82 
RT9N 83232 42691787 487433 72977 327650 25694 72893 46956 11 
RT9T 16849 70245212 376484 15013 470682 23091 14985 19162 46 
RT10N 44944 48311893 362386 38256 292579 20410 38101 21634 2 
RT10T 42297 55048172 483918 37831 468270 24006 37747 64878 42 
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RT11N 97007 74481282 192418 82776 557978 17994 82757 168629 1577 
RT11T 43566 51185511 315209 36290 779596 35373 36253 316816 723 
RT12N 21696 53866573 201183 17493 518465 13572 17182 75546 30 
RT12T 18947 51619614 551584 16519 341611 32887 16478 36449 59 
RT13N 37515 42435289 229239 32781 319737 20156 32715 48729 4 
RT13T 57997 74446240 470690 50836 508365 25345 50751 57156 32 
RT14N 82895 41915825 562818 70257 363086 29696 70213 44746 618 
RT14T 132916 48035590 430829 116631 370048 28358 116350 62063 464 
RT15N 85852 51753938 284966 73510 241447 17462 73377 35652 179 
RT15T 105534 45461331 592632 91832 364479 34997 91699 44542 272 
RT16N 99157 52662204 749205 85535 416219 43843 85463 60039 992 
RT16T 93180 53381132 590318 79794 283392 28118 79741 34855 89 
RT17N 79290 50559600 94358 70685 200144 21259 70490 11568 6 
RT17T 87192 56401397 308720 76826 416337 102428 76742 67920 20 
RT18N 99273 45275146 75278 89013 664194 15774 88949 310182 2 
RT18T 110449 52601165 293778 92579 313101 109087 92420 78856 80 
RT19N 64078 47015510 55087 55196 214147 12505 55149 38604 28 
RT19T 91902 68820033 447806 78645 580995 56856 78539 126030 65 
RT20N 120428 69006835 70049 103244 590887 16026 103175 298105 59 
RT20T 21369 65272435 453176 18738 627297 68762 18714 173641 46 
Mean 75137 56672929 358996 64692 766244 29538 64490 421417 319 
Median 76886 53852539 369435 67149 404220 24223 66755 61730 62 
Std 33762 10467244 164660 28509 1037031 20958 28508 1020002 659 
RT: Rectal tissue; N: normal tissue; T: tumour tissue; 16S: 16S rRNA sequencing; RNA: RNA-Seq; ONT: Oxford 
Nanopore Technology sequencing. 
After mapping and processing, the taxonomy assignment rate was highest for 16S 
rRNA, at 85.8% of raw-reads, while RNA-Seq and ONT reads were assigned taxonomy 
at magnitude lower rates, at 0.007% and 0.001%, respectively (Table 3.12). An 
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amplification bias was found in the 16S rRNA dataset at the genus level, resulting in 
excessive levels of the Burkholderia genus, which was not reflected in the other 
platforms, and were removed before relative abundance calculations. 
Table 3.12. Percentage of reads retained and assigned taxonomy 
% Post-processing 
Assigned taxonomy 
Of total Of post-processed 
16S rRNA 86.1% 85.8% 99.7% 
RNA-Seq 1.4% 0.07% 55% 
ONT 8.2% 0.01% 1.1% 
 
3.4.2 Platform concordance 
The correlation between taxa at the phylum level between platforms was found to be 
highest between RNA and 16S rRNA sequencing, and lowest was between ONT and 
RNA sequencing (Figure 3.11), with one sample being negatively correlated; however, 
this was not statistically significant (rs = -0.067, p-value = 0.8987). The mean correlation 
between 16S rRNA and ONT sequencing was higher than between RNA and ONT 





Figure 3.11. Platform comparisons of the RC cohort at the phylum level, A) 16S rRNA vs ONT, B) RNA-Seq vs ONT and C) 
RNA-Seq vs 16S rRNA. The dashed line indicates the sample mean. 
75 
At the genus level (Figure 3.12), there was a more consistent concordance level than at 
the phylum level; however, the mean correlation ranged from 0.48–0.52 for ONT and 
16S rRNA comparisons with RNA-Seq, respectively (Table 3.13). 
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Figure 3.12. Platform comparisons of the RC cohort at the genera level, A) 16S rRNA vs ONT, B) RNA-Seq vs ONT and C) 
RNA-Seq vs 16S rRNA. The dashed line indicates the sample mean. 
At the species level, the concordance was higher than at the genus level (Figure 3.13), 
with both 16S rRNA and RNA sequencing had a mean correlation with ONT 
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sequencing of 0.55 (Table 3.13), and between 16S rRNA and RNA-Seq, it was 0.62. One 
sample (RT13N) had a non-statistically significant negative correlation when comparing 
RNA and ONT sequencing (ρ = -0.06, p-value = 0.4375 (Figure 3.13B). 
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Figure 3.13. Platform comparisons of the RC cohort at the species level, A) 16S rRNA vs ONT, B) RNA-Seq vs ONT and C) 
RNA-Seq vs 16S rRNA. The dashed line indicates the sample mean. 
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Table 3.13. Mean correlation between platforms and rectal dataset 
Taxonomic Level 
16S rRNA vs. ONT 16S rRNA vs. RNA ONT vs. RNA 
ρ p-value ρ p-value ρ p-value 
Phylum 0.68 <2.2 × 1016 0.83 <2.2 × 1016 0.58 <2.2 × 1016 
Genus 0.49 <2.2 × 1016 0.53 <2.2 × 1016 0.48 <2.2 × 1016 
Species 0.56 <2.2 × 1016 0.63 <2.2 × 1016 0.55 <2.2 × 1016 
 
In contrast to our published CRC study [371], the overall concordance was higher 
between 16S rRNA and both ONT and RNA sequencing at each taxonomic level (Table 
3.14), with the most considerable improvement being at the species level. The 
concordance between ONT and RNA-Seq decreased at the phyla and genera levels; 
however, there was an improvement seen at the species level. Across all taxonomic 
levels, the highest concordance was seen between 16S rRNA and RNA-Seq.  
Table 3.14. Changes in mean correlation between platforms compared to Taylor et al. 2020 
Taxonomic Level 16S rRNA vs. ONT 16S rRNA vs. RNA-Seq ONT vs. RNA-Seq 
Phyla +0.009 +0.023 -0.092 
Genus +0.135 +0.161 -0.035 
Species +0.363 +0.440 +0.204 
 
Each platform's taxa identification rate was investigated in terms of the number of raw-
reads per species identified (Table 3.15). Read efficiency was evaluated without 
taxonomic filtering, as filtering cut-offs are often arbitrary, and the same cut-off would 
not be applicable cross-platform.  
Table 3.15. Number of different bacterial taxa detected using each sequencing platform 
 RNA-Seq 16S rRNA ONT 
Phyla detected 33 21 7 
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Genera detected 900 314 70 
Species detected 2512 459 129 
Unique phyla 13 1 0 
Unique genera 621 39 0 
Unique species 2111 95 0 
Raw reads per-species 902,435 6548 111,316 
 
For every 900,000 reads, RNA-Seq could identify a species, while 16S rRNA was more 
efficient as reads were amplified from bacterial specific genes and were with 6548 reads 
per species identified, despite 16S rRNA data being known to be less reliable at 
distinguishing between taxa at the species level. ONT data was the least efficient, with 
substantially fewer taxa being detected overall, and even fewer being detected on a per-
raw read basis. Furthermore, no unique taxa were detected when compared to other 
platforms (Table 3.15).  
3.4.3 Platform composition 
Figure 3.14 shows the relative bacterial abundance in the CHCH cohort using each 
platform. The proportions of each phylum varied between platforms (Figure 3.14A), with 
RNA-Seq and 16S rRNA sequencing having more comparable levels of Bacteroidetes and 
Proteobacteria; ONT sequencing detected a comparatively higher proportion of 
Bacteroidetes and Firmicutes.  
The proportional differences between each platform at the genera level were smaller, 
with each displaying more consistent levels of each taxon (Figure 3.14B); however, ONT 
sequencing detected fewer genera overall. In particular, ONT sequencing detected fewer 




Figure 3.14. Comparison of relative abundance in Rectal samples between sequencing platforms. A) The phyla level and B), the 
genus level. 
When comparing the number of species uniquely detected by different platforms, ONT 
sequencing did not detect any unique species, while RNA-Seq and 16S rRNA 
sequencing detected 2548 and 66 unique species, respectively (Figure 3.15). 
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Figure 3.15. Comparison of bacterial species detection between each sequencing platform. 
 
3.4.4 Community standard evaluation 
To assess ONT sequencing's accuracy and to determine the effect of lower read counts 
and quality, a microbial community standard had DNA extracted, was sequenced and 
had taxonomy assigned using the same methodology as other samples. The standard 




Figure 3.16. ONT sequencing of microbial community standard using increasing Kraken2 confidence scores. Actual represents 
the proportion of each species advertised in the community standard. 
Yeast species were under detected regardless of the confidence score used. A confidence 
score of 0.2, detected yeast more accurately; however, this was at the expense of 
reduced bacterial detection accuracy. A confidence score of 0.1 gave the most consistent 
and accurate results; however, there was an over-estimation of Enterococcus faecalis and 
reduced detection of Salmonella enterica, Escherichia coli and Pseudomonas aeruginosa 
(Figure 3.16).  
Table 3.16. ONT sequencing of community standard using increasing Kraken2 confidence scores. 
 Kraken2 Confidence Level   




Enterococcus faecalis 33.87% 45.17% 51.29% 9.46% 12 + 
Bacillus subtilis 12.46% 6.83% 3.35% 4.63% 12 + 
Lactobacillus fermentum 11.87% 13.79% 16.36% 3.77% 12 + 
Staphylococcus aureus 11.72% 12.03% 11.45% 4.93% 12 + 
Salmonella enterica 10.13% 5.45% 3.85% 28.48% 12 - 
Listeria monocytogenes 8.04% 8.39% 6.82% 2.54% 12 + 
Escherichia coli 5.93% 3.53% 3.15% 26.44% 12 - 
Pseudomonas aeruginosa 3.86% 2.621% 1.87% 15.99% 12 - 
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Saccharomyces cerevisiae 1.05% 1.273% 1.20% 0.31% 2 Yeast 
Cryptococcus neoformans 0.51% 0.55% 0.42% 0.15% 2 Yeast 
 
Additionally, microbial compositions contained 0.198%, 0.065% and 0.043%, species not 
in the community standard using 0.1, 0.2 and 0.3 confidence levels, respectively. These 
results show that ONT sequencing is adequate for sequencing and detecting bacterial 
species. 
 
3.5 Discussion  
3.5.1 Analysis 1: mapping methodology 
The tests on the effect of host mapping in different scenarios were performed to test the 
hypothesis that the taxonomic assignment software, Kraken2, could classify reads into 
both prokaryotic and eukaryotic categories, negating the need for host genome mapping 
before assignment.  
Using the Synth dataset, human reads were not wholly removed via mapping, with 
approximately 11% of the resulting data being classified as eukaryotic, and if not 
accounted for were classified as bacterial in origin. The results show that non-bacterial 
reads can be classified if the appropriate reference is included in the database, and that 
host mapping is an imperfect process, with residual host reads leading to higher type 1 
error rates, if not binned by a secondary filter such as during taxonomic classification. 
Using host mapping improved accuracy by 0.05% when using the All_DB; however, 
compute time increased more than a nine-fold with the addition of host-mapping. 
Using the two clinical datasets (CRC-RNA and Rec-ONT) and host mapping, alpha 
diversity was significantly different when using host mapping and the Bac_DB for 
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taxonomic assignment compared to the All_DB. There were no statistically significant 
differences in either dataset when using the All_DB with or without host mapping.  
In the CRC-RNA dataset, differences in mean diversity were statistically significant 
when using the All_DB compared to the Bac_DB, except for the Simpson diversity 
index; implying that taxonomic dominance is not influenced by database choice or prior 
host mapping in the CRC-RNA dataset. In the Rec-ONT dataset differences in Simpson 
diversity were statistically significant when comparing the use of the All_DB to the 
Bac_DB, which may reflect the higher inter-sample read number differences not present 
in the CRC-RNA dataset. 
The results demonstrate that using a database containing only bacterial genomes can alter 
the results of metagenomic analyses. Misassigned residual reads after host mapping may 
result in inflation of microbial diversity or misreporting the presence and abundance of 
clinically relevant taxa. 
Using the All_DB, Bacteroidetes were increased by 10% and more than 30% in the CRC-
RNA and Rec-ONT datasets, respectively, compared to using the Bac_DB. Proteobacteria 
were decreased using the All_DB by four-fold in the CRC-RNA dataset, and by more than 
50% in the Rec-ONT dataset. Additionally, the abundance of Fusobacteria was increased 
when using the All_DB, while regardless of the database or dataset used, the relative 
levels of Firmicutes remained consistent. The differences in detection could be clinically 
relevant as, for example, Bacteroidetes contain several taxa associated with health and 
disease, such as B.fragilis, and health-associated F. prausnitzii and Lactobacillus species. 
Additionally, Proteobacteria contains important pathogens like Shigella flexneri and 
cancer-associated microbes such as Helicobacter pylori and Escherichia coli [375].  
There were also differences at the genus level depending on the taxonomic database used. 
Important and potentially pathogenic genera, such as Klebsiella, Pasteurella, Mycoplasma, 
Yersinia and Staphylococcus were present in the most abundant genera when the Bac_DB 
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was used. Several consequential taxa were found to be among the most abundant when 
the All_DB was used, such as oral microbes Leptotrichia and Lachnoanaerobaculum [376] 
[377], the foodborne pathogen Campylobacter [378], Hungatella, which was recently 
associated with brain aneurysms [379], SCFA-producing Eubacterium [380], and Alistipes 
which has been implicated in cancer, inflammatory disease and mental health [381]. 
Metagenomic data from tissue samples has been used to study microbiome composition 
for classification or grouping of disease states, such as IBD [382], or CRC signatures [93, 
109], and potentially for CRC diagnosis and predicting survival [180, 383]; however, 
without appropriate measures to remove host sequences, the results and interpretation 
of data in these and other studies may be incorrect.  
Overall, the results of the first analysis demonstrate that not only is mapping to the host 
genome before bacterial taxonomic assignment insufficient for removal of host reads, but 
that host mapping may be largely redundant when the host genome is included in the 
taxonomic assignment database. Adopting a broad taxonomic classification database that 
includes the host genome is shown to increase the accuracy and speed of metagenomic 
analyses.  
3.5.2 Analysis 2: RC dataset platform comparison 
In Analysis 2, ONT sequencing was compared to 16S rRNA sequencing and RNA-Seq 
in their ability to analyse RC samples' tissue microbiomes using the methods 
implemented in previous CRC studies [93, 371]. The analysis was carried out using host 
contaminated samples extracted from human tissue. No attempt was made to reduce 
the amount of host genomic material during extraction methods; only 16S rRNA 
sequencing specifically selected microbial DNA via selective PCR primers.  
For ONT sequencing, samples were barcoded and sequenced as multiplexed libraries. 
Due, in part, to lacking an amplification step, the number of bacterial reads were several 
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orders of magnitude lower than the other platforms. In addition, the synthesis-free 
nanopore sequencing method can only read sequences once as they pass through a pore, 
in contrast to the bridge amplification used in Illumina sequencers which can sequence 
the same strand multiple times. Another factor in the low number of post-mapping ONT 
reads was that almost half of the ONT reads were not barcoded, which may introduce 
sampling bias. The loss of barcodes is a common factor in ONT sequencing generally, as 
the high molecular weight DNA becomes prone to breakage as it is purified, and 
stabilising proteins are lost. 
Based on the initial comparative study, concordance results between the sequencing 
platforms was initially promising [371]. Concordance of phyla, genera and species 
assignment between 16S rRNA and ONT sequencing was 67.6%, 35.8% and 19.5%; 
between 16S rRNA and RNA-Seq, 80.5%, 36.7% and 18.9%; and between ONT and RNA-
Seq, 66.7%, 51.5% and 35%. Despite the low numbers of reads acquired using ONT 
sequencing, more than a 1300 species could be taxonomically assigned, most of which 
could also be detected using RNA-Seq data. It has been theorised that long ONT reads 
might compensate for a lower number of reads by being more efficient, as it is possible 
to discriminate between species using larger query sequences; Wommack et al. [384] 
showed that long reads could detect 72% more hits than short read lengths of up to 400bp 
at twice the read depth. Although ONT sequencing is known to have an inherently high 
error rate, which was also observed in this study (Figure 3.10), this can be compensated 
for by using longer reads [385]. Additionally, ONT data is known to suffer at shorter read 
lengths (<1000 bp) in terms of taxonomic classification, and this is particularly the case 
when using Kraken2 [386]. 
Implementing the methodological changes from Analysis 1, the concordance between 
platforms was increased compared to the initial study, likely due to the methodological 
changes; using the All_DB for all taxonomic assignment and a taxonomic confidence 
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score. Removal of excessive Burkholderia levels from the 16S rRNA dataset from 
amplification bias was justified in that it resulted in better concordance (Figure 3.12) and 
preserved genus representation between platforms (Figure 3.14), which was improved 
between both RNA-Seq and ONT compared to the CRC study [371]. Concordance 
increased at the species level when comparing ONT and RNA-Seq; however, 
concordance was reduced at both the phyla and genera levels (Table 3.14), which was 
likely due to residual host sequences no longer being misassigned to the same taxa. The 
highest concordance was between RNA-Seq and 16S rRNA in line with the previous CRC 
study, while the lowest was between ONT and RNA-Seq.  
As Kraken2 has been recently shown to be an accurate method of 16S rRNA taxonomic 
classification [387], the benefit of utilising the same taxonomic database for all 
comparisons likely had the largest impact on concordance compared to the prior CRC 
study [371]. The DADA2 and the SILVA132 databases previously used for 16S rRNA 
taxonomic assignment may have contained naming differences compared to the Bac_DB 
used for the ONT and RNA-Seq reads, and that taxa were absent from one database were 
present in the other, and vice versa. Additionally, removing residual human and non-
bacterial reads may explain the increased concordance between other platforms and 16S 
rRNA sequencing in this study.  
When comparing ONT with RNA-Seq, some samples had low or negative correlations, 
due to some samples having few reads after mapping which could be assigned taxonomy 
and the effect of the relative transform on the dataset. For example, the RNA-Seq 
taxonomy for sample RT13N contained 122 species ranging in abundance from 0.00328 
to 0.2547; however, the ONT taxonomy for the same sample contained a single species 
(Bacteroides cellulosilyticus), giving it an abundance of 1, while it appeared in the RNA-Seq 
dataset an abundance of 0.000328.  
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Using the All_DB also reduced the detection efficiency of all three platforms compared 
to the previous CRC study, with almost 21-fold more reads being required per species 
identified for RNA-Seq, 124-fold more for ONT reads, and 1.75-fold more 16S rRNA reads. 
It should be noted that 16S rRNA is known to discriminate between species poorly; 
however, the efficiency decrease was magnitudes smaller than with other platforms 
when using the All_DB, likely due to the lack of impact from host reads. Despite the 
reduction in species detection, ONT sequencing still outperformed RNA-Seq on a raw-
read per species detection basis, requiring eight-fold fewer reads per species detected.  
ONT sequencing had high error rates, lower concordance with other platforms, and 
detected species less efficiently than in the previous CRC study. To demonstrate that 
ONT sequencing data could be used for microbial community evaluation, a community 
standard was sequenced using the same methodology as the CHCH cohort ONT samples. 
The results showed that ONT sequencing was capable of sequencing bacteria close to the 
proportions of a given sample; however, additional species not included in the 
community standard were classified using different confidence scores. The additional 
species identified did not exceed 0.2% of the compositional total when using the most 
accurate confidence score of 0.1. These additional species may be due to bleed over from 
other multiplexed samples or indicate the limitations that Kraken2 has in identifying 
species. Overall, based on the community standard analysis results, a confidence score of 
0.1 and a species abundance cut-off of 0.2% per sample was utilised for analyses moving 
forward. However, this may not be sufficient for 16S rRNA, and RNA-Seq analyses as the 
community standard was not used with these platforms, and there may be additional 
variance due to sequence quality and read numbers. 
3.6 Conclusions 
This chapter's results show that using a broad taxonomic assignment database that 
contains the human genome improves the accuracy and reduces the time required for 
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metagenomic studies while providing proportional information on the host-microbe 
content of a sample. Additionally, the increased accuracy and reduced interference from 
host reads increases inter-platform concordance; however, this improvement did not 
apply when comparatively few reads were supplied, such as the case for ONT 
sequencing concerning RNA-Seq. 
4 CHAPTER 4: RC MICROBIOME 
4.1 Introduction 
The microbiome has been implicated in sporadic CRC [388]; however, the relationship 
between the microbiome and chemoradiotherapy outcomes has yet to be thoroughly 
investigated. It has been shown that the microbiome can modify the pharmacokinetics 
of anti-cancer drugs, for example, Fusobacterium nucleatum can promote resistance to 5-
FU and platinum-based drugs used to treat CRC [389-392]. Additionally, the role of the 
microbiome in radiotherapy side effects, such as postradiotherapy diarrhoea, mucositis, 
fatigue, and other gastrointestinal side-effects has been well studied [393-396], as well as 
the effect of radiotherapy in altering the microbiome [397-399]. However, a link 
between radiotherapy outcomes and the microbiome has yet to be proven. In terms of 
direct microbiome-radiotherapy interactions, evidence points toward an 
immunomodulatory effect [242], such as gram-positive bacterial depletion with 
vancomycin leading to enhanced anti-tumour immune responses dependant on 
dendritic cell antigen presentation [400]. In contrast, other studies point toward 
microbial metabolites, such as vitamin D metabolism by microbiota contributing to 
radioresistance [401]. 
This chapter aimed to investigate the microbiomes of RC tissues, using RNA-Seq data 
using Kraken2, as described in Chapters 2 and 3. In the first section, alpha diversity was 
compared between tissues and response groups using Observed diversity, the total 
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transcription of taxa; Shannon diversity index, a measure of evenness within the 
sample; and the Simpson index, used to measure the level of dominance within a 
sample [402]. Microbiome composition, differential transcription, and beta-diversity 
were measured across response groups and patient tissues. The effect size of beta-
diversity measures by the response and metadata variables on the microbiome was 
calculated and tested. Transcriptional activity was correlated with response to find 
which taxa were most associated with response in each tissue type. Lastly, 
transcriptional alignment was used to determine the presence of enterotoxigenic 
Bacteroides fragilis.  
4.2 Methods 
Taxonomies were produced using host mapped reads from the sequencing data 
described in Chapter 3, and assigned taxonomy using Kraken2 v2.0.7 and the All_DB 
with a confidence score of 0.1, as described in Chapter 2. Diversity and composition 
were analysed and visualised using the phyloseq v1.28 [316], ape v5.4 [353], Pavian v1.0 
[403] and VEGAN 2.5 [352] R packages. Samples were rarefied to 90% of the sample 
sum of the lowest sample before alpha diversity calculations. The statistical significance 
of alpha diversity differences between tumour and normal tissues and response groups 
was tested using Wilcoxon signed-rank tests, and p-values were adjusted for false 
discovery rate (FDR) using Benjamini and Hochberg (BH) correction [358].  
Filtering was done after alpha-diversity analysis as singletons are rare taxa are used for 
calculating diversity indices. Additionally, there is no gold standard for taxa filtering, 
and thresholds are mostly arbitrary, with choices varying between researchers and the 
data used [404]. Low abundance taxa with a read count lower than 30 in 20% of samples 
were removed after alpha diversity analysis for compositional barplots and differential 
transcription. For beta-diversity analyses, taxa with more than five reads in 20% of 
samples were retained to preserve greater sample heterogeneity. Significance of 
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differences between tissues and response groups in taxa boxplots was measured using 
Wilcoxon signed-rank tests, and p-values were adjusted for FDR with Benjamini and 
Hochberg [358]. 
Effect sizes were calculated using adonis function, and homogeneity of variable 
dispersions was calculated with betadisper, both part of the VEGAN [352] R package. 
Differential microbial transcription was analysed with edgeR [356], relative log 
expression, a likelihood ratio test, and p-values were adjusted for false discovery rate 
(FDR) with Benjamini and Hochberg [358]. Correlations between relative abundance 
and response were calculated using Spearman’s rank correlation, and p-values were 
adjusted for FDR with Benjamini and Hochberg [358]. Extracted reads assigned to B. 
fragilis were aligned to a reference genome using STAR v2.6.1 [271] without splice 
aware alignment. Scripts and code used for the analyses can be found at 
https://github.com/William-S-Taylor/MSc. 
4.3 Results 
First, each platform compared in the previous chapter was tested for sample depth and 
appropriateness for community analysis, then alpha diversity, composition, beta 
diversity and effect sizes were analysed. Finally, RNA-Seq data was used to determine 
if the most transcriptionally active taxa were expressing a particular gene. 
4.3.1 Rarefaction 
Rarefaction curves were calculated from the taxonomies of ONT (Figure 4.1a), 16S 
rRNA (Figure 4.1b) (microbial abundance) and RNA-Seq (Figure 4.1c) (transcriptomic 
activity). The 16S rRNA and ONT datasets contained data from the Christchurch 
(CHCH) cohort (n = 20), while the RNA-Seq dataset contained data from both he CHCH 
and Peter MacCallum cohort (PM). The ONT dataset sample sums ranged from 2714 to 
2 with a standard deviation of 635, and half of the sample sums were below 60; 
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therefore, rarefaction could not be performed without reducing the data considerably. 
Additionally, the 16S rRNA dataset was also adversely affected by rarefaction (reducing 
total taxa from 671 to 489); however, the rarefied RNA-Seq dataset contained the 
greatest number of taxa (1916) and samples and therefore had the greatest likelihood of 
detecting significant response group variability. 
 
Figure 4.1. Dataset rarefaction curves. a) ONT; b) 16S rRNA, c) RNA-Seq. 
Due to the impact of rarefaction and the uneven and lower sample sizes of the other 
taxonomies, only the RNA-Seq taxonomy was utilised for microbiome analysis. 
Rarefaction reduced the number of taxa (Figure 4.2) in the RNA-Seq dataset by 46% 
(3534 to 1916). Post-rarefaction, each sample was normalised to taxa sample sums of 
4216 to give a balanced comparison between samples. 
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Figure 4.2. Effect of rarefaction on the RNA-seq taxonomy. a) RNA-Seq pre-rarefaction, b) RNA-Seq post-rarefaction. 
4.3.2 Alpha diversity 
Alpha diversity differences were tested for statistical significance (p > 0.05) using 
Wilcoxon signed-rank tests, and FDR correction was performed with Benjamini and 
Hochberg. Comparisons were made between tissue types, tissues of Dworak score 
groups, and the differences between tissues when grouped into high and low response 
grades (Dworak Four and Three, and Dworak Two and One, respectively) (Figure 4.3). 
The differences between the Shannon diversity scores of Dworak One and Two normal 
tissues, and the Simpson diversity scores between of Dworak Two tumour and normal 
tissues were found to be statistically significant (p = 0.047 and p = 0.049, respectively) 





Figure 4.3. Alpha diversity of bacterial transcription. a) Tissue comparison, b) Dworak score tissue comparison, c) response 
grade tissue comparison. *: p < 0.05; ns: not statistically significant. Comparisons that were not statistically significant in at 
least one instances are not shown. 
4.4 Microbiome compositions and differential analysis 
The relative level of bacterial transcription within samples was hypothesised to be 
associated with response. These levels would theoretically be different between the 
tumour and normal tissues of different response groups. Therefore, the relative 
transcriptional activity was plotted to compare the phyla and genus expression of 
different tissues and response groups, followed by differential expression analysis to 
determine these differences' statistical significance. Samples were grouped to assess the 
differences between high (Dworak Four and Three) and low (Dworak Two and One) 
response groups. 
4.4.1 Compositions and differential transcription 
At the phylum level, samples were mainly dominated by Proteobacteria, with 25 
samples being comprised of more than 90% Proteobacteria. In comparison, the 
taxonomies of three samples were comprised of mainly Bacteroidetes, the normal tissue 
96 
of a Dworak One patient, the normal and tumour tissue of a Dworak Two patient, the 
normal tissue of a Dworak Three patient, and the tumour tissue of a Dworak Four 
patient (Figure 4.4). On average, the top three most transcriptional active phyla were 
Proteobacteria, Bacteroidetes and Firmicutes, followed by Fusobacteria and 
Actinobacteria. Fusobacteria transcription was the highest in those samples with a 
Dworak score of Two. Fusobacteria transcription was detected in the normal samples of 
complete responders; however, at less than 1% of total transcriptional abundance. 
Cyanobacteria and Tenericutes had low transcriptional activity. Verrucomicrobia had 
the highest activity in the normal and tumour tissues of a Dworak Three patient (9.5% 
and 2.2%, respectively), followed by the normal and tumour tissues of a Dworak Four 
patient (8.3% and 2.3%, respectively). The Dworak Three patient with the highest 
Verrucomicrobia activity levels also had considerable levels of Spirochates in their 
normal and tumour tissues (38% and 0.5%, respectively) which were 163 and two times 
higher, respectively, than the sample with the next highest level. 
 
Figure 4.4. Relative transcriptional phylum activity ordered by tissue type and Dworak score. 
Analysis of the differential expression of phyla showed that Cyanobacteria had 
statistically significant (FDR corrected p-value < 0.05) differential transcription between 
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tissues (Figure 4.5). Overall, there was 1.55-fold more Cyanobacteria transcription in 
tumour tissues than normal tissues (Figure 4.5a), while in the high and low response 
groups, there was 2.27-fold and 1.33-fold higher Cyanobacteria transcription in tumour 
tissues (Figure 4.5a,b). No other comparison yielded phyla with statistically significant 
fold-change differences. 
 
Figure 4.5. Differential transcription of Cyanobacteria between normal and tumour tissues. a) tumour vs normal, b) high 
responder tumour vs normal, c) low responder tumour vs normal. 
At the genus level, samples were dominated mainly by Bacteroides, the ‘Other’ category, 
and Pseudomonas (Figure 4.6). Fusobacterium transcription was highest in Dworak Two 
patients' tissues, while the least was found in Dworak Four patients, with the majority 
occurring tumour tissues. Bacteroides were most transcriptionally active in Dworak One 
samples, while a Dworak Four patient had the highest transcription levels of 




Figure 4.6. Relative genera transcriptional activity, ordered by tissue type and Dworak score. 
After correcting for FDR, analysis of differential expression at the genus level revealed 
that only Corynebacterium had lower expression in tumours compared to normal tissues 
(-0.46), while six genera had statistically significant (p < 0.05) log2 fold change 
differences > 1 (Figure 4.7a). Campylobacter and Porphyromonas  had the highest levels of 
differential transcription between tumour and normal tissues (4.93-fold; p = 1.28 × 10-10 
and 3.13-fold; p = 2.59 × 10-5, respectively), followed by Streptococcus, Clostridium, 
Bacteroides and Collinsella (1.59-fold; p = 0.00014, 1.31-fold; p = 0.00015, 1.24-fold; p = 
0.012, and 1.68-fold; p = 0.016, respectively) (Figure 4.7a).  
In contrast, in the high responder group, 12 genera had higher transcriptional activity in 
tumours than normal tissues with a log2 fold-change higher than one (Figure 4.7b), 
while in the low responder group three genera had higher transcriptional activity 
(Figure 4.7c). Campylobacter had similar fold-differences between tumour and normal 
tissues in both high and low response groups (4.7-fold and 5.03-fold, respectively). 
When assessing the log2 fold changes differences between these groups (fold change 
differences of fold change differences between tumour and normal samples), it was 
found that Hungatella, Butrycimonas, Flavonifractor and Oscillibacter were more 
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transcriptionally active in the high responder compared to the low responder group 
(Figure 4.7d). 
 
Figure 4.7. Differentially expressed genera between tissues. a) tumour vs normal, b) high responder tumour vs normal, c) low 
responder tumour vs normal, d) high and low responder tumour vs normal tissue differences. 
The differences between tissue types of each response group were then tested, showing 
a statistically significant (p < 0.05) log2 fold difference (>1), in the transcriptional activity 
of 21 genera in the tumour tissues of high and low responders (Figure 4.8a). The 
greatest differences in transcriptional activity between high and low responder tumour 
tissues were those of Butyricimonas, Flavonifractor, Odoribacter and Alistipes, all of which 
had higher transcriptional activity in high responders (4.92-fold, 2.60-fold, 2.51-fold and 
2.19-fold, respectively) (Figure 4.8a). Genera with higher transcriptional activity in the 
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tumour tissue of low responders were Veillonella, Staphylococcus, Brevundimonas, 
Cutibacterium and Stenotrophomonas (1.60-fold, 1.32-fold, 1.23-fold, 1.17-fold and 1.01-
fold, respectively) (Figure 4.8a). Between the normal tissues of high and low 
responders, Hungatella were found to have statistically significant higher transcription 
in low responder normal tissues (5.44-fold) (Figure 4.8b). 
 
Figure 4.8. Differential transcription of genera between tissues. a) high responder vs low responder tumour tissue, b) low 
responder normal vs normal tissue. 
Differential relative transcriptional activity of eight species was found between tumour 
and normal tissues (Figure 4.9a). The greatest differences were higher levels in tumour 
tissue of Campylobacter ureolyticus, Lachnospiraceae bacterium GAM79, and Porphyromonas 
asaccharolytica (4.00-fold, 2.29-fold and 1.91-fold, respectively), and lower levels of 
Hungatella hathewayi, Fusobacterium nucleatum and Bacteroides thetaiotaomicron (2.37-fold, 
2.16-fold and 1.76-fold, respectively), in comparison to normal tissues (Figure 4.9a). 
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Between the tumour and normal tissues of high responders, six species were 
significantly higher in tumour tissues, Butyricimonas faecalis, Eubacterium rectale, Alistipes 
finegoldii, Streptococcus pyogenes, Bifidobacterium longum and Clostridium saccharobutylicum 
(4.17-fold, 3.16-fold, 2.95-fold, 2.92-fold, 1.75-fold and 1.98-fold, respectively) (Figure 
4.9b). In contrast, within low responders, two species had significantly higher levels of 
transcription in tumours (C. ureolyticus: 4.79-fold and L. bacterium GAM79: 2.12-fold), 
while three had significantly higher levels in normal tissues (F. nucleatum: 3.11-fold, H. 
hathewayi: 2.93-fold and B. thetaiotaomicron: 2.16-fold) (Figure 4.9c). When assessing the 
differences in the log2 fold changes between response group tissues, it was found that 
the differences in transcription of H. hathewayi, B. faecalis, A. finegoldii and E. rectale were 
higher between the tumour and normal tissues of high compared to those of low 




Figure 4.9. Differential transcription of species between tissues. a) tumour vs normal, b) high responder tumour vs normal 
tissue, c) low responder tumour vs normal tissue, d) high and low responder tumour vs normal tissue differences. 
Between the tumour tissues of high and low responders, 15 species were significantly 
differentially transcribed (Figure 4.10a). Of those with higher transcription in high 
responder tumour tissues, B. faecalis, E. rectale, S. pyogenes and A. finegoldii had the 
greatest differences compared to the tumour tissue of low responders (3.33-fold, 2.35-
fold, 1.98-fold and 1.80-fold, respectively). C. saccharobutylicum was also significantly 
higher in high responder tumour tissue (1.50-fold) (Figure 4.10a), as when compared to 
respective normal tissues (Figure 4.10b). 
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The species with the greatest differential transcription between the tumour tissues of 
response groups were Actinomyces oris, Cutibacterium acnes, Stentrophomonas maltophilla, 
Ralstonia pickettii, R. insidiosa and Cupiavidus metallidurans 1.77-fold, 1.75-fold, 1.67-fold, 
1.37-fold, 1.33-fold, and 1.32-fold, respectively) (Figure 4.10a). H. hathewayi was found to 
be 5.56-fold lower in the normal tissue of the high response group compared to the low 
response group (Figure 4.10b). 
 
Figure 4.10. Differential transcription of species within tissues. a) high responder vs low responder tumour tissue, b) low 
responder normal vs normal tissue. 
Those species found to have significant differential transcription in at least one 
comparison were used in comparisons between Dworak scores and tissue types. 
Significance testing (FDR adjusted p < 0.05) showed nine species to be differentially 
transcribed between different Dworak response group tissues (Figure 4.11). The two 
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species with the highest relative transcription were C. ureolyticus, F. nucleatum and H. 
hathewayi. C. ureolyticus transcription levels were significantly different between the 
tumour and normal tissues of Dworak four patients (Figure 11a), and F. nucleatum 
between Dworak Two tumour and normal tissue, and Dworak Three and Four normal 
tissues (Figure 4.11b). 
 H. hathewayi had significantly different transcription levels between Dworak Four 
tumour and normal tissues, Dworak Four and Dworak Three tumour tissues and 
Dworak Four and Dworak Two and One tumour tissues (Figure 4.11c). Less 
transcriptionally active species with more than one significant difference were 
Paraburkholderia fungorum (Dworak One and Two tumour tissues; Dworak Two tumour 
and normal tissues) (Figure 4.11g), Pseudomonas sp. NC02 (Dworak Two tumour and 
normal tissues; Dworak Two and Dworak One and Three tumour tissues) (Figure 
4.11h), and Ralstonia insidiosa (Dworak One tumour and normal tissues, Dworak Two 




Figure 4.11. Relative transcription levels of differentially transcribed species with atleast one statistically significant differences 
between Dworak score tissue groups. a) Campylobacter ureolyticus, b) Fusobacterium nucleatum, c) Hungetalla hathewayi, d) 
Clostridium saccharobutylicum, e) Bifidobacterium longum, f) Stenotrophomonas maltophila, g), Paraburkholderia fungorum, h) 
Pseudomonas sp. NC02, i) Ralstonia insidiosa.  *: p < 0.05; **: p <0.01; ***: p < 0.001; **** p < 0.0001. 
4.5 Effect size and beta-diversity 
Beta diversity was investigated between Dworak score groups and tissues using non-
metric dimensional scaling (NMDS) plots and distance metrics: Bray–Curtis 
dissimilarity (compositional dissimilarity), Jensen–Shannon divergence (similarity 
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between probability distributions) and the Jaccard index (similarity between unique 
members). Bray–Curtis (BC) takes taxa abundance into account (in this case, the level of 
transcription) to measure dissimilarity, while Jensen–Shannon divergence (JSD) 
measures similarity and has been used to establish enterotypes [177]. The Jaccard index 
(JI) does not take abundance into account and can be seen as a difference in the presence 
and absence of taxa in respective samples. 
The effect size of gender, age, cohort, Dworak score and tissue on the homogeneity of 
dispersion within nested groups was assessed using adonis R2 values. The homogeneity 
of each variable was tested using betadisper and the distance from centroids. 
4.5.1 Beta-diversity 
Using NMDS plots of calculated distance metrics, little clustering and high 95% 
confidence interval overlap could be seen within Dworak group tumour tissue samples 
(Figure 4.12a–c) or normal tissue samples (Figure 4.12d–f), indicating little difference 
between the groups. Using BC and the JI resulted in very similar clustering of samples. 
Additionally, when clustering samples by tissue types, substantial interpersonal 
variability was seen with each distance metric, with tumour tissues tending to be more 
distant from the centre (Figure 4.12g–i). 
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Figure 4.12. Beta-diversity non-metric dimensional scaling (NMDS) plots of bacterial transcription in tissues and Dworak 
groups. a) Bray–Curtis tumour tissue, b) Jenson–Shannon tumour tissue, c) Jaccard index tumour tissue, d) Bray–Curtis 
normal tissue, e) Jenson–Shannon normal tissue, f) Jaccard index normal tissue. Lines in the following indicate sample pairs; 
circles indicate tumour tissue and triangles are normal tissues.  g) Bray–Curtis tumour and normal tissue, h) Jenson–Shannon 
tumour and normal tissue, i) Jaccard index tumour and normal tissue. Ellipses represent 95% confidence intervals. 
4.5.2 Effect sizes 
In testing individual variables, the effect of Dworak as a variable had the largest single 
effect size (0.032–0.038) with JSD and JD displaying slightly higher effect sizes than BC, 
followed by cohort (0.019–0.023) and tissue (0.014–0.02) (Figure 4.13). However, these 




Figure 4.13. Variable effect sizes  
As homogeneity of dispersion within variables used is a condition for the use of adonis,  
homogeneity of dispersion was tested using betadisper. It can be seen that there was 
significant dispersion within the cohort variable (Table 4.1), so the lack of significance of 
the above effect size of this variable may not be due to real differences in centroids. 
Table 4.1. Variable homogeneity test results 
Distance  Cohort Dworak Tissue 
Bray–Curtis 
sum of squares 0.128 0.038 0.055 
mean squares 0.128 0.013 0.055 
p-value 0.020 0.690 0.127 
Jensen–Shannon 
sum of squares 0.128 0.020 0.018 
mean squares 0.128 0.007 0.018 
p-value 0.019 0.468 0.124 
Jaccard sum of squares 0.147 0.037 0.088 
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mean squares 0.147 0.012 0.088 
p-value 0.022 0.694 0.062 
 
4.6 Correlation with response 
Species abundance and relative transcription were correlated with response grades to 
determine which species potentially have a role in treatment outcomes. Taxa were 
filtered to those with at least 30 reads in 20% of samples, separated into phylum, family, 
genus and species groups. Their relative abundances were correlated with Dworak 
scores in respective tissues using Spearman correlation with Benjamini and Hochberg 
FDR correction. 
4.6.1 Results 
Within tumour tissues, although no taxa were correlated with Dworak scores overall; 
Bacteroides caccae was positively correlated with a poor response (Dworak One) (Figure 
3.14). Although not statistically significant after FDR correction, the phyla Fusobacteria 
and the family Fusobacteriaceae were negatively correlated with a poor response 
(Dworak one), while the genera Escherichia and the species B. vulgatus were positively 
correlated with a poor response with unadjusted p-values < 0.05 (Figure 3.14). 
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Figure 4.14. Correlation heatmap of tumour tissue taxa and Dworak scores. s_: species; g_: genus; f_family; p_ phylum. X 
symbols indicate no statistical significant correlation (FDR > 0.05). 
Of those taxa with correlations with a poor response (Dworak One), it was seen via 
scatter plots (Figure 4.15) that the correlation of any taxa with response was only slight 
and not statistically significant, and that considerable variation existed within response 
groups, particularly in regards to Dworak Two samples.  
Additionally, as Fusobacteria and Fusobacteriaceae were significantly correlated with a 
poor response, the most transcriptionally active species in the Fusobacterium genus (F. 
nucleatum) was investigated (Figure 4.15f); however, it was not found to have a 
significant association with response.  
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Figure 4.15. Taxa correlated with response in tumour tissues. Blue Line = regression line; grey bars: 95% confidence interval. 
C. ureolyticus correlated negatively with Dworak scores within normal tissues and 13 
other taxa correlated with poor response. However, after FDR correction, ten taxa 
correlated with poor response were statistically significant (Figure 4.16).   
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Figure 4.16. Correlation heatmap of normal tissue taxa and Dworak scores. 
At the Phylum level, Bacteroidetes and Proteobacteria were positively and negatively 
correlated with a poor response (0.39 and –0.39, respectively) (Figure 4.17a,b). The 
families Pseudomonadaceae and Bacteroidaceae correlated with poor response (–0.36 
and 0.39, respectively) (Figure 4.17c,d); Enterobacteriaceae was also negatively 
correlated with poor response, but this was not statistically significant after FDR 
correction (FDR = 0.068). The Pseudomonas and Bacteroides genera were negatively (–




Figure 4.17. Phyla, families and genera correlated with response in normal tissues. 
The negative correlations of E. coli, Klebsiella pneumoniae and Salmonella enterica with 
poor response (–0.36,  –0.42 and –0.41, respectively) were statistically significant (Figure 
4.18a,b,c). B. fragilis and Odoribacter splanchicus were positively correlated with a poor 
response (0.36 and 0.35, respectively); however, the later was not statistically significant 
after FDR correction (Figure 4.18d,e). C. ureolyticus, which was negatively correlated 
with response had very low transcription levels across samples except for one Dworak 
Two sample in which considerably higher levels were seen (Figure 4.18e), and after 




Figure 4.18. Species correlated with response in normal tissue. 
4.7 Alignment with bacterial genomes 
B. fragilis was the most consistently transcriptionally active species across all samples 
(RNA-Seq reads: mean = 8557, median = 183, max = 346490, min = 2, SD= 43402). Due to 
its correlation with poor response, reads assigned to the species were aligned with a B. 
fragilis reference genome to determine the genes being transcribed which may explain 
its role in response. However, insufficient RNA-Seq reads were present for accurate 
differential expression analysis [405], with only seven samples having more than 10,000 
reads per sample before mapping to the reference genome. All tumour and normal 
tissue reads were aligned to the B. fragilis genome to determine if the bft toxin was being 
expressed. As can be seen in Figure 4.19, no expression of the bft gene was detected at 
the time of sampling. 
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Alpha-diversity between tissues and response groups was not statistically significant in 
most instances. However, Shannon diversity differences were statistically significant 
between Dworak One and Two normal tissues, which could be due to two factors: a) 
the comparative differences in the number of samples; b) the differences found between 
the poorest responders (Dworak One) and moderate responders (Dworak Two) may be 
due to the more selective microenvironment compared to higher responders (which did 
not have statistically significant differences). Of these, the evidence provided would 
suggest a), as the impact of the microenvironment on diversity could not be confirmed 
with such small and uneven sampling.  Additionally, when grouping into high and low 
response groups, no statistically significant difference was seen, supporting the idea 
that the difference in sample sizes contributed to the outcome. 
There was a statistically significant Simpson diversity difference between the tumour 
and normal tissues of Dworak Two patients; again, the difference may be due to the 
higher number of samples in the Dworak Two group (22 of 40, 55%) allowing greater 
discrimination between respective tissues. However, as with Shannon diversity, when 
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combined with Dworak One patients into the low response group, there was no 
statistically significant difference between the low and high responders, again 
indicating that the statistically significant differences resulted from the insufficient 
sample sizes in this study. Alternatively, the difference between Dworak One and Two 
patient tissues' selective microenvironments may make grouping them inappropriate. 
However, under the assumption that the statistically significant findings between 
Dworak Two tissues and between Dworak Two and One normal tissues are valid, the 
results would indicate that there may be increased intrapersonal tissue differences in 
moderate responders. Simultaneously, the increased diversity in the normal tissues of 
the poorest responders (Dworak One) may contain additional taxa from the more 
selective radioresistant tumour environment that does not occur in less radioresistant 
tumours. 
4.8.2 Filtering 
For correlation and differential expression analyses, taxa were filtered to those 
represented by 30 reads in at least 20% of samples, while for beta-diversity analysis, 
taxa with read counts of five or higher in at least 20% of samples were retained. The less 
stringent filtering for beta-diversity analysis was done to retain more variability 
between sample groups, while in correlation and expression analyses, only the most 
accurately identified taxa were retained. 
The filtering threshold was chosen to eliminate taxa that would be uninformative, while 
still retaining some rarer taxa, as excessive filtering would leave only the core 
microbiome. Filtering thresholds have implications for microbiome studies overall, as to 
how researchers decide to group, filter and display sample data can impact results and 
their interpretation. As such, caution is advised when interpreting study results 
utilising less than a few hundred samples per group, as small sample sizes (as used 
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here) can contribute to the loss of taxa from filtering that would otherwise be 
informative to study outcomes [406]. 
4.8.3 Composition and differential transcription 
Proteobacteria transcription dominated most samples, the abundance of which has been 
used as a marker of dysbiosis and disease in the gut [407]; however, this pertains 
mainly to studies performed in faecal samples, the results of which are not directly 
applicable to tissue studies [164]. As many pathogenic taxa are found in the 
Proteobacteria phylum, the compromised and inflammatory gut-tissue environment of 
cancer patients may allow the expansion of such taxa, allowing discrimination between 
response groups microbiome variation between individuals can often be attributed to 
interpersonal differences between Proteobacteria taxa [408].  
Cyanobacteria were the only phyla to have statistically significant higher transcriptional 
activity in tumours, and these differences were higher in high responders than low 
responders. Cyanobacterial toxins have been identified as contributing to modulation of 
the innate immune system in the mucosa, and some have been identified as producing 
carcinogenic compounds [409]. Additionally, species of Cyanobacteria used in food and 
supplements such as Arthrospira sp. are known to have radioresistant properties [410]; 
however, how this might contribute to tumour radiosensitivity is unknown.  
When comparing differentially transcriptionally active genera, Campylobacter was found 
to be five-fold higher in tumour than normal tissues, across response grades; however, 
this is likely due to contributing to and therefore survivability in inflammatory 
environments [411], and maybe an indicator of tissue inflammation more generally. 
Additionally, the Campylobacter species most prominently transcribed in this study, C. 
ureolyticus, was not evenly transcribed across samples, indicating that a few samples 
may drive this result. 
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More interestingly, when comparing the differences between the tumour differences 
between high and low responders, it was found that Hungatella and Butyricimonas were 
6–7-fold and Flavonifrator and Oscillibacter 3-fold more transcriptionally active in high 
responder tumour tissues compared to normal tissues, compared to the differences 
between tissues of low responders. These results indicate that relative differences 
between the transcription of these genera between tumour and normal tissue biopsies 
could be used prognostically to indicate tumour regression outcomes.  
Hungatella are anaerobic bacteria that have been associated with CRC in the past, 
particularly in consensus molecular subtype 1 (CMS1), characterised by 
immunogenicity and hypermutation [93]. Additionally, in a study by Xia et al., 
Hungatella hathewayi colonisation in mice promoted epithelial cell proliferation, 
immunoreactivity, and the methylation of SOX11, THBD, SFRP2, GATA5, and ESR1 
tumour suppressor genes, and could be contributing to hypermethylation more 
generally [412]. In addition to Hungatella hathewayi, Xia et al. also found that and 
Fusobacterium nucleatum was associated with increased methylation of MTSS1, RBM38, 
PKD1, and PTPRT [412]. The above may have implications for response to tumour 
regression. 
Indeed, these two species were identified in this study, along with Bacteroides 
thetaiotaomicron, to have lower differential expression in tumour tissues compared to 
normal tissues in low responders. However, B. thetaiotaomicron has been reported to 
reduce inflammation in irritable bowel disease cell and animal models [413]. 
Additionally, H. hathewayi was seen to be more than 5.5-fold lower in the normal tissues 
of high responders compared to low responders, indicating that they may contribute to 
diverting increased immune activity away from the tumour site in low responders. 
However, this would require further investigation. 
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In this study, high responder tumours contained more than three-fold higher B. faecalis 
compared to low responders and were found to have higher transcription in high 
responder tumours relative to normal tissues, and these differences being five-fold 
higher compared to low responders. Butyricimonas, are anaerobic butyrate producers, of 
which one species has been implicated in causing septic shock in a CRC patient [414], 
indicating that they may have high immunogenicity in addition to their butyrate 
production. Butyrate can upregulate PPARγ signalling maintains epithelial hypoxia by 
driving mitochondria toward β-oxidation of fatty acids and can act as an energy source 
for colonocytes and other bacterial species, such as Salmonella enterica [415].  
Flavonifractor has been reported as more abundant in healthy controls when studying 
CRC microbiomes [416, 417], and its higher transcription was identified here as being 
more than three-fold higher in tumour compared to normal tissues of high responders 
compared to low responders. The above indicates that the tumour microenvironment of 
high responder tumour tissues may be more similar to healthy tissues than poor 
responders. The effect of Flavonifractor on response may involve an immune regulatory 
function, as oral supplementation in of F. plautii has been found to suppress Th2 pro-
inflammatory immune responses [418].  
A. finegoldii was the most prominently transcribed species in the Alistipes genus and was 
found to have higher differential transcription in the tumours of complete responders, 
three-fold higher transcription in tumour than normal tissues in high responders, 
compared to the differences of tumour and normal tissues of low responders. A. 
finegoldii is a propionate producer [419], a SCFA that that can stimulate PYY and GLP-1 
in colonic cells, reducing energy intake [420] and can utilise saturated fatty acids for 
membrane production [421]. Oscillibacter transcription was detected in high responders' 
tumours, which has been correlated with high-fat diets and reduced intestinal barrier 
function [422]. In conjunction, the above species gives further evidence for the benefit of 
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high-fat diets on radiotherapy outcomes, as has been demonstrated in randomised 
controlled studies on ketogenic and high-fat diets in radiotherapy of RC [423], having 
benefits to quality of life and body mass in gastrointestinal cancers [424]. The results 
here indicate a microbial metabolism component that may impact outcomes in the 
tumour microenvironment; however, this requires further investigation as the taxa may 
be selected for by a beneficial diet, rather than having an impact on response 
themselves. 
The above evidence may suggest that the contribution to CRC by H. hathewayi and F. 
nucleatum via methylation of tumour suppressor genes may result in increased 
radiosensitivity due to enhanced immunogenicity and methylation; however, this 
requires further investigation, particularly with the similarly associated Flavonifractor, 
and B. thetaiotaomicron having a role in ameliorating inflammation. Additionally, it may 
be possible that high-fat diets may encourage the colonisation of tissues with 
Oscilliobacter and A. finegoldii, altering tumour metabolism in conjunction with butyrate 
produced by B. faecalis, pushing tumour metabolism toward ketogenic metabolism, and 
starving glucose dependant tumours, reducing cellular proliferation [425]. However, 
although ketogenic diets are generally well tolerated, further investigation is required 
on the interactions between radiotherapy, the microbiome and ketogenic diets in RCs 
[426]. 
4.8.4 Beta diversity and effect sizes 
Beta diversity was measured using Bray–Curtis (BC) Jensen–Shannon distance (JSD), 
and the Jaccard index (JI). It was not possible to use UniFrac measures as they rely on 
phylogenetic relationships between assigned reads. Due to the random nature of total 
RNA-sequencing from tissue samples, the lack of phylogenetic relationship between 
different reads from the same species would result in heavily distorted results. 
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There was little difference between the BC distance and the JI clustering of tumour and 
normal tissues or by Dworak score, indicating that incorporating transcriptional 
abundance does not substantially affect clustering of samples beyond that established 
by the presence or absence of unique taxa. All beta-diversity analysis showed that 
patient tumour tissues might be more diverse than normal tissues; however, the level of 
interpersonal variability and cluster overlap suggests this is not always the case. 
Effect sizes showed that using beta diversity, Dworak scores and tissue variables 
explain little of patients' microbial transcription variability. However, this leaves the 
majority of variability to be explained by other unknown factors, of which genetic 
dissimilarity and differences in environmental exposure between patients are likely the 
major contributing factors. 
4.8.5 Correlations with response 
Only Campylobacter ureolyticus transcription was correlated with Dworak score in 
normal tissues; however, this was not found to be statistically significant and was likely 
driven by two samples with higher than normal levels. Although no statistically 
significant taxa were found to be correlated with Dworak scores, several were seen to be 
correlated with a poor response (Dworak One), but not conversely negatively correlated 
with a complete response (Dworak Four). The phylum Fusobacteria and family 
Fusobacteriaceae were both correlated with poor response, but not F. nucleatum, the 
most transcriptional active member species. Similarly, the Escherichia genus was 
positively correlated with poor response, but not E. coli, its most transcriptionally active 
member species within tumour tissues; however, it was within normal tissues. This 
effect may be due to a species-level assignment limitation as multiple closely related 
species were included in the database.  As most reads assigned to Fusobacteria were 
also assigned to Fusobacteriaceae, only some reads likely had species-specific content; 
most reads assigned to a family or genus would be largely homologous between 
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member species, which indicates that only a minority of reads produced from species-
specific regions can discriminate between species. 
Two Bacteroides species, B. vulgatus and B. caccae, were also positively correlated with a 
poor response. B. vulgatus is known to reduce inflammation by reducing microbial 
lipopolysaccharide production [427], while B. caccae has been implicated in appendicitis, 
intra-abdominal infections [428] and ulcerative collitis [429], indicating it may 
contribute to anti-bacterial inflammatory immune responses.  The Bacteroidetes 
phylum, the Bacteroidaeceae family, and the Bacteroides genus were positively 
correlated with a poor response within normal tissues. B. fragilis was the only species in 
the Bacteroides genus that was significantly correlated with a poor response. B. fragilis 
strains have been implicated in CRC due to bft enterotoxin expression [430], while other 
strains have been suggested as a probiotic and have been shown to enhance 
phagocytosis and polarisation of macrophages to the M1 phenotype [431], which would 
improve tumour clearance. As the most abundant species with consequential strain 
differences, the reads assigned to B. fragilis were extracted and aligned to a 
representative genome to determine the differential expression occurring in different 
tissues and response groups. Although the number of reads was too small to identify 
differentially expressed genes, it was possible to determine that no bft expression was 
occurring in any samples, indicating that if enterotoxigenic strains were present, they 
could not actively express the bft toxin. Due to the limitation in the read depth and 
sampling consistency across samples, it cannot be said what strains of B. fragilis are 
involved or what role they have in radiotherapy outcomes and should therefore be 
further investigated. 
Salmonella enterica was negatively correlated with a poor response; however, there was 
high interpersonal variability. The species S. enterica, similar to B. fragilis, has several 
subdivisions which may have different roles in environments [432], and assignment 
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could not be resolved to the subspecies level. However, considering the previously 
discussed ability to feed on butyrate, one hypothesis for its association with response is 
that in poor responders, it can metabolise available butyrate, depriving host tissues of 
its effects, while in higher responders, it may be selected for higher levels of butyrate, 
but its metabolism does not deplete the pool available for host uptake. Additionally, 
Salmonella species have been suggested as a novel anti-cancer therapy, showing some 
success in animal models alone and in conjunction with radiotherapy, through a direct 
growth inhibition of tumours and immune mediation, inhibiting Tregs and increasing 
CD8 T cell populations [433, 434]. Similarly, E. coli were identified as being negatively 
correlated with poor response and had substantial amounts of variability between 
different strains, which makes forming a hypothesis around the mechanism of effect on 
response difficult. However, as all E. coli are facultative anaerobes, they may reduce the 
available oxygen in the microenvironment. Additionally, as they are one of the fastest 
replicating prokaryotes [435], their relatively high transcription may result from the 
temporary environment of the colonoscopy pre-treatment, after which the biopsies were 
collected. 
 Although both the Pseudomondaceae family and the Pseudomonas genus were 
negatively correlated with poor response, no Pseudomonas species was correlated with 
response. Pseudomonas sp. NC02 transcription was significantly higher in low 
responders' tumours compared to those of high responders; however, given that P. sp. 
NC02 is a soil bacteria with no evidence of human gut colonisation, and that the 
database used for taxonomic assignment contained 127 species and strains of the 
Pseudomonas genus, it is possible that this species was likely misidentified, largely due 
to its 99% similarity to both P. yamanorum and P. fluorescens [436]. Odoribacter 
splanchnicus was also negatively correlated with poor response. However, due to its 
high inter-sample transcriptional variability (mean reads assigned per sample: 340; SD: 
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1353) and that it is closely related to other significantly transcriptionally active species 
in the genus Butyricimonas [437], O. splanchnicus may have also been misidentified. 
Although identification of O. splanchnicus is more likely than P. sp. NC02, as it has been 
reported in the human gut [438]. 
Overall, since taxa were correlated with a poor response but not inversely correlated 
with a complete response or Dworak scores, it may be possible that taxa can contribute 
to or are selected by the tissue microenvironment of poor responders, but not of higher 
responder groups. It could be that the selective environment of poor responders is more 
extreme, with the more subtle selective pressures of other responder groups not being 
assessed with the small sample sizes employed in this study. 
 
4.8.6 Limitations 
A strong limitation of this study was the unbalanced design, using two low powered 
cohorts, and more samples having a Dworak Score of two than any other group. 
Furthermore, the inability to perform differential gene expression on individual taxa or 
to resolve them beyond a species designation leaves only speculative functional 
contributions to tumour regression. Transcriptional sequencing and taxa assignment 
error may play a role in the results of this study. Finally, the speculative cohort effect 
may have further affected the data and subsequent interpretation of results.  
4.9 Conclusions 
Based on the results of this study, microbial alpha or beta diversity does not contribute 
to enhanced or decreased response rates to radiotherapy in RCs. However, the 
increased transcription of individual species such as Hungatella hathewayi, Fusobacterium 
nucleatum, Butyricimonas faecalis, Alistipes finegoldii, Bacteroides thetaiotaomicron, and B. 
fragilis may contribute to response by modulating metabolism and anti-tumour immune 
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responses. Additional research is required with higher sample sizes, more per-response 
group power and higher bacterial read depth; to resolve contributing species to strain 
designations and to evaluate the contribution of differential gene transcription within 
those strains to radiotherapy outcomes. 
5 CHAPTER 5: IMMUNE CELL INFILTRATION 
5.1 Introduction 
The immune system's role in response to therapy is widely accepted [439], with the field 
of immunotherapy taking advantage of this fact [440]. Neo-antigens produced in 
damage-associated molecular patterns (DAMPs) are thought to trigger immune 
responses against tumour tissues, with natural killer T cells and CD8 T cells being most 
implicated in cytotoxicity induced tumour regression [441].  
More recently, macrophages and dendritic cells have also been implicated, with 
different phenotypes having alternative responses [442]. So-called tumour tolerant cells 
such as D0 dendritic cells are implicated in preventing the immune system from taking 
action against tumour cells [443]. M2 tumour-associated macrophages (TAMs) have 
paradoxical roles in increased tumour growth and fibrosis, while M1 or tumour-
sensitive macrophages have been identified as having a tumour clearing role [444, 445]. 
The latter action of these macrophages may be linked to their role in tissue remodelling 
actions [446], such as differentiating from macrophages to osteoclasts [447]. Evidence 
for this role comes from the lipopolysaccharide (LPS) and RANK-L induced 
differentiation to osteoclastic phenotypes, as well as the association of high osteonectin 
with higher responses to radiotherapy [448] [449]. A study in mice has shown that 
osteonectin deletion decreased M1 macrophage levels and fibrosis in heart tissues. 
Overall, the implications of this remain to be thoroughly investigated [450]. 
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The immune system’s interaction with the microbiome has been a source of much 
contention in the research community over the last decade. Irritable bowel syndrome 
(IBS), inflammatory bowel disease (IBD) and other inflammatory diseases are associated 
with dysbiosis, which can cause inappropriate immune responses, resulting in 
pathologies [451]; suggesting that the microbiome can modulate immune activity in the 
gut  [289]. Additionally, different cytokine levels have been associated with disruptions 
to the microbiome, e.g., IL-6 and IL-10, implicated in autoimmune reactions such as 
colitis and Crohn’s disease [452].  
In this chapter, the aim was to measure the abundance of different immune cells within 
RC biopsies of tumour and normal tissues and test if they are correlated with response. 
Immune cells correlated with response to therapy were then correlated with the 
abundance and transcription of identified bacterial species within the respective tissues. 
The hypotheses of this chapter were:  
- Particular immune cells present in tumour tissues modulate the response to 
chemoradiotherapy (CRT) in RCs.  
- The transcription of different bacteria partly regulates relevant immune cells. 
5.2 Methods 
The Salmon tool [287] was used to quantify host gene expression using RNA-Seq data 
from the RC cohort (n = 40), using the GRCH38p12 transcriptome. The relative levels of 
immune cells in each sample were predicted using 500 permutations of the digital 
cytometry tool, CIBERSORT, which utilises support vector regression (SVR) to compute 
the proportion of immune cells based on gene expression data [284]. The ESTIMATE R 
package v1.0.13 was used on RC cohort RNA-Seq gene expression data to provide 
immune and stromal scores, while the ESTIMATE score was used to assess tumour 
purity [282]. Tumour purity was calculated using the formula: Tumour purity = cos 
127 
(0.6049872018+0.0001467884 × ESTIMATE score). The significance of differences 
between tissue and response groups was measured using Wilcoxon signed-rank tests 
with Benjamini and Hochberg False discovery rate (FDR) correction [453] and Kruskal–
Wallis tests. 
Spearman rank sum correlation with Benjamini and Hochberg correction was used to 
establish a correlation between the level of relative immune cells and response. Bacterial 
transcription levels were evaluated as described in the Methods chapter (Section 2.6), 
with microbial RNA expression being assigned taxonomy with Kraken 2 v2.0.7[338]. 
Taxa were filtered for the most transcriptionally active bacteria with a cut-off of at least 
30 reads in 20% of samples, which were converted to relative levels. Spearman 
correlation was used to ascertain the relationships between taxonomic abundance and 
transcription levels using Benjamini and Hochberg for FDR correction. Scatterplot 
regression lines were built using the linear-model (lm) method in the geom_smooth() 
function of ggplot2 v3.3.2 [315]. 
Scripts and code used for the analyses and supplementary tables can be found at 
https://github.com/William-S-Taylor/MSc. 
5.3 Results 
5.3.1 Immune cell profiling 
Between tumour and normal tissues, there were significantly lower levels of B memory 
cells (4.67-fold), CD8 T cells, (2.77-fold), plasma cells (1.86-fold) detected in tumour 
tissues. In comparison, there were significantly higher levels of activated mast cells (2.3-
fold), M0 macrophages (2.6-fold), neutrophils (3.32-fold) and M1 macrophages (8.76-
fold) (Figure 5.1, Supplementary Table 5.1).  
128 
 
Figure 5.1. Statistically significant fold-change differences between immune cells in tumour tissues and normal tissues. 
There were statistically significant differences between tumour and normal tissues in 
the abundance of B memory cells, plasma cells, CD8 T cells, activated mast cells, M0 
macrophages, neutrophils and M1 macrophages (Figure 5.2a–g). The abundance of 
plasma cells, activated mast cells and CD8 T cells had the greatest overlap between 
tissues; however, in terms of the abundance of B memory cells, activated mast cells and 




Figure 5.2. Abundance of immune cells significantly differentially abundant between normal and tissues. a) memory B cells; b) 
plasma cells; c) CD8 T cells; d) activated mast cells; e) M0 macrophages; f) neutrophils; g) M1 macrophages. * p <= 0.05, ** p <= 
0.01, *** p <= 0.001, **** p <= 0.0001. 
Within Dworak groups, the differences between tissue types were not consistent. The 
largest group, Dworak Two (n = 22), had significant differences between tissues for the 
same immune cells as the entire cohort; however, no other Dworak group had 
statistically significant differences between tissues. 
There were significant differences between detected immune cells in the tumour tissues 
of complete responders (Dworak Four) and the average abundance of incomplete 
responders (Dworak One–Three) in the abundance of Tregs, resting and activated mast 
cells (Error! Reference source not found.). The highest differences were seen for M1 
macrophages (Error! Reference source not found.). There were no statistically 
significant differences between normal tissues (Supplementary Table S5.2). 
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Figure 5.3. Significant fold differences between the detected immune cells in the tumour tissues of complete and incomplete 
responders. 
Dworak scores were grouped into a high response group (Dworak Four and Three) and 
a low response group (Dworak Two and One). No detected immune cells were 
significantly different between the tumour or normal tissues of the two groups, after 
FDR correction. 
However, there were significant differences in the abundances of resting and activated 
mast cells (Figure 5.4a,b), Tregs (Figure 5.4c) and M1 macrophages (Figure 5.4d) 
between the tumour tissues of complete responders (Dworak Four) and incomplete 
responders (Dworak One–Three). 
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Figure 5.4. The abundance of immune cells significantly differentially detected between tumours of complete and incomplete 
responders. a) activated mast cells; b) resting mast cells; c) T regulatory cells (Tregs); d) M1 macrophages. ** p < 0.01; *** p < 
0.001. 
5.3.2 ESTIMATE scores 
ESTIMATE was used to establish tumour purity within tumour samples, giving stromal 
and immune scores, and an ESTIMATE score used to measure of tumour purity. 
However, there was no statistically significant correlation between tumour purity, 
stromal or immune scores and Dworak scores, before or after FDR correction 
(Supplementary Table S5.2). 
5.3.3 Immune cell correlations with response 
After FDR correction, no immune cells were significantly correlated with Dworak 
scores in normal tissues; however, within tumour tissues, M1 macrophages and resting 
mast cells had statistically significant positive correlations with Dworak scores of 0.46 
and 0.51, respectively (Figure 5.5).  
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Figure 5.5. Immune cell abundance vs Dworak scores in tumour tissues. a) relative abundance of resting mast cells, a) M1 
macrophages, b) resting mast cells. Blue line: regression line; grey bars: 95% confidence interval. 
The significance of differences between immune cells significantly correlated with 
Dworak scores in tumours was tested between response and tissue types (Figure 5.6).  
There were statistically significant differences between the M1 macrophage levels in the 
tumour and normal tissues of Dworak Four and Dworak Two patients and between 
Dworak Four and Dworak One–Three tumour tissues (Figure 5.6a). Comparisons 
between relative levels of resting mast cells in tumour tissues showed statistically 
significant differences between the tumour and normal tissues of Dworak One and 




Figure 5.6. Abundance of immune cells correlated with response in tumour cells. a) M1 macrophages, b) resting mast cells. * p < 
0.05; ** p < 0.01. 
5.3.4 Correlation with the microbiome 
In Chapter 4, the microbiome was correlated with chemoradiotherapy response, in a 
possibly immune-mediated manner. The relative transcription of microbial taxa was 
correlated with the abundance of immune cells to investigate possible interactions 
between the microbiome and the immune system. Spearman correlation with Benjamini 
and Hochberg FDR correction was used to find statistically significant correlations 
between bacterial transcription with immune cell abundance. Taxa with more than 30 
reads across at least 20% of samples were retained for the correlation analysis, with a 
focus on taxa correlating with response in Chapter 4. 
5.3.5 Bacteria–immune correlations 
M1 macrophages correlated with Dworak scores within tumour tissues but did not have 
any statistically significant correlation with bacterial transcription. M1 macrophages 
were positively correlated with Campylobacter ureolyticus, Campylobacteraceae, and 
negatively with Cyanobacteria, Bacteroides vulgatus, Desulfovibrio, Alistipes finegoldii and 
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Alistipes; however, these correlations were not statistically significant after FDR 
correction (Supplementary Figure S5.1). 
M1 macrophages were negatively correlated with Pasteurellaceae in normal tissues (r = 
-0.439) (Figure 5.7a). Additionally, Bacteroides vulgatus was negatively correlated with 
resting dendritic cells within tumour tissues (Figure 5.7b). In contrast, activated 
dendritic cells were correlated with Clostridium saccharobutylicum, Salmonella enterica and 
Escherichia coli and its parent genus were positively correlated with activated dendritic 
cells (Figure 5.7c–f). Activated mast cell levels in tumour tissues were negatively 
correlated with Dworak scores (r = 0.303, p = 0.04); however, were not statistically 
significant after FDR correction (FDR adjusted p-value = 0.15). 
 
 
Figure 5.7. Scatterplot of M1 macrophages, dendritic cells and correlated bacterial transcription. a) Pasteurellaceae vs M1 
macrophages; b) Bacteroides vulgatus vs Resting dendritic cells, c) Clostridium saccharobutylicum vs Activated dendritic cells; 
d) Salmonella enterica vs Activated dendritic cells; e) Escherichia vs Activated dendritic cells; f) Escherichia coli vs Activated 
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dendritic cells. r: Spearman’s Rho; FDR: false discovery rate adjusted p-value. Lines of regression are coloured by tissue type; 
grey bars indicate 95% confidence intervals. 
Activated mast cells were positively correlated with Bacteroides dorei transcription 
(Figure 5.8a), while activated mast cells were positively correlated with resting mast 
cells (Figure 5.8b). Bifidobacteriaceae was negatively correlated with resting mast cells, 
but in normal tissues (Figure 5.8c). 
 
 
Figure 5.8. Scatterplot of mast cells and correlated bacterial transcription. a) Bacteroides dorei vs Activated mast cells, b) B. dorei 
vs resting mast cells, c) Bifidobacteriaceae vs Resting mast cells. r: Spearman’s Rho; FDR: false discovery rate adjusted p-value. 
Lines of regression are coloured by tissue type; grey bars indicate 95% confidence intervals. 
The transcription of Bacteroides fragilis was correlated with naïve B cells and CD8 T cells 
in tumour tissues (Figure 5.9a,b), while Eubacterium rectale was correlated with 
eosinophils and resting natural killer (NK) cells (Figure 5.9c,d). Streptococcus pyogenes 
transcription was positively correlated with follicular T helper cells in normal tissues 
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(Figure 5.9e) while the transcription of the family Flavobacteriaceae was in tumour 
tissues (Figure 5.9f).   
 
Figure 5.9. Scatterplot of B, T and eosinophils and correlated bacterial transcription. a) Bacteroides Fragilis vs Naïve B cells; b) 
B. fragilis vs CD8 T cells; c) Eubacterium rectale vs Eosinophils; d) Eubacterium vs Resting natural killer cells; e) Streptococcus 
pyogenes vs Follicular T helper cells, f) Flavobacteriaceae vs Follicular T helper cells. r: Spearman’s Rho; FDR: false discovery 
rate adjusted p-value. Lines of regression are coloured by tissue type; grey bars indicate 95% confidence intervals. 
 
Neutrophils were the immune cell which most correlated with bacterial transcription in 
normal tissues. Although neutrophils had a small negative correlation with Dworak 
scores in normal and tumour tissues (r = -0.191 and -0.032, respectively), this was not 
statistically significant (p = 0.236, FDR = 0.533; p = 0.841, FDR = 0.906, respectively). In 
normal tissue, the transcription of the phyla Proteobacteria and Bacteroidetes were 
negatively and positively correlated with the abundance of neutrophils, respectively 
(Figure 5.10a,b). E. coli transcription and that of the parent genus Escherichia were 
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negatively correlated with neutrophils in normal tissue (Figure 5.10c,d), as well as 
Pseudomonas sp. NC02 and its parent genus Pseudomonas (Figure 5.10e,f). 
 
 
Figure 5.10. Phyla, genera and species transcription correlated with neutrophils. r: Spearman’s Rho; FDR: false discovery rate 
adjusted p-value. Lines of regression are coloured by tissue type; grey bars indicate 95% confidence intervals. 
Additionally, Hungatella hathewayi transcription and that of its parent genus Hungatella 
were positively correlated with neutrophil levels in normal tissues (Figure 5.11b,a), 
along with Butyricimonas faecalis and its parent genus Butyricimonas (Figure 5.11d,c). 
138 
 
Figure 5.11. Genera and species correlated with neutrophils. r: Spearman’s Rho; FDR: false discovery rate adjusted p-value. 
Lines of regression are coloured by tissue type; grey bars indicate 95% confidence intervals. 
Transcription of the genus Alistipes and the species’ Flavonifractor plautii, B. fragilis and 
Odoribacter splanchnicus were positively correlated with neutrophil abundance in normal 
tissues (Figure 5.12a,c,e,f). B. fragilis was also negatively correlated with neutrophil 
abundance in tumour tissues, but this was not statistically significant after FDR 
correction (Figure 5.12e). Clostridium saccharobutylicum and Salmonella enterica 




Figure 5.12. Additional taxa transcription correlated with neutrophil abundance. r: Spearman’s Rho; FDR: false discovery rate 
adjusted p-value. Lines of regression are coloured by tissue type; grey bars indicate 95% confidence intervals. 
M1 macrophage abundance was significantly different between Dworak Two and Four 
tumour and normal tissues, and the tumour tissues of Dworak Four patients and those 
of Dworak Three–One patients, with the highest levels being in Dworak Four tumour 
tissues (Figure 5.13a). Resting mast cell abundance was significantly different between 
tumour and normal tissues of Dworak One and Two patients, as well as between the 
tumour tissues of Dworak Four patients and those of Dworak One and Two patients 
(Figure 5.13b). Additionally, the tumour tissues of Dworak Four patients were the only 
tumour samples to have a consistent abundance of resting mast cells (Figure 5.13b).  
The abundance of activated mast cells was higher across samples than resting mast 
cells, with statistically significant differences between the normal and tumour tissues of 
Dworak One and Two tumour patients, and between Dworak Four, Three, Two and 
One tumour tissues (Figure 5.13c). Eosinophils were most abundant in Dworak Two, 
140 
and Three tumour and normal tissues, respectively, and significant differences were 
found between the normal tissues of Dwoark Four and Three patients, between Dworak 
Three tumour and normal tissues, and between Dworak Three and One normal tissues 
(Figure 5.13h). Neutrophil abundance was significantly different between Dworak Two 
tumour and normal tissues and was in low abundance in normal tissues generally, and 
Dworak Four tumour tissues (Figure 5.13j). The abundance of resting dendritic cells was 
only evident in four samples, one normal sample, and three tumour samples, all from 
Dworak Two patients (Figure 5.13d). In contrast, activated dendritic cells were found in 
abundance across all Dworak groups and tissues (Figure 5.13e); additionally, and along 
with the abundance of naïve B cells (Figure 5.13f) and follicular T helper cells (Figure 
5.13i), were not significantly different between the tissues or Dworak groups. 
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Figure 5.13. Immune cell levels correlated with bacterial transcription. a) M1 macrophages; b) resting mast cells; c) activated 
mast cells; d) resting dendritic cells; e) activated dendritic cells; f) naïve B cells; g) CD8 T cells; h) eosinophils; i) follicular helper 
T cells; j) neutrophils. * indicate significance of FDR adjusted Wilcoxon signed-rank tests; *: p < 0.05; **: p < 0.01. Not 
statistically significant comparisons not shown. 
5.4 Discussion 
5.4.1 Myeloid lineage most correlated with radiotherapy response 
In this study, the common myeloid progenitor lineage was of most consequence for 
response correlations, with mast cells and M1 macrophages being correlated with 
radiotherapy response in tumour tissues; indicating that interference with myeloid 
differentiation is the major contributor to the production of effector cells contributing to 
tumour regression. M1 macrophage correlations with response were likely due to the 
142 
34-fold higher levels in complete responders compared to other groups. Resting mast 
cells were also positively correlated with response, indicating that the mitigation of an 
allergic response may be prognostically relevant. Macrophages are well understood to 
have a role in radiotherapy and radiation-induced cellular injury where they play a role 
in cellular clearance and fibrotic wound responses; a characteristic of tumour regression 
[450].  
5.4.2 M1 macrophages associations with bacterial transcription 
Although not statistically significant after FDR correction, the negative correlations of 
Campylobacteraceae and C. ureolyticus, and positive correlations of Cyanobacteria, B. 
vulgatus, Desulfovibrio, Alistipes and A. finegoldii transcription with M1 macrophages 
should be further investigated. It is known that Campylobacter can infect macrophages, 
and can direct M1 macrophages to target Campylobacter cells [454], which may 
interfere with their anti-tumour role. Cyanobacteria toxins are known to have 
immunomodulatory and carcinogenic effects [409] [455]; however, the direct interaction 
with M1 macrophages is unknown. [427]. B. vulgatus are known to modulate the 
immune system via lipopolysaccharide production [427], which may decrease M1 
macrophage levels by reducing LPS induced cytokines. Desulfovibrio species have been 
shown to infect macrophages and alter their gene expression [456], and their LPS has 
been shown to stimulate TNF-a secretion more so than other bacterial LPS [457]. 
Alistipes are bile tolerant [458] and in obesity, studies have been shown to alter polarised 
macrophage ratios [459]; additionally, they are produced of short-chain fatty acids 
(SCFAs) and can reduce glucose uptake, and incorporate saturated fatty acids into their 
membranes [419, 421]. Cholesterol uptake by macrophages is the principal cause of 
atherosclerosis, maintaining a pro-inflammatory response [460]. The most compelling 
evidence for M1 macrophage CRC microbiome interactions comes from studies into 
oral bacteria causing differential polarisation of macrophages, particularly in regards to 
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Porphyromonas gingivalis [461, 462] [463]; however, this was not detected in this study, 
likely due to the limitations of sample sizes and sequencing depth. Within normal 
tissues, Pasturellaceae were negatively correlated with M1 macrophages, which may be 
due to toxin production causing potential macrophage differentiation to an osteoclastic 
lineage [464]. 
Taking the above into account, it may be that the microbiota in high responders act in a 
lipid-rich environment and limit tumour glucose utilisation. By preventing monocytes 
from being ‘distracted’ by other microenvironment factors such as fat and resident 
microbiota, they can differentiate and polarise to anti-tumour M1 macrophages. 
 
5.4.3 Mast cells and bacterial transcription 
Mast cells have a role in allergen response, pathogen recognition, and wound healing 
[465], and have been shown to dysregulate T cell regulation in CRC [466]. Due to the 
varied roles of mast cells, their abundance alone does not indicate any particular 
pathway for their interaction with tumour regression, which may differ between 
patients. However, their pathogen recognition role may be essential for their 
involvement in tumour regression; indeed, B. dorei transcription was negatively and 
positively correlated with resting and activated mast cells, respectively.  Studies have 
demonstrated that gut commensals and Bacteroides species specifically can suppress 
mast cell degranulation and reduce reactivity [467, 468]; however, these studies did not 
focus on B. dorei. B. dorei may have a role in immune modulation more directly, as has 
been shown by a study which found high levels of the species preceding autoimmunity 
onset [469]. Unfortunately, the species B. vulgatus, B. dorei and B. xylanisolvens are very 
closely related and can be challenging to differentiate from one another [470]. 
Additionally, the negative correlation of Bifidobacteriaceae with resting mast cells 
conflicts with the literature, with Bifidobacteria species being shown to have suppressive 
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effects on mast cells  [471]. B. longum transcription was two-fold higher in tumours 
compared to normal tissues in high responders, which may indicate that its role is 
microenvironment dependant, as otherwise, it would have a similar correlation in 
tumour tissues, where it was found to be more transcriptionally active. Therefore, the 
potential interaction of B. dorei and Bifidobacteraceae species on mast cells in the 
tumour microenvironment should be further investigated.  
Small sample sizes likely influenced the correlation of resting mast cells with 
radiotherapy response, although they were detected mainly within the tumour tissues 
of complete responders (Dworak Four). However, the low abundance of resting mast 
cells indicates that a minority of samples may have driven possible correlations. 
 
5.4.4 Bacterial transcription and immune cells not correlated with response 
Several other immune cells were correlated with bacterial transcription that was 
previously implicated in response in Chapter Four. The correlation of B. fragilis 
transcription with both naïve B cells and CD8 T cell abundances was of particular note, 
as their interaction with these cells, and the immune system more generally has been 
well studied [472], and tumour regression has been suggested to be dependent on CD8 
T cells [473]. B.fragilis capsular polysaccharide A (PSA) is the most immunomodulatory 
aspect of this species, as when binding to B cells, it can result in CD8 T cell anti-
inflammatory IL-10 secretion [474]. The maintenance of a population of naïve B cells, is 
of particular note, as it could indicate that once radiation therapy commences, they can 
uptake and present tumour antigens. In contrast, previously activated B cells would 
present antigens from the tumour microenvironment. Indeed, studies suggest that 
infiltrating B cells are a possible prognostic indicator for radiation therapy [475], which 
be reduced during chemotherapy [476]. The above may indicate that B. fragilis 
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transcription plays a role in maintaining the anti-tumoral potential of the immune 
system before radiation therapy, and prevents non-tumour antigen presentation, which 
would not increase until radiation-induced tumour cell death, and thus, increased 
tumour neo-antigen availability [477].  
 Eubacterium rectale is a well-studied and abundant bacteria in the gut; however, 
maintains many subspecies which are more prevalent in different parts of the world, 
with carbohydrate metabolism, exopolysaccharide and motility operons contributing 
most to their diversity [478]. The correlation of E. rectale transcription with eosinophils 
is interesting, as it was found at much higher levels in tumour tissues of high 
responders, eosinophilia is a rare but known complication of radiation therapy [479], 
and eosinophil levels have been suggested as prognostic markers for several cancers 
[480-482]; being involved in radiation-induced fibrosis in intestinal tissues [483]. NK 
cells are known to play a major role in anti-tumour activity in radiation therapy [484], 
and E. rectale has been associated with a decrease in NK activity in the past [485]. Taken 
together, it may indicate that E. rectale may act before radiotherapy to preserve anti-
tumour immunogenic potential to be activated during therapy generation of tumour 
antigens via tumour ablation [486]. 
Follicular T helper cells are required for the generation of high-affinity antibodies and 
memory B cell formation, which are critical anti-tumour immunity, and mitigation of 
relapse [486, 487]. Flavobacteriaceae and S. pyogenes transcription was correlated with 
follicular T helper (Fth) cells, in normal and tumour tissues, respectively. Fth cells have 
been associated with reduced tumour growth and higher survival rates in some cancers 
[488]. Flavobacteriaceae is the parent family of Flavonifractor, which had more than 2.5-
fold higher transcription in the tumour tissues of high responders compared to low 
responders. As was suggested in the discussion of Chapter Four, Flavonifractor may 
confer a benefit to tumour regression rates in an immune-modulatory way, particularly 
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by suppressing Th2 pro-inflammatory responses [418]. Fths play a role in lowering 
immune reactions to commensal microbiota in the gut by modulating IgA secretion 
[489] and Fth differentiation from the common Th2, and Fth progenitor cell is a STAT3 
dependent process [490, 491], which has been suggested as a therapeutic target in 
cancer therapies as it a known promoter of cellular proliferation [492, 493]. Taking these 
pieces of evidence into account, it may be that the correlation of Flavobacteriaceae with 
Fth, and its child genus’ association with high responder tumour tissue, may indicate 
that they are associated with STAT3 expression, which has been associated with both 
tumour progression inhibition [494] and accelerated tumour growth [495], in a 
microbiota dependent manner. 
 
5.4.4.1 Bacterial transcription associations with dendritic cells 
Activated dendritic cells (aDCs) in tumour tissues were negatively correlated with 
Dworak scores, but this was not statistically significant. Additionally, the transcription 
of E. coli and B. vulgatus were correlated with poor response, while the former was 
positively correlated with aDCs, the latter was negatively correlated with resting 
dendritic cells (rDCs). The transcription of these species could contribute to a poor 
response by generating antigen presentation against them, rather than the tumour. 
Indeed, studies on E. coli antigen presentation by DCs shows that it occurs readily, to 
the extent that has been suggested that E. coli antigen uptake by DCs could be used in 
anti-tumour immunotherapy [496, 497]. However, a recent study showed that E. coli but 
not B. vulgatus was able to attenuate intestinal inflammatory in a colitis model [498]. 
Therefore, these taxa may interact differently with the immune system, and this is likely 
to be strain-dependent.  The transcription of C. saccharobutylicum and S. enterica were 
also implicated in response, and they were both correlated with aDCs. C. 
saccharobutylicum is used in the generation of biobutanol in the biofuel industry; 
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therefore its species assignment may be speculative.  Furthermore, the correlation of 
DCs and response was not statistically significant, and the precise role of DCs in 
radiotherapy response is not well understood [499]; however, they play a critical role in 
tumoural-immunity via antigen presentation. Therefore, further research is needed into 
the role of DCs and their relationship with tumour infiltrating bacteria and 
radiotherapy response; as similar to other immune cells, the preservation of rDCs until 
after radiotherapy may be critical for the uptake of tumoural, rather than bacterial or 
microenvironmental antigens [477].  
 
5.4.4.2 Neutrophils have the most microbial associations 
Neutrophils are a known contributor to radiation therapy responses, contributing to 
radioresistance in some cancers [500], and their abundance has been suggested as a 
biomarker for radiotherapy outcomes, depending on their phenotype (anti-tumour N1, 
pro-tumour N2) [501]. The different phenotypes of neutrophils, similar to the 
polarisation of macrophages, is likely to be dependant on the tumour 
microenvironment [502]. However, CIBERSORT does not differentiate between 
neutrophil phenotypes, so it remains unknown if N1 or N2 was more abundant in the 
study population. It may be that no statistically significant correlation was found as 
neutrophils generally are not correlated with response, but N1 or N2 phenotypes may.  
 
Neutrophil abundance was highest in tumour tissues, and Dworak Four tumours had 
the lowest levels, which may be due to the low sample size (Dworak Four n = 5); it also 
could indicate that neutrophil levels are prognostically relevant for a complete 
response. Despite this, no bacterial transcription was correlated with neutrophil 
abundance in tumour tissues, with all significant correlations being found in normal 
tissues. As the normal tissue biopsies were collected adjacent to tumour tissue, the 
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abundance of neutrophils in these tissues could provide a reservoir from which to 
migrate to the tumour microenvironment during radiotherapy as part of the early 
wound repair response [503, 504].  
The transcription of the Proteobacteria phylum generally and the contained species E. 
coli, Pseudomonas sp. NC02, S. enterica, as well as C. saccharobutylicum in the Firmicutes 
phylum, were negatively correlated with neutrophil levels in normal tissues. Low 
neutrophil levels may be due to strains of E. coli being able to cause apoptosis and 
necrosis in neutrophils [505, 506]. Neutrophils also react in different ways to 
Pseudomonas species, with most studies on cystic fibrosis patients showing decreased 
clearance abilities of neutrophils against Pseudomonas [507], and dying and dead 
neutrophils have been shown to facilitate Pseudomonas biofilm production [508]. 
Salmonella species have been shown to use flagellar motility to agonise neutrophil ROS 
production [509], while some Clostridium toxins have been shown to inhibit neutrophil 
proliferation [510]. The above evidence may indicate that the taxa can neutralise 
neutrophils via killing and disrupting their proliferation and bacterial clearance actions, 
triggering biofilm formation that shields the taxa from further neutrophil attention. 
However, as much of this evidence is not specific to the species identified here, further 
investigation is required. 
The transcription of the Bacteroidetes phyla and the contained species Odoribacter 
splanchnicus, B. fragilis, Butyricimonas faecalis and Alistipes, as well as the Firmicutes 
Hungatella hathewayi and Flavonifractor plautii, were correlated with neutrophil 
abundance in normal tissues. Consistent with the literature, Alistipes are known to 
induce and thrive in inflamed environments [381, 511]. At the same time, Hungatella has 
been found in greater abundance in CRC tissues of the immunogenic subtype [93], and 
H. hathwayi specifically is immunoreactive [412]; however, their interaction with 
neutrophils specifically has not been investigated. Additionally, the oral administration 
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of F. plautii has been demonstrated to lower the Th2 immune response [418], in which 
neutrophils have an immunomodulatory role [512] and is thought to be required for 
some neutrophil associated inflammation [513]. O. splanchnicus has been shown to 
reduce neutrophil attraction into mucosa via IL-8 inhibition, while B. fragilis PSA has 
similar anti-inflammatory properties [514]. B. faecalis is a butryate producer, which is 
known to stimulate colonic Tregs, which, in turn, are known to limit neutrophil 
responses [515]. Taken together, it is likely that in comparison to the negatively 
correlated taxa in normal tissues, taxa which were positively correlated with neutrophil 
levels can be explained by immuno-tolerance activities. Therefore they likely do not 
stimulate neutrophil abundance but also do not inhibit their proliferation or migration. 
Overall, the immune system can interact with the complex tumour microenvironment 
in different ways. An allergic pro-inflammatory response can be triggered, causing 
myeloid cells to differentiate via the mast cell lineage. Alternatively, myeloblasts can be 
differentiated to neutrophils, eosinophils or the monocyte/macrophage lineage. The 
monocyte/macrophage lineage can result in anti-microbial effector cells via LPS 
stimulated cytokines, an anti-lipid response similar to that seen in atherosclerosis, or an 
anti-tumour response.  
Based on the correlations with response and with bacterial transcription, the immune 
anti-tumour response may only be achieved when macrophages and other immune 
cells are free to exhibit anti-tumour activity and are not distracted by aspects of the 
tumour microenvironment. Non-tumour immune activity may occur via direct infection 
by microbes and their antigens; generating an antimicrobial response, or effector cells 
may react to other aspects of the tumour microenvironment (i.e., lipids, cellular debris), 
in the absence of potent immunogenic targets and tumour antigens. Furthermore, the 
suppression of antigen presenting cells (APCs) before radiotherapy may be critical, 
preserving naïve and resting APC populations to uptake and display tumour neo-
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antigens as tumour cells die, rather than displaying antigens of the tumour 
microenvironment. 
 
5.4.5 Study limitations 
It is possible that CIBERSORT’s digital cell cytometry for evaluating immune cell 
abundance may not be completely accurate [516]; therefore, real-world cytometry 
should be used in future to confirm these associations, particularly in regards to the 
phenotypic subtypes of immune cells (i.e., neutrophils). The immune cell abundance (as 
seen in Figure 5.13) showed that immune cells were not evenly represented across 
samples, indicating that the identified assocaitions may be due to outlier samples, 
which was particularly evident for less abundant immune cells, and in Dworak Two 
patients. Additionally, the small sample sizes, particularly in regards to the limited 
numbers of Dworak One, Four and Three response groups, reduces the power of this 
study to determine associations of immune cells with radiotherapy response properly. 
Furthermore, Kraken2 may have misclassified some of the bacterial taxa, particularly at 
the species level, and the filtering process may have removed consequential taxa which 
may have been retained with larger sample sizes. Additionally, species-level 
designations do not fully elucidate the capabilities of the taxa identified, and strain and 
subspecies level designations are required for a more accurate analysis. Finally, some 
species correlations, particularly B. dorei with mast cells, B. frag with naïve B and CD8 T 
cells, Flavobacteriaceae with follicular T helper cells, and correlations with neutrophils 
need to be investigated further, as correlations may have been due to the low number of 




Overall, the abundance of resting mast cells and M1 macrophage levels in tumour 
tissues were the most robust indicator for chemoradiotherapy response. The results 
indicated that interference with myeloid differentiation might be the major contributor 
to the production of effector cells contributing to tumour regression. The positive role of 
microbial transcription in immune modulation before radiotherapy likely involves 
suppressing the APC and effector cell populations before radiation ablation occurs, 
allowing them to be available for rapid uptake of and action toward tumour antigens. 
Additionally, beneficial microbes prevent the immune system from establishing a non-
tumour response in reaction to elements of the microenvironment (i.e., allergic, anti-fat, 
anti-microbial), which may persist during or inhibit anti-tumour responses once 
radiotherapy commences. 
The association and specific mechanisms and roles of microbial species on immune-
mediated response to radiotherapy require further investigation with larger samples 
sizes, and both in vitro and in vivo laboratory experiments. 
 
6 CHAPTER 6: BIOMARKER ANALYSIS 
6.1 Introduction 
Prognostic markers for CRC radiotherapy treatment have not been well elucidated, 
with 10% to 25% of cases resulting in complete response. Few biomarkers for 
radiotherapy response have been discovered and may not be universally applicable 
[517-523]. The microbiome has been investigated in terms of response to radiotherapy, 
with most studies focusing on the role of the microbiome in radiotherapy side effects 
such as mucositis, radiation-induced diarrhoea and other gastrointestinal symptoms 
[393, 394, 396, 399], and few focusing on the prognostic value of the microbiome [524]. 
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The role of the immune system in terms of differential responses to therapy in RC has 
been increasingly implicated, particularly in regards to antigen-presentation inhibition 
and depletion of tumour infiltrating leukocytes, as well as the abscopal effect of distant 
metastatic tumour regression post-radiotherapy [250, 439-443]. 
In this chapter, the aim was to investigate possible biomarkers based on pre-therapy 
biopsies, from tumour and adjacent normal tissues via block supervised sparse partial 
least squares discriminant analysis (sPLS-DA). The microbiome, gene expression, and 
estimated immune cell infiltrates were the blocks used as putative markers for response 
to therapy, in an attempt to classify patients into response groups before the 
commencement of therapy. By finding biomarkers indicative of response to therapy, it 
would be possible to direct patients to alternative treatments or accelerate them to 
surgery; thus, increasing disease-free survival in RC patients, decreasing unnecessary 
side effects and reducing treatment costs. 
6.2 Methods 
Microbial species relative abundance and relative transcriptional abundance was 
determined as previously described (Section 2.6). Immune cell abundance was 
estimated as described in Section 5.2. The level of gene expression was quantified as 
described in Section 2.6 using SALMON v1.2.1 [287], using the quasi-alignment method, 
which quantifies gene expression based on the reference transcriptome (GRCH38p12) 
and imported into R using the tximport package v1.16.1. The three datasets were input 
to DIABLO (Data Integration Analysis for Biomarker discovery using Latent 
cOmponents) [359], as part of the mixOmics data integration project R package v 6.12.2 
[525]. 
The microbiome species data from the RNA-Seq experiments were utilised, as well as 
the immune dataset. The gene expression dataset was adjusted before analysis using the 
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filterByExpr function in edgeR [356], removing any genes with a count of less than 100 
in all samples in each tissue group (n = 40). Gene expression filtering left 13,613 genes 
out of the original 36,622 for normal and tissue samples. Additionally, it was found that 
pre-sequencing ribodepletion was not complete, with substantive levels of RNA subunit 
genes, particularly RNA28S and 45S, remaining, which were removed. The final gene 
expression dataset contained 13,587 genes. 
Tumour and normal tissue data were normalised separately via centred log-ratio 
transform (CLR), to avoid overcorrection and loss of treatment effects. The CLR 
transform maps a composition in Aitchison-simplex to euclidean vector subspace, 
allowing consequent matrices to be singular, and allow the use of classical multivariate 
dataset analysis [526]. Any potential batch/cohort effect was removed using the 
removeBatchEffect function in limma [527].  
Sparse partial least squares regression (sPLS) was used for variable selection [528], 
which includes Least Absolute Shrinkage and Selection Operator (LASSO) penalisations 
on pairs of loading vectors, allowing minor coefficients to be forced to zero values and 
permitting varied coefficient sizes in the same model [528]. Raw inputs were used to 
establish the categorisation ability using variables which in the immune and bacterial 
transcription data met an R2 threshold of ≥ 0.2 or ≤–0.2 and within the gene expression 
dataset of ≥ 0.01 or ≤–0.01.  
The data was split into training and test sets (1), and the training set was reduced 
manually, variable by variable, to the point where further removal reduced the 
predictive ability of the variable sets, as assessed by 5-fold leave-one-out (loo) cross-
validation centroid distribution in the mixOmics R package (v6.12.2) [525]. Weighted 
vote error rates were used to establish response group classification overall error rates 
and overall balanced error rates; the latter being more accurate due to the uneven 
number of individuals in each response group.  
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Table 6.1. Training and test datasets 
Response Dworak Train Test 
Complete Four 3 2 
Intermediate 
Three 4 2 
Two 17 5 
Poor One 4 2 
 
The goal was to iteratively remove variables to find the most discriminatory set, using 
the lowest number of inputs, and without disrupting the ability to predict response 
groups. Once a reasonable error rate had been reached, the test set response grade was 
established based on the training set output. 
It was determined that Dworak scoring may not be a true continuous variable due to 
the nature of its allocation (different pathologists may assign different scores based on 
different thresholds) and that there may be differences between a potential poor 
responder with an unusually high response, and a potential complete responder with 
an unusually low response. Therefore, it was decided to change the model into one with 
a more simple logical model of three groups, complete (Dworak Four), intermediate 
(Dworak Two and Three) and poor (Dworak one), allowing for simpler categorisation. 
Heatmaps were generating using the cimDIABLO command, a method similar to 
classical hierarchical clustering.  
Gene roles were taken from data acquired from the Human Gene Database: 
https://www.genecards.org/, and Gene Ontology information was taken from 




6.3.1 Batch/cohort effect testing and removal 
Post-CLR-normalisation of datasets, the cohort effect was visualised using sPLS-DA 
(Figure 6.1). There was found to be a cohort effect, which was most evident in gene 
transcription data. 
 
Figure 6.1. sPLS-DA plot of the cohort effect on data. N: Normal tissue; T: Tumour tissue; CHCH: Christchurch cohort; PM: 
Peter MacCallum cohort; RT: RC patient. 





Figure 6.2. sPLS-DA plot of batch effect adjusted data. 
6.3.2 Initial categorisation 
Once the data had been normalised and adjusted for batch effects, the datasets were 
used for discriminant analysis, using the expression of 13,587 genes, 22 immune cell 
types and 160 bacterial taxa in tumour and normal adjacent tissues (Figure 6.3).  
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Figure 6.3. Heatmap of clustering by Dworak scores using unadjusted data. 
The lack of clustering also impacted the ability to predict response based on the input 
variables. The lowest error rates were found in predicting Dworak Four patients (0.4, 
Table 6.2). Overall error and balanced error rates were high, at 0.74–0.79 and 0.64–0.74, 
respectively, depending on the component used. 
Table 6.2. Classification error rates for Dworak scores using unadjusted data. 
Dworak comp1 comp2 comp3 comp4 comp5 comp6 
One 1.00 0.67 0.67 0.67 0.83 0.67 
Two 0.73 0.86 0.82 0.91 0.82 0.77 
Three 0.83 0.83 0.83 0.83 0.83 0.83 
Four 0.40 0.20 0.40 0.40 0.40 0.60 
Overall.ER 0.74 0.74 0.74 0.79 0.77 0.74 
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Overall.BER 0.74 0.64 0.68 0.70 0.72 0.72 
ER: Error rate; BER: Balanced error rate. 
To maximise the differences between response groups, patients were then grouped into 
response grades, complete (Dworak Four), intermediate (Dworak Two and Three) and 
poor, (Dworak One). There was a similar lack of clustering using the input variables 
using response grades (Figure 6.4), as was seen when using Dworak scores. However, 
this allowed for more straightforward variable selection. 
 
Figure 6.4. Heat map of clustering by response grade using unadjusted data. 
Characterisation of patients by response grade reduced the error rates substantively, as 
distinguishing between three categories is a lower resolution process. The overall and 
balanced error rates decreased by 0.1–0.25 and 0.02–0.22, respectively (Table 6.3). 
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Table 6.3. Classification error rates for response grades using unadjusted data. 
Response comp1 comp2 comp3 comp4 comp5 comp6 
Complete 0.60 0.40 0.20 0.40 0.60 0.80 
Intermediate 0.57 0.54 0.50 0.54 0.46 0.43 
Poor 1.00 0.83 0.67 0.67 0.83 0.83 
Overall.ER 0.64 0.56 0.49 0.54 0.54 0.54 
Overall.BER 0.72 0.59 0.46 0.53 0.63 0.69 
ER: Error rate; BER: Balanced error rate. 
6.3.3 Highly correlated variables 
Sparse partial least squares (sPLS) regression was utilised to identify meaningful 
variables for categorising samples. Each dataset (x) was computed against the CIP 
response grades (y), and variables were retained if the immune and bacterial 
transcription data R2 was ≥ 0.025 or ≤–0.025, and for gene expression, ≥ 0.01 or ≤–0.01. 
The approach yielded 38 and 42 taxa, 13 and 14 immune cells, and 152 and 101 genes for 
tumour and normal tissues, respectively. Compared to the unadjusted dataset, the 
correlated data could characterise patients more effectively (Figure 6.5).  
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Figure 6.5. Heat map of clustering of regression grades post-variable regression. 
The reduced datasets provided improved error rates as low as 0.46 and balanced error 
rates as low as 0.45, depending on the component used (Table 6.4). 
Table 6.4. Error rates post variable regression 
Response comp1 comp2 comp3 comp4 comp5 comp6 
Complete 0.40 1.00 0.80 0.80 0.60 0.80 
Intermediate 0.46 0.43 0.50 0.39 0.43 0.43 
Poor 0.50 0.50 0.50 0.50 0.50 0.50 
Overall.ER 0.46 0.51 0.54 0.46 0.46 0.49 
Overall.BER 0.45 0.64 0.60 0.56 0.51 0.58 
 
At this point, the dataset was split into training and test sets. Within the training set, the 
number of variables was iteratively reduced by one and its impact on clustering and 
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error rate evaluated. If removal of the variable reduced accuracy and clustering, it was 
restored. 
The final iterated datasets contained five and 14 taxa, six and eight immune cells, and 21 
and 18 genes in tumour and normal tissues, respectively. This allowed for the clustering 
of three of four poor responders within the training set, and two of three complete 
responders (Figure 6.6).  
 
 
Figure 6.6. Heatmap of clustering by response grade using the final model. 
When investigating sPLS-DA plots of variable sets used in the classification, tumour 
and normal genes were the most discriminatory, followed by normal immune cells. The 
taxa dataset had a considerable overlap between them in comparison (Figure 6.7). 
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Figure 6.7. Variable sPLS-DA plots 
Validation of the final model showed overall error rates between 0.07–0.43 and 0.1–0.52 
for balanced error rates (Table 6.5). Using component two gave the lowest error and 
balanced error rates at 0.07 and 0.1, respectively. 
Table 6.5. Final model error rates 
Response comp1 comp2 comp3 comp4 comp5 
Complete 0.67 0.00 0.33 0.33 0.67 
Intermediate 0.38 0.05 0.10 0.10 0.14 
Poor 0.50 0.25 0.50 0.50 0.50 
Overall.ER 0.43 0.07 0.18 0.18 0.25 
Overall.BER 0.52 0.10 0.31 0.31 0.44 
However, using component five gave the test set the greatest prediction accuracy, with 
only one intermediate patient being misclassified as a complete responder (Table 6.6). 
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Complete Intermediate Poor 
Truth 
Complete 2 0 0 
Intermediate 1 6 0 
Poor 0 0 2 
 
Receiver operating characteristic curve calculation showed that the highest 
contributions to accuracy came from gene expression data, followed by immune and 
bacterial transcription (Figure 6.8).  
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Figure 6.8. ROC curves of each dataset in the final model using component five. ROC: receiver operating characteristic; T: 
tumour tissue; N: normal tissue. 
According to the area under the curve (AUC) statistics, gene expression data was the 
most statistically significant measure for predicting response (Table 6.7). The only other 
variable set that was statistically significant was tumour immune cells, which could 
discriminate between poor responders and other patients. 
Table 6.7. Area under the curve (AUC) response grade classification data using component five 
  






AUC 0.827 0.578 0.625 
p-value 0.069 0.542 0.431 
Tumour AUC 0.400 0.612 0.708 
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AUC 0.771 0.623 0.722 
p-value 0.053 0.236 0.087 
Tumour 
AUC 0.760 0.687 0.979 










AUC 0.973 0.850 1.000 
p-value 0.008 0.006 0.002 
Tumour 
AUC 1.000 0.993 1.000 
p-value 0.005 <0.001 0.002 
 
6.3.4 Biomarker investigation 
6.3.4.1 Genes 
Based on the AUC statistics, gene expression data was the strongest and most 
statistically significant for predicting patient responses to radiotherapy. In both tumour 
and normal tissue, no other dataset was more capable of predicting outcomes.  
Most genes had negative loading weights on poor responders in tumours, while the 
greatest loading was from ING4, a tumour suppressor, and LOC101928333, a GRM8 
anti-sense lncRNA. Of genes included in response to therapy in tumour tissues, seven 
were lncRNAs, of which five remain uncharacterised. However, besides LOC101928333, 
LOC112268238 is known to protect formylmethionine-tRNA from hydrolysis (Figure 
6.9a). Tumour genes predictive of complete response had roles as tumour suppressors, 
growth regulation, and glutamate receptor silencing. GO terms related to response in 
tumour tissues were related to immune-related biological processes, including immune 
effector process (GO:0002252), neutrophil-mediated immunity (GO:0002446), myeloid 
leukocyte mediated immunity (GO:0002444), immune system process (GO:0002376), 
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leukocyte mediated immunity (GO:0002443), leukocyte activation (GO:0045321); 
however, no GO term was statistically significant. 
The genes expressed in normal tissues that were retained in the model and had highest 
loading weights toward complete response were for the PRR5-ARHGAP8 read-through 
transcript, of which the role has yet to be determined, PLUT is a lncRNA and has a role 
in transcription upregulation and is associated with diabetes (Figure 6.9b). HLA-DRB3 
is typically expressed in antigen-presenting cells for recognition by CD4 T cells, while 
FBXW4 is involved in ubiquitination and may have a role in WNT signalling. 
The Gene Ontology (GO) terms most related to genes retained in the model in normal 
tissues were response to stimulus (GO:0050896), cell communication (GO:007154), 
signal transduction (GO: 007165), cellular response to stimulus (GO: 0051716), 
signalling (GO: 0023052) and macromolecule metabolic process (GO:0043170); however, 
these were not statistically significant.  
A full list of genes and their roles can be found in Supplementary Table S6.1, while a list 
of GO terms can be found in Supplementary Table S6.2. 
 
 
Figure 6.9. Weight loadings on response from genes on component five. a) tumour genes; b) normal genes. 
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6.3.4.2 Immune cells and bacterial transcription 
According to the AUC statistics, the only statistically significant discriminatory power 
of the immune cell dataset was the abundance of tumour immune cells in 
differentiating poor responders from others. 
Indeed the cells with the highest discriminatory power within tumour tissues were B 
memory cells loading on an intermediate response, while eosinophils and resting 
dendritic cells loaded against an intermediate response. Activated dendritic cells 
weighted toward a poor response (Figure 6.10). 
 
Figure 6.10. Loadings weights on response from tumour immune cells on component five. 
According to the AUC statistics, no bacterial transcription in either tumour or normal 
tissues was statistically significant in terms of their contribution to response. A full list 
of all bacterial transcription, immune cells and gene transcription included in the final 
model can be found in Supplementary Table S6.3. 
168 
6.4 Discussion 
In the final model, the expression of 21 and 18 genes, the transcription of five and 14 
bacteria, the abundance of eight and six immune cells, in tumour and normal tissues, 
respectively, were used to classify patients into different response groups with 94.1% 
accuracy, with 7.14% overall and 9.92% balanced error rates.  
6.4.1 Biomarkers 
It could be seen in the sPLS-DA plots that the level of overlap between response groups 
indicate that different blocks may compensate for the lack of predictive ability of others.  
6.4.1.1 Bacterial transcription and immune cells 
According to the AUC statistics, there were no taxa that were found to be statistically 
significant in their predictive ability, which was not unsurprising, as in Chapter Four it 
was found that bacterial transcription accounted for little variation between response 
groups. Bacterial transcription may have some role in radiotherapy response; however, 
this is likely indirect and immune dependant. As suggested previously, the microbiota's 
contributing role in complete response may be one of support and non-interference, as 
excessive anti-microbial stimulation before therapy commencement may reduce the 
number of cells available for neo-antigen presentation and differentiation into anti-
tumour effector cells [529]. 
Overall, this may be due to the lesser importance of immune activation before 
radiotherapy, which is thought to stimulate anti-tumour responses. It may be the case 
that immune cells are useful for classifying poor responders as anti-tumour activity is 
less likely to occur than in intermediate and complete responders before therapy. 
However, although tumour immune cells were relevant for predicting poor outcomes, 
this may also be an erroneous conclusion, as their abundance was predicted from gene 
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expression data, so it may be the case that gene expression data effectively inputted to 
the model twice. 
6.4.1.2 Genes 
As normal genes were predicting response demonstrates that normal tissue biopsies can 
deliver untapped and important accessory information for research and clinical 
applications. Tumour genes predictive of response contained five uncharacterised long 
noncoding RNAs, and two characterised lncRNAs, one being an anti-sense silencer for a 
glutamate receptor and ribosomal binding assistance (LOC101928333 and 
LOC112268238, respectively). In normal tissues, LINC01473 remains uncharacterised. 
Overall, this may indicate that lncRNAs have an untapped role as prognostic indicators 
for radiotherapy response; however, they largely remain poorly understood and 
uncharacterised [530]. 
Normal tissue gene expression indicated that genes most predictive of response in 
normal tissues were related to enteric nerve stimulation and repair, immune regulation, 
protein digestion and transcription regulation. Enteric nerve-related genes may indicate 
the rectum's baseline non-pathological status, as it houses extensive enteric nerve 
conditions compared to the rest of the large intestine [531]. As radiation-induced nerve 
damage is a common complication of radiation therapy [532] and maintaining enteric 
nerve function is critical for intestinal health [533], they may provide a novel prognostic 
indicator for post-radiation quality of life. 
ING4, TUSC2, HRASLS2 were three tumour suppressor genes from tumour tissue in the 
final model that weighted loadings toward a complete response, and against a poor 
response, respectively, although the latter only slightly. The above may indicate that the 
gene is not operating the same way in all patients due to: a) The gene is mutated in 
some patients; b) the response element the gene targets is mutated or not expressed; c) 
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there is an issue with being translated to protein via missing chaperone proteins or 
protective RNAs.  
The inclusion of genes associated with GO terms related to macromolecular and protein 
metabolic processes is also of interest and could indicate that these tumours can take 
advantage of necrotic or burst cells in the microenvironment. Alternatively, they may 
have an increased capacity to degrade crosslinked proteins resulting from ionising 
radiation ROS generation, a known radioresistance mechanism in other species [534]. 
6.4.2 Study limitations 
One limitation of this study was the low sample sizes from multiple study centres. 
Although typically a strength, multi-study centres generally increase a studies power; 
however, in this instance, it may contribute to a cohort effect, and adjusting for the 
cohort effect, the treatment effect may be interrupted or have its power otherwise 
reduced. Additionally, due to the inter-cohort differences (only one poor and one 
complete responder in the PM cohort), the predictive model's utility may be restricted 
to geographical regions, reducing their potential application across geographical 
borders. 
Another issue is that Dworak scores should not be considered a true continuous 
variable. Each sample scoring is subjective and relies on the section analysed being 
representative of the area and differences between institutional or individual techniques 
and methodologies. The distinction between groups is based on the histopathologist's 
subjective view; a borderline Dworak Two maybe another pathologist’s Dworak Three, 
and vice versa. The effect may be exacerbated by the study's multi-centre design, as the 
translation from one grading system to another may lead a Dworak Two to be classified 
as Dworak Three in one instance, and not in another.  
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Ideally, a better way to classify tumour regression for future analyses would be the 
percentage of fibrosis over a set area, or tumour size reduction as a percentage of the 
original. Using tumour reduction or overall fibrosis would allow linear allocation of 
variables, rather than utilising classification methods which rely on data which may not 
be truly continuous. Unfortunately, it may not be that tumour regression is in reality, a 
continuous variable with universally defined characteristics. The variability within the 
studied cohort indicates that response to radiotherapy may be a ‘complex trait’ with 
multiple factors to be taken into account, not least of all, the expression of multiple 
genes.  
There were more subtle differences between a moderate response and a near-complete 
response (Dworak Two and Dworak Three), along with the small number of Dworak 
Three samples making them challenging to characterise. Additionally, the molecular 
causation of ‘near-complete’ is likely less distinct, and not necessarily due to a lesser 
variable dose than that received by complete responders, which may be what led them 
to be grouped with other response groups more often. 
Patients were grouped into response grades, complete (Dworak Four), intermediate 
(Dworak Two and Three) and poor, (Dworak One), to better characterise their response 
to therapy. The alternative grouping aimed to increase the signal for the two extreme 
responses, complete and poor; and created a third response category, intermediate, 
which was more easily characterised as not poor or complete. However, using a 
triplicate grouping also presents issues; primarily that a lack of a clear signal for 
intermediate patients may be that they are presenting an inhibited complete response or 
radiosensitisation of a poor response, which is difficult to gauge in the group due to the 
groups’ non-uniformity, and the goal of reducing variables as much as possible. 
Generating a larger, more variable group for non-complete or non-poor responders is 
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an imprecise method of characterisation, and if used in clinical settings, would not be a 
reliable way of determining the extent of tumour regression a patient could expect. 
Overall, the largest issue was the small sample size, making the training and test sets 
even smaller (n = 22 and n = 17, respectively); therefore, the model testing should not be 
considered rigorous and may still contain overfitting. The final model should be tested 
against a larger cohort containing data from multiple geographical locations to 
determine its true prediction accuracy, as the results here may only be valid for the 
studied cohorts. Additionally, the sPLS-DA methodology employed here is one of many 
regression-based machine learning approaches to multi-omics datasets, and alternatives 
such as Random Forest may provide more robust results [535]. Finally, the potential 
biomarkers were derived purely in silico and remain to be validated in a biological 
setting. 
6.4.3 Conclusions and future directions 
The panel of biomarker genes identified here could be used in clinical investigations, as 
RT-qPCR and staining for gene expression and immune cell detection would be most 
appropriate and effective. Providing RNA-Seq for all patients undergoing prognostic 
analysis is not currently feasible; however, if costs and technical limitations are reduced, 
a pipeline utilising the methods in this study could be used to predict response in a 
single step, rather than with sequential staining or microarrays which may be 
complicated and costly with more than 20 targets. 
The multi-omic design employed here benefited from allowing data blocks that were 
predictive of one response but not another to compensate for the non-discrimination of 
another, leading to a more refined signature from a single sequencing experiment. 
Additionally, the predictive model could not be improved by further removing of 
variables; this indicates that response to therapy is a complex and likely further 
173 
involves genes and cells in the microenvironment unidentified by this study, both 
human and not. 
7 CHAPTER 7: DISCUSSION 
As described in Chapter 1, response to therapy for RC remains unpredictable, which 
carries a high-cost burden, both financially and in terms of patient survival rates and 
quality of life.  Being able to predict which patients would respond to therapy and to 
what extent would be a valuable tool for patients and clinicians to determine which 
patients would likely have a high therapeutic response, which should be directed to 
alternatives and be given an accelerated path to surgery. Of the many aspects of the 
tumour microenvironments, it was discussed that the microbiome might play a role in 
carcinogenesis and these established microbial communities may, in turn, impact 
therapeutic response rates. 
7.1 Methodological improvements 
First, the typical methodology for analysing shotgun sequencing data was assessed and 
improved upon by including the human genome in the taxonomic database. The time-
consuming process of aligning sequencing data to the human genome to remove host 
reads before taxonomic assignment was shown to be incomplete, leaving substantial 
residual host reads that were given taxonomic assignment, affecting the interpretation 
of study results. It was shown that there was a non-statistically significant difference in 
taxonomic assignment accuracy when host mapping was employed in conjunction with 
a taxonomic database containing the host genome, making the rate-limiting step in 
microbiome analysis of host contaminated shotgun sequencing data largely redundant. 
The result of this first study demonstrates that it would be possible to increase the 
speed at which microbiome analysis of shotgun sequencing is performed by more than 
nine-fold, while simultaneously increasing taxonomic assignment accuracy by 
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approximately 11%. However, it remains possible that these results are only applicable 
to the taxonomic assignment and aligning algorithms used in this study. 
7.2 Platform comparisons 
The concordance between three sequencing platforms in their comparative ability to 
evaluate the microbiome: high throughput shotgun RNA-Sequencing; long-read, low 
depth Oxford Nanopore Technology (ONT) multiplexed sequencing; and 16S rRNA 
amplicon sequencing. It was found that ONT data produced the least reads; however, 
the resulting taxonomies remained mostly concordant with the other higher depth 
sequencing platforms at higher taxonomic levels. At the species level, the concordance 
between all platforms was decreased. Overall 16S rRNA sequencing was more 
concordant with RNA-Sequencing taxonomies than either was with those produced by 
ONT sequencing. This result may be due to 16S rRNA sequencing is usually assessed 
with dedicated algorithms and that Kraken2’s ability to accurately assign taxonomies to 
16S rRNA data is a recent development and may not yet be adequately benchmarked. 
Additionally, the three platforms measure different things in fundamentally different 
ways. For instance, 16S rRNA requires amplification of the 16S rRNA markers gene, 
while the RNA-Sequencing relies on cDNA translation of transcripts and allows the 
assessment of actively transcribed genes, and finally, ONT sequencing is a direct DNA 
sequencing method with no amplification or translational steps. All of these techniques 
carry with them inherent flaws, with the low sequence output of ONT sequencing being 
the most severe. The inherent error rates of ONT sequencing and resulting low numbers 
of bacterial reads without the benefit of microbial DNA selection or higher throughput 
resulted in only two taxa identified some samples. It was decided that due to the 
highest and most consistent sample depth across the largest number of samples, RNA-
Sequencing and bacterial transcription should be utilised for further analysis. 
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Additionally, RNA-Sequencing was performed on 40 patient samples, as opposed to the 
other two platforms, which were only performed on the CHCH cohort (n = 20).  
7.3 Microbial transcription in RC 
Assessing microbial transcription in RC tumour and normal tissues showed that alpha 
diversity was not a significant contributor to response and that individual taxa may 
contribute to chemoradiotherapy outcomes in RC. Overall, Proteobacteria transcription 
dominated across all samples and was correlated with a poor response, while 
Bacteroidetes were negatively correlated with poor response in normal tissues.  
Subsequently, taxa within these phyla showed similar correlations, with the 
Pseudomonas and Bacteroides genera positive and negative correlations with response. 
The results showed that species such as C. ureolyticus, B. caccae, B. vulgatus, B. fragilis, E. 
coli, K. pneumonia, S. enterica, and O. splanchicus were most likely to be contributing to 
response to radiotherapy. Due to low read depths at the species level, it was not 
possible to properly investigate their differential gene expression to determine their 
direct contributions to response. However, it was possible to determine that B. fragilis, 
one of the most transcriptionally active species, was not producing the bft toxin, which 
is thought to contribute to carcinogenesis. 
It was hypothesised that due to the number of correlations of microbial transcription 
occurring in normal tissues and what is known about the correlated species identified, it 
was possible that the microbiome impacts response to therapy by modulating the 
immune system directly and via changes in the microenvironment. These changes were 
speculated to be due to altering the metabolism of lipids, reducing allergic 
inflammatory responses and mitigating anti-bacterial responses, which would be 
concordant with the literature on the benefit of high-fat diets during cancer treatments; 
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however, the direct interaction with the microbiome and immune system requires 
additional investigation. 
Additionally, due to most correlations being with poor response and not with response 
generally, the extreme nature of the microenvironment of the poorest responders may 
give them the strongest microbial selection pressure, and thus the strongest microbial 
signature. 
However, not being able to determine the precise activities of putatively involved taxa 
in response rates, and that some bacterial species may have been misassigned means 
that further investigation should be carried out to validate these results and to 
investigate the generated hypotheses. 
7.4 Immune infiltration  
The presence of immune cells in the respective tissues of RC patients was assessed by 
using RNA-Sequencing data and a support vector regression algorithm, which resulted 
in predictions for the abundance of different immune cells and phenotypes within 
patient samples. Each immune cell population was correlated with response and 
bacterial transcription data. 
Statistically significant correlations of M1 macrophages and resting mast cells within 
tumour tissues with response identified them as the strongest immune predictor of 
response. The reasons for this was determined to be the higher populations of these cell 
types within complete responders, with M1 macrophages being involved in tumour 
clearance and mast cells having allergic inflammatory and pathogen clearing roles. It 
was hypothesised that these immune cells are reacting to elements of the 
microenvironment, with the microbiome possibly modulating anti-tumour immune 
responses, preventing the inflammatory role of mast cells and allowing M1 
macrophages to infiltrate and act upon tumour tissues.  
177 
The abundance of immune cells was correlated with bacterial transcription and was 
found to be associated with a variety of antigen-presenting and effector cells. It was 
hypothesised that bacterial cells allow for the preservation of antigen-presenting cells 
that would otherwise display bacterial antigens or those in the tumour 
microenvironment, instead of tumour neo-antigens that would be produced en masse 
after ablative ionising radiation therapy. The hypothesis was supported by the 
proportion of resting effector cells in conjunction with the transcription of bacteria 
associated with butyrate production, immune tolerance of gut microbiota, changes in 
tissue metabolic uptake of glucose and lipids and immune stimulation.  
Overall, the evidence of the investigation of possible interactions between the 
microbiome and the immune system indicates that, although they may not have a direct 
effect on anti-tumour responses, they may modulate the immune system to prevent 
non-anti-tumour action and maintain the immune system for a rapid anti-tumour 
response upon the commencement of radiation treatment. However, the possibility 
remains that the immune cells identified in silico are not present in the predicted 
proportions and that the phenotypic plasticity of immune cells, particularly neutrophils, 
remains to be evaluated and may play a role in divergent radiotherapy response. 
 
7.5 Biomarker analysis 
In the final analysis, the bacterial transcription, immune cell abundance and gene 
expression data were used to determine if a model could be formed to predict response 
to radiotherapy. The aim was to build a predictive model using the least number of 
predictive markers. The number of discriminant variables was reduced one by one 
using a training dataset of 28 samples, in order to reduce the number of variables that 
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would have to be investigated in a clinical setting while preserving the predictive 
ability of the model.  
The final model contained 21 and 18 genes, the transcription of five and fourteen 
bacteria and the abundance of eight and six immune cells in tumour tissues, normal 
tissues, respectively. The model could accurately classify poor and complete responders 
in the test dataset, while one intermediate responder was incorrectly classified as a 
complete responder. The overall error rate of the final model, as assessed by cross-fold 
validation, was ~7%. The strongest predictive value came from the gene expression in 
tumour and normal tissues, and the infiltration of immune cells in tumour tissues, 
which was of particular note, as it shows that normal tissue biopsies have additional 
prognostic power which could be utilised in future assessments of RC patients. 
Additionally, this may be due to the normal tissue providing a baseline for gene 
expression, which was strengthened in the predictive model when combined with 
pathological tumour gene expression. 
During the formation of the predictive model, it was determined that the variability in 
Dworak Two and Three patients made classifying them into their respective Dworak 
score groups too challenging.  It was surmised that Dworak scores might not be a true 
continuous variable as some Dworak scores were translated from another scoring 
method, and different histopathologists, centres and countries were utilised which may 
add variability of the interpretation of different samples. For instance, a poor responder 
may be a moderate or poor responder depending on the histopathologists’ 
interpretation, the section used and the time between surgery and completion of 
treatment. Additionally, a near-complete response may be due to an inhibited anti-
tumour response that would have otherwise been complete, while another patient’s 
near-complete response may be an enhanced anti-tumour response that would have 
otherwise been moderate or poor.  
179 
An alternative grouping strategy was adopted to determine the strongest predictors 
utilising the most extreme outcomes of poor and complete response, allowing the 
Dworak Two and Three patients to have their responses categorised as not poor or 
complete. The alternative strategy made finding predictive variables more straight 
forward; however, this came at the cost of more refined classifications. It was suggested 
that an alternative measure of tumour regression could be used which would make 
evaluating it as a true continuous variable more straightforward, such as percentage of 
fibrosis or comparative tumour and lesion sizes in comparison to the pre-treatment 
tumour.  
Besides the categorisation strategy, the predictive biomarker analysis was hindered by 
the number of samples in the respective training and test sets with non-representative 
numbers of responders in each. Additionally, the model may, to an extent, be the result 
of overfitting, as the immune cell abundance was derived from gene expression data; it 
may have led to the inclusion of some variables in the model multiple times, albeit in an 
abstracted way. 
7.6 Study limitations 
This study suffered most from the limits of sample sizes overall and for respective 
response groups in each cohort, with the PM cohort only containing one complete 
responder and one poor responder. Additionally, the lack of full access to the PM 
cohort’s medical history precluded the accounting for additional variables which may 
impact treatment response, such as ethnicity, comorbidities, and other medications 
taken during treatment. Furthermore, the number of samples in each response group 
were not representative, with the majority of samples being moderate responders 
(Dworak Two), while six or less were near complete, complete or poor responders. 
There was also a sex imbalance, with the majority of the patients being male, which may 
have contributed to erroneous study interpretations, particularly in the case of 
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incorporating gene expression data into the biomarker model. Additionally, biopsies 
were collected by different clinicians from different centres, and interpersonal 
differences due to patient condition, tumour size and preference of the clinician may 
have changed the depth and size of biopsies, as well as the distance from the tumour of 
adjacent normal tissue collection.  
7.7 Conclusions and future directions 
This study demonstrated that microbiome assessment accuracy and speed can be 
improved with a simple methodological change, that taxonomies built from ONT 
sequencing are comparable to 16S rRNA amplicon and RNA-Sequencing if read 
numbers are high enough. The study also found a possible interaction between the 
microbiome and the immune system, directly via modulating stimulation and microbial 
immune tolerance, and indirectly by modulating the tumour microenvironment. It was 
hypothesised that the microbiome might influence response to therapy by preventing 
the immune system from acting on aspects of the microenvironment including bacteria, 
lipids or allergic inflammatory responses, and maintaining naïve effector and antigen-
presenting cells to act on neo-antigens produced from radiotherapy-induced tumour 
cell death. 
Finally, the biomarker analysis suggested possible prognostic molecular markers to 
predict response to radiotherapy in RC patients, with tumour infiltrating immune cells 
and tumour and normal tissue gene expression being the key determinants, indicating 
an untapped strength of dual biopsies in clinical practice. 
Overall, this study provides methodological improvements and a panel of potential 
biomarkers that could be used in future validation studies to assess prediction of 
radiotherapy responses in RC patients. The panel of biomarkers should be further 
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investigated in biological and clinical settings and with larger sample sizes to validate 
and potentially refine them. 
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